company_name,perm_id,data_type,disclosure,metric_description,metric_name,metric_value,nb_points_of_observations,pillar,Industry,year,metric_value_scaled,metric_value_log,standard_metric
Achillion Pharmaceuticals Inc,4295902590,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,52,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Loxo Oncology Inc,5040059115,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,43,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
RaySearch Laboratories AB (publ),4295889885,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Immunitybio Inc,5046045471,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Rapid Nutrition PLC,5042944492,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,236,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
HLS Therapeutics Inc,5062411003,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,229,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vaxcyte Inc,5040942643,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,215,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Silence Therapeutics PLC,4295895614,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,204,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kuros Biosciences AG,4295890889,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,203,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Legend Biotech Corp,5056412290,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,199,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Immunovant Inc,5068663165,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,198,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alterity Therapeutics Ltd,4295857196,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aptose Biosciences Inc,4295861982,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,189,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Astria Therapeutics Inc,4298140380,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Astria Therapeutics Inc,4298140380,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Avenue Therapeutics Inc,5045106861,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,182,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ProQR Therapeutics NV,5038906661,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,182,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Quince Therapeutics Inc,5042946656,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,182,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Galectin Therapeutics Inc,4295908397,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,181,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Brainstorm Cell Therapeutics Inc,4295899439,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,179,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Chinook Therapeutics Inc,4298084379,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,177,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
89Bio Inc,5071508069,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,171,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Enliven Therapeutics Inc,5050721453,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,169,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Animalcare Group PLC,4295894891,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,168,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
NeuBase Therapeutics Inc,4295905287,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,168,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Minerva Neurosciences Inc,5035525714,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,166,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mustang Bio Inc,5045675573,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,163,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alexion Pharmaceuticals Inc (Pre-Merger),4295905466,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,160,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
DaShenLin Pharmaceutical Group Co Ltd,5000560542,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,160,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
TCR2 Therapeutics Inc,5048737252,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,158,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dong Suh Companies Inc,4295882549,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,156,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CASI Pharmaceuticals Inc(Pre-Merger),4295906369,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,155,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
GP Strategies Corp,4295904038,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,155,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
IMV Inc,4297852426,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,155,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Advanz Pharma Corp Ltd,5073343758,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,147,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Arena Pharmaceuticals Inc,4295900428,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,146,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CohBar Inc,5037441109,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,146,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Nymox Pharmaceutical Corp,5052544527,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,145,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SillaJen Inc,5040702572,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,144,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Magenta Therapeutics Inc,5052528282,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,143,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
PhaseBio Pharmaceuticals Inc,5035400506,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,143,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ContraFect Corp,5001150224,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,143,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kaleido Biosciences Inc,5051609503,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,142,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
9 Meters Biopharma Inc,5037627414,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,137,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tricida Inc,5041066023,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,137,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Oyster Point Pharma Inc,5050914678,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,135,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AMAG Pharmaceuticals Inc,4295903284,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,135,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AMAG Pharmaceuticals Inc,4295903284,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,135,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Tyme Technologies Inc,5044009440,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,134,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
GW Pharmaceuticals Ltd,4295894440,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,133,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
GW Pharmaceuticals Ltd,4295894440,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,133,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hitachi High-Tech Corp,4295878681,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,132,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Satsuma Pharmaceuticals Inc,5052544073,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,119,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
PPD Inc,5071172659,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,117,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Five Prime Therapeutics Inc,4296891332,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,113,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
GlaxoSmithKline Consumer Healthcare Ltd,4295872411,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,112,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
PRA Health Sciences Inc,5043464896,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,110,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kindred Biosciences Inc,5037962380,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,110,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Correvio Pharma Corp,5063766186,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,106,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Correvio Pharma Corp,5063766186,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,106,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Akouos Inc,5059037223,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,103,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bio-On SpA,5035553307,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,89,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,434,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,431,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,423,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,414,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Novartis AG,4295890628,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,414,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,414,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,408,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,405,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,403,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,403,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,392,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,391,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ALK-Abello A/S,4295866060,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,391,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,390,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,388,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,386,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,385,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Corcept Therapeutics Inc,4295899705,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,384,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,383,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,382,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CVS Health Corp,4295903627,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,1.0,381,E_opportunity,Biotechnology & Pharmaceuticals,2020,4.511698835079361e-05,0.6931471805599453,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,381,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,378,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,378,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,376,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,376,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,376,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,1.0,373,E_opportunity,Biotechnology & Pharmaceuticals,2020,4.511698835079361e-05,0.6931471805599453,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,372,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,372,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,371,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Perrigo Company PLC,5040203322,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,371,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Siegfried Holding AG,5000066884,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,371,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,370,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,370,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,368,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,368,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,368,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
CSL Ltd,4295856855,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,367,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ucb SA,4295859381,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,367,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Lupin Ltd,4295873497,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,366,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Grifols SA,4295889506,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,365,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,363,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,363,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,363,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Virbac SA,4295866672,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,362,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,360,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,360,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,359,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tsumura & Co,4295878528,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,357,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Evotec SE,5068477440,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,356,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Orion Oyj,4295866566,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,356,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Prestige Consumer Healthcare Inc,4295907295,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,355,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,355,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,1.0,355,E_opportunity,Biotechnology & Pharmaceuticals,2020,4.511698835079361e-05,0.6931471805599453,Drug_Safety
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,355,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Bio Rad Laboratories Inc,4295908554,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,354,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,354,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mesa Laboratories Inc,4295907138,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,354,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,1.0,354,E_opportunity,Biotechnology & Pharmaceuticals,2020,4.511698835079361e-05,0.6931471805599453,Drug_Safety
Biomarin Pharmaceutical Inc,4295912660,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,353,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biomarin Pharmaceutical Inc,4295912660,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,353,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,352,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
DXP Enterprises Inc,4295906126,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,352,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
DXP Enterprises Inc,4295906126,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,352,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,351,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,351,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
IDEXX Laboratories Inc,4295906763,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,1.0,349,E_opportunity,Biotechnology & Pharmaceuticals,2020,4.511698835079361e-05,0.6931471805599453,Drug_Safety
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,347,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,347,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,347,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,346,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hypera SA,4297927148,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,346,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Celldex Therapeutics Inc,4297103233,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,346,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hypera SA,4297927148,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,346,E_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,344,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ionis Pharmaceuticals Inc,4295906873,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,343,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,343,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,341,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alkermes Plc,5035456435,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,340,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,339,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,339,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pacira Biosciences Inc,4297853578,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,339,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Neurocrine Biosciences Inc,4295907381,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,339,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,338,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Genmab A/S,4295866092,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,338,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Insight Enterprises Inc,4295906810,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,337,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,337,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Amicus Therapeutics Inc,4295902550,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,335,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Viatris Inc,5035523437,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,335,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Amicus Therapeutics Inc,4295902550,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,335,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
ICON PLC,4295874891,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,334,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,334,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,333,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
American Superconductor Corp,4295905527,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,332,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Phibro Animal Health Corp,5034074360,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,332,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,331,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fate Therapeutics Inc,4296275166,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,330,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ACADIA Pharmaceuticals Inc,4295903398,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,330,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fate Therapeutics Inc,4296275166,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,330,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
ANI Pharmaceuticals Inc,4295902157,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,329,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bavarian Nordic A/S,4295866173,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,329,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Supernus Pharmaceuticals Inc,4297350707,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,329,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Wockhardt Ltd,4295873567,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,328,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,327,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Werner Enterprises Inc,4295908451,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,327,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Roche Holding AG,4295890594,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,1.0,326,E_opportunity,Biotechnology & Pharmaceuticals,2020,4.511698835079361e-05,0.6931471805599453,Drug_Safety
Integra Lifesciences Holdings Corp,4295906823,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,324,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,323,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Quest Diagnostics Inc,4295904788,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,322,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
3SBio Inc,4295863999,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,322,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Starpharma Holdings Ltd,4295856781,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,322,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Blackmores Ltd,4295856664,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,321,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Omega Healthcare Investors Inc,4295904656,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,320,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
United Therapeutics Corp,4295915261,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,320,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Amphastar Pharmaceuticals Inc,4297971432,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,319,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,319,E_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Zhejiang Nhu Co Ltd,4295864955,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,318,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,318,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
argenx SE,5000263797,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,318,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
BioCryst Pharmaceuticals Inc,4295905725,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,318,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,316,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Heron Therapeutics Inc,4295905439,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,316,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Novavax Inc,4295904633,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,316,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Heron Therapeutics Inc,4295905439,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,316,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,316,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aclaris Therapeutics Inc,5037844397,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,315,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bachem Holding AG,5000073936,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,315,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pacific Biosciences of California Inc,4296988897,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,315,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Agenus Inc,4295912530,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,315,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Oriola Oyj,4295866498,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,315,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Beigene Ltd,5046048089,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,313,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Rigel Pharmaceuticals Inc,4295915993,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,313,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,313,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,313,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Denali Therapeutics Inc,5045948499,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,313,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ligand Pharmaceuticals Inc,4295907009,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,312,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tong Ren Tang Technologies Co Ltd,4295864045,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,312,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Precigen Inc,4297774183,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,311,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,311,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,311,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sarepta Therapeutics Inc,4295905395,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,311,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Intellia Therapeutics Inc,5044066446,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,310,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vanda Pharmaceuticals Inc,4295899966,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,310,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,310,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
H Lundbeck A/S,4295866154,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,308,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Science Applications International Corp,5039584611,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,308,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Enanta Pharmaceuticals Inc,4296904058,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,307,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fulgent Genetics Inc,5051396874,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,306,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fulgent Genetics Inc,5051396874,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,306,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
MannKind Corp,4295903432,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,305,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Agios Pharmaceuticals Inc,4298032874,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,304,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Agios Pharmaceuticals Inc,4298032874,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,304,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,304,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,303,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Prothena Corporation PLC,5037961722,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,303,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sangamo Therapeutics Inc,4295914874,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,303,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mesoblast Ltd,4295858844,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,303,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Halozyme Therapeutics Inc,4295915674,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,302,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Inovio Pharmaceuticals Inc,4295901003,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,302,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Seres Therapeutics Inc,5037639494,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,301,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Editas Medicine Inc,5040699642,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,300,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zealand Pharma A/S,4295989612,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,300,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,300,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Collegium Pharmaceutical Inc,5045917401,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,300,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Apellis Pharmaceuticals Inc,5000744891,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,299,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Eagle Pharmaceuticals Inc,4296474346,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,299,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Amneal Pharmaceuticals Inc,5062782308,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,299,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Apellis Pharmaceuticals Inc,5000744891,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,299,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Akebia Therapeutics Inc,4297878446,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,299,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Akebia Therapeutics Inc,4297878446,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,299,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Anika Therapeutics Inc,5068320253,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,298,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,298,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
American Vanguard Corp,4295903372,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,297,E_opportunity,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
American Vanguard Corp,4295903372,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,297,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,297,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hisamitsu Pharmaceutical Co Inc,4295877610,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,297,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,297,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hisamitsu Pharmaceutical Co Inc,4295877610,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,297,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,296,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Guardant Health Inc,5041079009,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,296,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
MorphoSys AG,4295869785,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,296,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Seagen Inc,4295901424,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,295,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Humanwell Healthcare Group Co Ltd,4295865648,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,294,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Nektar Therapeutics,4295906807,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,294,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Myriad Genetics Inc,4295907228,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,294,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Avid Bioservices Inc,4295915112,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,293,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Theravance Biopharma Inc,5040202678,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,292,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Knight Therapeutics Inc,5046438291,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,292,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,291,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sosei Group Corp,4295880658,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,291,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Yuhan Corp,4295881557,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,291,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,290,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Oxford Biomedica PLC,4295895244,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,290,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Huadong Medicine Co Ltd,4295864428,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,290,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Accelerate Diagnostics Inc,5038034917,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,290,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Coherus BioSciences Inc,5037455589,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,289,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ironwood Pharmaceuticals Inc,4295940206,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,289,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Moderna Inc,5066596648,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,289,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SIGA Technologies Inc,4295914936,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,288,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pharma Mar SA,5000066579,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,288,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Natural Grocers By Vitamin Cottage Inc,5037624117,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,288,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,286,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Krka dd Novo Mesto,4295888307,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,286,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Travere Therapeutics Inc,4296438961,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,285,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Arvinas Inc,5046736907,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,285,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Catalyst Pharmaceuticals Inc,4295902234,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,285,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
PTC Therapeutics Inc,4296025423,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,285,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Jazz Pharmaceuticals PLC,4297329846,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,284,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Almirall SA,4295889280,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,1.0,283,E_opportunity,Biotechnology & Pharmaceuticals,2018,4.511698835079361e-05,0.6931471805599453,Drug_Safety
Harrow Health Inc,4295902339,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,283,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
VBI Vaccines Inc,4295861984,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,283,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,283,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vaxart Inc,4295907233,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,283,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vifor Pharma AG,4295890653,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,283,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Almirall SA,4295889280,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,283,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
WAVE Life Sciences Ltd,5041069029,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,282,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cara Therapeutics Inc,4297277386,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,282,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
XOMA Corp,5037133783,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,281,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,280,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Otsuka Holdings Co Ltd,5000073379,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,279,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Puma Biotechnology Inc,4297723879,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,279,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
OptiNose Inc,5043339171,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,279,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,279,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,279,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Proto Labs Inc,4298059665,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,279,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Boiron SA,4295867491,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,279,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Revance Therapeutics Inc,4296286413,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,278,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biotest AG,4295868772,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,278,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alliance Pharma PLC,4295896230,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,278,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
MeiraGTx Holdings PLC,5063761745,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,278,E_opportunity,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Arbutus Biopharma Corp,5063095367,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,278,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Retail Opportunity Investments Corp,4295912075,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,278,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biotest AG,4295868772,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,278,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Taisho Pharmaceutical Holdings Co Ltd,5035303233,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,277,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Twist Bioscience Corp,5040185976,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,277,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Royalty Pharma PLC,5031889023,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,276,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Revolution Medicines Inc,5044506598,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,274,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,274,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Organogenesis Holdings Inc,5067949286,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,274,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Camurus AB,5035523580,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,273,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Intra-Cellular Therapies Inc,5038989170,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,273,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Core Laboratories NV,4295884861,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,272,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Indivior PLC,5044066242,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,272,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Probi AB,4295890448,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,272,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Meridian Bioscience Inc,4295907136,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,271,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Deciphera Pharmaceuticals Inc,5057832486,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,271,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vir Biotechnology Inc,5052795509,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,271,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,270,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Horizon Therapeutics PLC,5037276891,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,270,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Axsome Therapeutics Inc,5039864624,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,270,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Lifecore Biomedical Inc,4295906967,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,270,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Horizon Therapeutics PLC,5037276891,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,270,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Axsome Therapeutics Inc,5039864624,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,270,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Harvard Bioscience Inc,4295902196,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,269,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aquestive Therapeutics Inc,5031994451,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,269,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,269,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Acrux Ltd,4295858548,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,268,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Marker Therapeutics Inc,5066581785,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,267,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
TG Therapeutics Inc,4295912581,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,267,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Celltrion Inc,5000076514,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,267,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Polynovo Ltd,4295857937,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,266,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Protagonist Therapeutics Inc,5037933405,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,266,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,266,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Endo International PLC,5040791002,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,266,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
G1 Therapeutics Inc,5035526162,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,266,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
G1 Therapeutics Inc,5035526162,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,266,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Alaunos Therapeutics Inc,4295902600,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,265,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Benchmark Holdings PLC,5003638730,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,265,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
STADA Arzneimittel AG,4295869543,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,265,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zai Lab Ltd,5057819640,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,265,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ibio Inc,4298054794,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,265,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hansa Biopharma AB,4298014997,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,264,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,264,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Redcare Pharmacy NV,5052123270,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,264,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Voyager Therapeutics Inc,5041076755,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,264,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Syneos Health Inc,5040258481,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,263,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Celltrion Pharm Inc,4295882372,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,263,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Midsona AB,4295890221,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,263,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pieris Pharmaceuticals Inc,5040241774,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,263,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Reata Pharmaceuticals Inc,5000090491,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,263,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,263,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AcelRx Pharmaceuticals Inc,4297543075,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,262,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cellectis SA,4295868150,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,262,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Faes Farma SA,4295889471,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,262,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SSY Group Ltd,4295865393,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,261,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Karyopharm Therapeutics Inc,5001437822,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,261,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Syros Pharmaceuticals Inc,5037818300,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,260,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ascendis Pharma A/S,4297931709,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,260,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cosmo Pharmaceuticals NV,5051001094,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,259,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Cosmo Pharmaceuticals NV,5051001094,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,259,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aurinia Pharmaceuticals Inc,5000451880,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,258,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,258,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CorMedix Inc,5000592140,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,258,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
NGM Biopharmaceuticals Inc,4297800748,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,258,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Castle Biosciences Inc,5000451463,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,258,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Evolus Inc,5038792215,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,258,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
vTv Therapeutics Inc,5046056658,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,258,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Urogen Pharma Ltd,5035535486,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,258,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Arrowhead Pharmaceuticals Inc,4295913831,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,257,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Madrigal Pharmaceuticals Inc,4295899733,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,256,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ECO Animal Health Group PLC,4295895203,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,256,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Idorsia Ltd,5056400072,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,255,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sutro Biopharma Inc,5017515126,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,255,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alector Inc,5066605183,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,254,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fortress Biotech Inc,5035420209,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,253,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mersana Therapeutics Inc,4298068040,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,253,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Scandi Standard AB (publ),5040249601,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,253,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Atara Biotherapeutics Inc,5037937603,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,253,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fortress Biotech Inc,5035420209,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,253,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Albioma SAS,4295866947,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,252,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mithra Pharmaceuticals SA,5000960352,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,252,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Addex Therapeutics Ltd,4295890551,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,252,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AddLife AB,5050647517,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,252,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CytomX Therapeutics Inc,5040944268,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,252,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CEL-SCI Corp,4295903677,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,251,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Adaptive Biotechnologies Corp,5000627106,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,251,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Walvax Biotechnology Co Ltd,5001170754,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,251,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pharming Group NV,4295884868,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,251,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Molecular Templates Inc,4295908364,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,251,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cue Biopharma Inc,5046434620,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,250,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Arcturus Therapeutics Holdings Inc,5068339275,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,250,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cue Biopharma Inc,5046434620,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,250,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Beam Therapeutics Inc,5063164263,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,250,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Orexo AB,4295890191,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,249,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kala Pharmaceuticals Inc,5000621507,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,249,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Crinetics Pharmaceuticals Inc,5037611560,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,249,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Crinetics Pharmaceuticals Inc,5037611560,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,249,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Lexicon Pharmaceuticals Inc,4295914055,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,249,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Precision BioSciences Inc,5035539845,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,248,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Personalis Inc,5037652668,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,247,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Assembly Biosciences Inc,5001158603,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,247,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Scholar Rock Holding Corp,5060509019,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,247,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Esperion Therapeutics Inc,4295900449,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,247,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Intercept Pharmaceuticals Inc,4296966741,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,247,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
MEI Pharma Inc,4295899598,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,246,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kiniksa Pharmaceuticals Ltd,5063731859,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,246,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Syndax Pharmaceuticals Inc,4297793633,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,246,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Morphic Holding Inc,5066537246,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,246,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,246,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kura Oncology Inc,5044341506,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,245,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Clinuvel Pharmaceuticals Ltd,4295856451,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,245,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Oxurion NV,4295859470,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,245,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
BioArctic AB,5035561399,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,245,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cyclerion Therapeutics Inc,5067843831,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,244,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Betta Pharmaceuticals Co Ltd,5000768225,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,244,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Beijing Tiantan Biological Products Corp Ltd,4295865264,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,244,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kalvista Pharmaceuticals Inc,4297340254,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,243,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
OBI Pharma Inc,5000693472,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,243,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Orgenesis Inc,4298422934,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,243,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Exagen Inc,4296127863,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,243,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Y-mAbs Therapeutics Inc,5051611538,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,243,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Corbus Pharmaceuticals Holdings Inc,5040943458,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,242,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sorrento Therapeutics Inc,4296491271,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,242,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
RVL Pharmaceuticals PLC,5065379339,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,241,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Taro Pharmaceutical Industries Ltd,4295875212,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,241,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Abeona Therapeutics Inc,4295911990,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,240,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Yunnan Baiyao Group Co Ltd,4295864051,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,240,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ADMA Biologics Inc,4297548856,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,240,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cidara Therapeutics Inc,5042263702,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,240,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Assertio Holdings Inc,5073962717,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Apeloa Pharmaceutical Co Ltd,4295863743,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
BridgeBio Pharma Inc,5052793334,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AB Science SA,5000727830,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Affimed NV,5043318185,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zhejiang Huahai Pharmaceutical Co Ltd,4295864835,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Jounce Therapeutics Inc,5038067073,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,239,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Rhythm Pharmaceuticals Inc,5043464231,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,238,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cogent Biosciences Inc,5043324118,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,237,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Trulieve Cannabis Corp,4296507565,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,237,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mayne Pharma Group Ltd,4295858866,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,237,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mirati Therapeutics Inc,5039800567,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,236,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Krystal Biotech Inc,5057764486,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,236,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
HOOKIPA Pharma Inc,5067945220,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,236,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pliant Therapeutics Inc,5046715672,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,235,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Iovance Biotherapeutics Inc,5056411750,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,235,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Molecular Partners AG,4297804675,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,234,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aptinyx Inc,5046706152,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,234,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Paratek Pharmaceuticals Inc,4295902313,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,234,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
bluebird bio Inc,5035523656,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,234,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aeglea Bio Therapeutics Inc,5038915440,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,233,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aurora Cannabis Inc,4297776358,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,233,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Immutep Ltd,4295857055,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,232,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Innate Pharma SA,4295866723,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,232,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cassava Sciences Inc,4295915956,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,231,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Seegene Inc,5000846840,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,231,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Acorda Therapeutics Inc,4295909042,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,231,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Synlogic Inc,5000782315,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,231,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Champions Oncology Inc,4295912832,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,230,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Akero Therapeutics Inc,5064611248,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,230,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Solid Biosciences Inc,5040932912,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,229,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aravive Inc,4298508493,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,229,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Homology Medicines Inc,5046317196,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,229,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Rocket Pharmaceuticals Inc,4297060461,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,228,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Fulcrum Therapeutics Inc,5051602622,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,228,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SAGE Therapeutics Inc,5036384269,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,227,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Selecta Biosciences Inc,4298128957,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,227,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Harpoon Therapeutics Inc,5046317800,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,227,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Gritstone bio Inc,5046716076,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,226,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
UNITY Biotechnology Inc,5042242039,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,226,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Atreca Inc,5037061527,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,225,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
IDEAYA Biosciences Inc,5046317163,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,225,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Avidity Biosciences Inc,5041069348,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,224,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Arcutis Biotherapeutics Inc,5071515336,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,224,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aytu Biopharma Inc,5046048674,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,224,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
DermTech Inc,5071164163,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,224,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
NextCure Inc,5048904889,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,222,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Replimune Group Inc,5064609639,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,221,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
X4 Pharmaceuticals Inc,5001432321,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,221,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Athenex Inc,4297156651,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,221,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fennec Pharmaceuticals Inc,4295862881,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,220,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Medipharm Labs Corp,5057974133,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,220,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
IGM Biosciences Inc,5000837249,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,219,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Avalo Therapeutics Inc,5036216067,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,219,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Jilin Aodong Pharmaceutical Group Co Ltd,4295864286,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,219,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Avalo Therapeutics Inc,5036216067,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,219,E_opportunity,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Cronos Group Inc,5052536942,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,219,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Allogene Therapeutics Inc,5063310679,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,219,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ovid Therapeutics Inc,5045853309,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,218,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hualan Biological Engineering Inc,4295865475,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,218,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sinovac Biotech Ltd,4295863966,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,218,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Beijing Tongrentang Co Ltd,4295865333,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,217,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Beijing Tongrentang Co Ltd,4295865333,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,217,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
China Resources Double-Crane Pharmaceutical Co Ltd,4295864997,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,217,E_opportunity,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Beijing SL Pharmaceutical Co Ltd,4295865485,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,217,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Marinus Pharmaceuticals Inc,4296927359,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,217,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Avecho Biotechnology Ltd,4295858250,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,217,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dong-E-E-Jiao Co Ltd,4295864992,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,216,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Karuna Therapeutics Inc,5036220029,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,216,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Nkarta Inc,5061699475,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,216,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kodiak Sciences Inc,4298009606,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,214,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Xeris Pharmaceuticals Inc,4297260021,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,214,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Guangzhou Kingmed Diagnostics Group Co Ltd,5043415350,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,214,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Forte Biosciences Inc,4297884814,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,213,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Beyondspring Inc,5052143727,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,213,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dbv Technologies SA,4295983024,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,212,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Catalyst Biosciences Inc,4295899884,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,211,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Lyra Therapeutics Inc,5000454023,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,211,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Savara Inc,4295915685,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,210,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
BioXcel Therapeutics Inc,5059088690,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,210,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Allergy Therapeutics PLC,4295894147,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,210,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zhejiang CONBA Pharmaceutical Co Ltd,4295865378,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,210,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Chembio Diagnostics Inc,4295900231,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,210,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Chembio Diagnostics Inc,4295900231,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,210,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Kangmei Pharmaceutical Co Ltd,4295865533,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,210,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Agile Therapeutics Inc,4295990208,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,209,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Centogene NV,5068331881,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,209,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Spectrum Pharmaceuticals Inc,4295907365,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,209,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Stoke Therapeutics Inc,5044099417,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,209,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Viking Therapeutics Inc,5042933582,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,208,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Nanjing King-friend Biochemical Pharmaceutical Co Ltd,5000520341,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,208,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aerie Pharmaceuticals Inc,4297213141,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,208,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SpringWorks Therapeutics Inc,5068659971,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,208,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
PDS Biotechnology Corp,5000474462,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,207,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Opthea Ltd,4295857664,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,207,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hexo Corp,5043460552,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,207,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Medical Developments International Ltd,4295857325,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,207,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
TaiMed Biologics Inc,4298124682,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,206,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bellicum Pharmaceuticals Inc,5000448724,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,206,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tonghua Dongbao Pharmaceutical Co Ltd,4295865440,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,206,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shanghai RAAS Blood Products Co Ltd,4298025328,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,205,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pulse Biosciences Inc,5064601827,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,205,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Rapt Therapeutics Inc,5046047686,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,205,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
BB Biotech AG,4295890616,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,205,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shenzhen Salubris Pharmaceuticals Co Ltd,4298150679,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,205,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Relmada Therapeutics Inc,5037949940,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,204,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mirum Pharmaceuticals Inc,5066605934,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,204,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Iteos Therapeutics Inc,5073964452,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,202,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Checkpoint Therapeutics Inc,4296562024,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,202,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alligator Bioscience AB,4295976193,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,202,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Telix Pharmaceuticals Ltd,5053083994,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,202,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Spero Therapeutics Inc,5042250852,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,201,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ergomed PLC,5042964908,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,201,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
scPharmaceuticals Inc,5042230367,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,200,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Exicure Inc,5055416070,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,199,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Clovis Oncology Inc,4298504105,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,198,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Adaptimmune Therapeutics PLC,5045847548,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,197,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shandong Buchang Pharmaceuticals Co Ltd,5000560344,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,197,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Liminal BioSciences Inc,4295861739,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,197,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Gossamer Bio Inc,5060473928,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,196,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Eton Pharmaceuticals Inc,5064704765,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,196,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Applied Therapeutics Inc,5053942137,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,196,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Surface Oncology Inc,5044199583,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,194,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aldeyra Therapeutics Inc,4297349911,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,194,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Genprex Inc,5036210734,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,194,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tasly Pharmaceutical Group Co Ltd,4295865148,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Guizhou Bailing Group Pharmaceutical Co Ltd,4298345796,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
AVROBIO Inc,5050307187,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CymaBay Therapeutics Inc,4297588727,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kezar Life Sciences Inc,5046058924,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Guizhou Bailing Group Pharmaceutical Co Ltd,4298345796,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Eloxx Pharmaceuticals Inc,4295914898,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CymaBay Therapeutics Inc,4297588727,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Eloxx Pharmaceuticals Inc,4295914898,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,192,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Jinyu Bio-Technology Co Ltd,4295864704,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,191,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Antares Pharma Inc,4295914166,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,191,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CTI Biopharma Corp,5060588775,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,191,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Curaleaf Holdings Inc,5045851306,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,190,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zentalis Pharmaceuticals Inc,5072818884,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,190,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Co-Diagnostics Inc,5040195339,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,190,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Burning Rock Biotech Ltd,5074555179,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,189,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Generation Bio Co,5060500613,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,189,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
PDL BioPharma Inc,4295907681,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Allakos Inc,5037990289,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Soleno Therapeutics Inc,4297184240,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Phathom Pharmaceuticals Inc,5069405688,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bionomics Ltd,4295856352,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Albireo Pharma Inc,4295904266,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,188,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Black Diamond Therapeutics Inc,5044168456,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,187,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
La Jolla Pharmaceutical Co,4295906958,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,187,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Evofem Biosciences Inc,4297632572,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,187,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Protara Therapeutics Inc,4296048186,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,187,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
BGI Genomics Co Ltd,5043316839,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,186,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shinpoong Pharmaceutical Co Ltd,4295881859,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,185,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Anavex Life Sciences Corp,4295899501,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,185,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Eiger BioPharmaceuticals Inc,4297271351,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,183,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Global Blood Therapeutics Inc,5037622915,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,183,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Xbrane Biopharma AB,5035526276,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,182,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Arix Bioscience PLC,5050720127,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,181,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd,5035524971,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,181,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cabaletta Bio Inc,5066607195,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,180,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sichuan Languang Development Co Ltd,4295863639,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,180,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Verrica Pharmaceuticals Inc,5045389384,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,178,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Enochian Biosciences Inc,5036384219,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,177,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Calithera Biosciences Inc,5000784443,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,175,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Turning Point Therapeutics Inc,5068346529,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,175,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hanmi Science Co Ltd,4295882141,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,175,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Paradigm Biopharmaceuticals Ltd,5044166860,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,174,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biohaven Pharmaceutical Holding Company Ltd,5040932194,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,172,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Rubius Therapeutics Inc,5045880503,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,172,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biohaven Pharmaceutical Holding Company Ltd,5040932194,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,172,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Wuhu Token Sciences Co Ltd,5000539211,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,171,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vyne Therapeutics Inc,5038045986,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,171,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Passage Bio Inc,5065980347,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,170,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tianjin Chase Sun Pharmaceutical Co Ltd,5000446260,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,170,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Evelo Biosciences Inc,5047108020,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,170,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Acceleron Pharma Inc,4296015497,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,169,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Galera Therapeutics Inc,5037989344,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,168,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Neoleukin Therapeutics Inc,4296262694,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,168,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Oncopeptides AB,4298493813,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,168,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Frequency Therapeutics Inc,5052794794,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,168,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Axcella Health Inc,5046040911,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,167,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Helixmith Co Ltd,4295881620,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,166,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Helixmith Co Ltd,4295881620,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,166,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Alteogen Inc,5035522960,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,164,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Devoteam SAS,4295868217,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,164,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Provention Bio Inc,5056411135,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,159,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Neurobo Pharmaceuticals Inc,5045853684,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,159,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Concert Pharmaceuticals Inc,4297543586,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,158,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aveo Pharmaceuticals Inc,4297278257,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,157,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
LogicBio Therapeutics Inc,5049432034,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,152,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dicerna Pharmaceuticals Inc,5034137552,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,144,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Adamas Pharmaceuticals Inc,4297309035,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,135,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Flexion Therapeutics Inc,4297906483,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,134,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mind Medicine (MindMed) Inc,5001198706,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,111,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bob Evans Farms Inc,4295905749,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,81,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Trillium Therapeutics Inc,5042941598,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,81,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Constellation Pharmaceuticals Inc,4296153489,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,75,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Array BioPharma Inc,4295901644,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,73,E_opportunity,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Aimmune Therapeutics Inc,5040059297,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,71,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aprea Therapeutics Inc,5071168699,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,69,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Keryx Biopharmaceuticals Inc,4295900456,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,67,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Foundation Medicine Inc,5000714889,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,61,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Diplomat Pharmacy Inc,4297771046,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,60,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Cassiopea SpA,5035325252,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,57,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Viela Bio Inc,5061208560,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,57,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Lundbeck Seattle Biopharmaceuticals Inc,4296032231,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,55,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Dova Pharmaceuticals Inc,5052128613,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,53,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Synthorx Inc,5042373556,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,52,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Audentes Therapeutics Inc,5040171536,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,49,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Majid Al Futtaim Holding LLC,5000030405,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,247,E_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Oryzon Genomics SA,4297159438,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,175,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Forma Therapeutics Holdings Inc,5037435569,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,107,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
INSYS Therapeutics Inc,5035155013,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,99,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
INSYS Therapeutics Inc,5035155013,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,99,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Celgene Corp,4295905897,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,99,E_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Eidos Therapeutics Inc,5055476555,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,94,E_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Forty Seven Inc,5005164140,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,93,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Immunic Inc,4295983152,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,90,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Akcea Therapeutics Inc,5046039618,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,78,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ECC Pharm Ltd,4295856905,quantitative,REPORTED,Does the company reports about take-back procedures and recycling programs to reduce the potential risks of products entering the environment?,TAKEBACK_RECYCLING_INITIATIVES,0.0,67,E_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
PharmaSGP Holding SE,5074558504,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
PharmaSGP Holding SE,5074558504,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PharmaSGP Holding SE,5074558504,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Loxam SAS,4297463274,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Loxam SAS,4297463274,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Geneuro SA,5035525137,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,133,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Athora Netherlands NV,4296558856,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,131,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Athora Netherlands NV,4296558856,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,131,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Anhui Huaheng Biotechnology Co Ltd,5043319507,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,115,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genetron Holdings Ltd,5071553510,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,104,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Medigen Vaccine Biologics Corp,5044030765,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,102,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
FYI Resources Ltd,4295857627,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,102,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Medigen Vaccine Biologics Corp,5044030765,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,102,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS,5034802731,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,98,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AMI Organics Ltd,5038066181,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,80,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AMI Organics Ltd,5038066181,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,80,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ultimovacs ASA,5038062852,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,75,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aether Industries Ltd,5064581591,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,67,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aether Industries Ltd,5064581591,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,67,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Adagio Therapeutics Inc,5076161534,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,67,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Glenmark Life Sciences Ltd,5071163514,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,55,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Glenmark Life Sciences Ltd,5071163514,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,55,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Achillion Pharmaceuticals Inc,4295902590,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,52,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Achillion Pharmaceuticals Inc,4295902590,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,52,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Synergy Pharmaceuticals LLC,5037621320,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,50,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Synergy Pharmaceuticals LLC,5037621320,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,50,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Loxo Oncology Inc,5040059115,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,43,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Loxo Oncology Inc,5040059115,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,43,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
InflaRx NV,5057951351,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,41,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rohto Pharmaceutical Co Ltd,4295877894,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rohto Pharmaceutical Co Ltd,4295877894,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Akeso Inc,5004716215,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Akeso Inc,5004716215,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Akeso Inc,5004716215,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Akeso Inc,5004716215,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Akeso Inc,5004716215,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
United Company RUSAL Plc,5000619007,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
United Company RUSAL Plc,5000619007,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Immunitybio Inc,5046045471,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Immunitybio Inc,5046045471,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
RaySearch Laboratories AB (publ),4295889885,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Certara Inc,5078554280,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Certara Inc,5078554280,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
RaySearch Laboratories AB (publ),4295889885,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Immunitybio Inc,5046045471,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Immunitybio Inc,5046045471,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Certara Inc,5078554280,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Immunitybio Inc,5046045471,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Certara Inc,5078554280,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Immunitybio Inc,5046045471,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Immunitybio Inc,5046045471,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Rapid Nutrition PLC,5042944492,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ASKA Pharmaceutical Holdings Co Ltd,5073682929,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ASKA Pharmaceutical Holdings Co Ltd,5073682929,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mochida Pharmaceutical Co Ltd,4295877793,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mochida Pharmaceutical Co Ltd,4295877793,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
HLS Therapeutics Inc,5062411003,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
HLS Therapeutics Inc,5062411003,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
HLS Therapeutics Inc,5062411003,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
VIVA Biotech Holdings,5064663384,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
VIVA Biotech Holdings,5064663384,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PharmaEngine Inc,5035255012,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PharmaEngine Inc,5035255012,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PharmaEngine Inc,5035255012,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PharmaEngine Inc,5035255012,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hikal Ltd,4295873814,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,215,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vaxcyte Inc,5040942643,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,215,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Vaxcyte Inc,5040942643,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,215,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vaxcyte Inc,5040942643,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,215,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vaxcyte Inc,5040942643,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,215,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hikal Ltd,4295873814,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,215,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hikal Ltd,4295873814,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,215,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hikal Ltd,4295873814,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,215,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neuland Laboratories Ltd,4295872314,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neuland Laboratories Ltd,4295872314,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neuland Laboratories Ltd,4295872314,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Summit Therapeutics Inc,5076940644,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Summit Therapeutics Inc,5076940644,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shandong Xinhua Pharmaceutical Co Ltd,4295864184,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Shandong Xinhua Pharmaceutical Co Ltd,4295864184,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Ascentage Pharma Group International,5071509965,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Ascentage Pharma Group International,5071509965,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sun Pharma Advanced Research Co Ltd,4295872154,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sun Pharma Advanced Research Co Ltd,4295872154,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Silence Therapeutics PLC,4295895614,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Silence Therapeutics PLC,4295895614,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hofseth Biocare ASA,5035906262,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Silence Therapeutics PLC,4295895614,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hofseth Biocare ASA,5035906262,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Jacobson Pharma Corporation Ltd,5050900566,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Supply_Chain_Integrity
Jacobson Pharma Corporation Ltd,5050900566,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kuros Biosciences AG,4295890889,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Jacobson Pharma Corporation Ltd,5050900566,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Jacobson Pharma Corporation Ltd,5050900566,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orchid Pharma Ltd,4295872729,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Medivir AB,4295890107,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Orchid Pharma Ltd,4295872729,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orchid Pharma Ltd,4295872729,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orchid Pharma Ltd,4295872729,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genovis AB,4295890384,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Genovis AB,4295890384,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Genovis AB,4295890384,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Genovis AB,4295890384,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Genovis AB,4295890384,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Genovis AB,4295890384,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,200,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,200,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Legend Biotech Corp,5056412290,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Legend Biotech Corp,5056412290,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Shattuck Labs Inc,5051773339,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Legend Biotech Corp,5056412290,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Legend Biotech Corp,5056412290,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shattuck Labs Inc,5051773339,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shattuck Labs Inc,5051773339,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Legend Biotech Corp,5056412290,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Immunovant Inc,5068663165,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,198,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Immunovant Inc,5068663165,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,198,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Immunovant Inc,5068663165,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,198,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Abbott India Ltd,4295873246,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Annexon Inc,5038791948,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pembangunan Perumahan (Persero) Tbk PT,4295933662,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pembangunan Perumahan (Persero) Tbk PT,4295933662,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Newron Pharmaceuticals SpA,4295875695,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Annexon Inc,5038791948,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Abbott India Ltd,4295873246,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fine Foods & Pharmaceuticals NTM SpA,5052128850,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Newron Pharmaceuticals SpA,4295875695,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Annexon Inc,5038791948,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Newron Pharmaceuticals SpA,4295875695,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Pembangunan Perumahan (Persero) Tbk PT,4295933662,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fine Foods & Pharmaceuticals NTM SpA,5052128850,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Annexon Inc,5038791948,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Seer Inc,5060207077,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,193,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Seer Inc,5060207077,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,193,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Chunghwa Chemical Synthesis & Biotech Co Ltd,4297933413,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,193,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Seer Inc,5060207077,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,193,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chunghwa Chemical Synthesis & Biotech Co Ltd,4297933413,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,193,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alterity Therapeutics Ltd,4295857196,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alterity Therapeutics Ltd,4295857196,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Alterity Therapeutics Ltd,4295857196,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ALX Oncology Holdings Inc,5074847748,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Wakamoto Pharmaceutical Co Ltd,4295878544,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sigilon Therapeutics Inc,5055943391,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Miko NV,4295859478,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Sigilon Therapeutics Inc,5055943391,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Miko NV,4295859478,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Miko NV,4295859478,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Marksans Pharma Ltd,4295873633,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Miko NV,4295859478,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Sigilon Therapeutics Inc,5055943391,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Novartis India Ltd,4295872270,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Marksans Pharma Ltd,4295873633,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novartis India Ltd,4295872270,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Miko NV,4295859478,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Miko NV,4295859478,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
PharmaEssentia Corp,4297703294,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,190,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PharmaEssentia Corp,4297703294,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,190,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Taiwan FamilyMart Co Ltd,4295892674,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aptose Biosciences Inc,4295861982,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Taiwan FamilyMart Co Ltd,4295892674,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aptose Biosciences Inc,4295861982,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Taiwan FamilyMart Co Ltd,4295892674,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aptose Biosciences Inc,4295861982,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BioInvent International AB,4295889923,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Alpha Teknova Inc,5002454841,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Indoco Remedies Ltd,4295873905,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alpha Teknova Inc,5002454841,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Antibiotice SA,4296440714,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bolt Biotherapeutics Inc,5057818417,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Antibiotice SA,4296440714,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Bolt Biotherapeutics Inc,5057818417,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Organon & Co,5080031678,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BioInvent International AB,4295889923,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Organon & Co,5080031678,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BioInvent International AB,4295889923,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Indoco Remedies Ltd,4295873905,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bolt Biotherapeutics Inc,5057818417,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Antibiotice SA,4296440714,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Antibiotice SA,4296440714,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Astria Therapeutics Inc,4298140380,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astria Therapeutics Inc,4298140380,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Antibiotice SA,4296440714,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Astria Therapeutics Inc,4298140380,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Astria Therapeutics Inc,4298140380,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alpha Teknova Inc,5002454841,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Indoco Remedies Ltd,4295873905,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Antibiotice SA,4296440714,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Antibiotice SA,4296440714,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
4D Molecular Therapeutics Inc,5046652758,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
4D Molecular Therapeutics Inc,5046652758,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Inozyme Pharma Inc,5052794383,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Inozyme Pharma Inc,5052794383,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ikena Oncology Inc,5059957115,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Granules India Ltd,4295873932,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kronos Bio Inc,5064284477,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kronos Bio Inc,5064284477,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ikena Oncology Inc,5059957115,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ikena Oncology Inc,5059957115,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kronos Bio Inc,5064284477,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ikena Oncology Inc,5059957115,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Granules India Ltd,4295873932,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kronos Bio Inc,5064284477,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Atea Pharmaceuticals Inc,5040791368,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Atea Pharmaceuticals Inc,5040791368,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zevra Therapeutics Inc,5044167023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Atea Pharmaceuticals Inc,5040791368,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zevra Therapeutics Inc,5044167023,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zevra Therapeutics Inc,5044167023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Atea Pharmaceuticals Inc,5040791368,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ProQR Therapeutics NV,5038906661,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Quince Therapeutics Inc,5042946656,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ProQR Therapeutics NV,5038906661,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Akoya Biosciences Inc,5056728883,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Quince Therapeutics Inc,5042946656,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Avenue Therapeutics Inc,5045106861,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Jiangsu Nhwa Pharmaceutical Co Ltd,4298052371,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Avenue Therapeutics Inc,5045106861,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Akoya Biosciences Inc,5056728883,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ProQR Therapeutics NV,5038906661,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Athira Pharma Inc,5057940063,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Galectin Therapeutics Inc,4295908397,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Athira Pharma Inc,5057940063,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Galectin Therapeutics Inc,4295908397,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Athira Pharma Inc,5057940063,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Athira Pharma Inc,5057940063,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Athira Pharma Inc,5057940063,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Imugene Ltd,4295858255,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Imugene Ltd,4295858255,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Imugene Ltd,4295858255,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Imugene Ltd,4295858255,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Ampio Pharmaceuticals Inc,5000686554,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Ampio Pharmaceuticals Inc,5000686554,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kyorin Pharmaceutical Co Ltd,4295880327,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Brainstorm Cell Therapeutics Inc,4295899439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Actinium Pharmaceuticals Inc,5039585048,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Actinium Pharmaceuticals Inc,5039585048,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Actinium Pharmaceuticals Inc,5039585048,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Actinium Pharmaceuticals Inc,5039585048,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Brainstorm Cell Therapeutics Inc,4295899439,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Brainstorm Cell Therapeutics Inc,4295899439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chinook Therapeutics Inc,4298084379,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Chongkundang Holdings Corp,4295880919,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Navamedic ASA,4297516229,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chinook Therapeutics Inc,4298084379,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Chongkundang Holdings Corp,4295880919,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chongkundang Holdings Corp,4295880919,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Austar Lifesciences Ltd,5044029401,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Frontage Holdings Corp,5068328255,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,176,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
SeQuent Scientific Ltd,4295873850,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,176,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Frontage Holdings Corp,5068328255,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,176,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
SeQuent Scientific Ltd,4295873850,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,176,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Caplin Point Laboratories Ltd,4296008194,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Caplin Point Laboratories Ltd,4296008194,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nanobiotix SA,4297696426,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nanobiotix SA,4297696426,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Caplin Point Laboratories Ltd,4296008194,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Adimmune Corp,4296974440,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Adimmune Corp,4296974440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rapid Micro Biosystems Inc,4297712966,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Merrimack Pharmaceuticals Inc,5001210278,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Merrimack Pharmaceuticals Inc,5001210278,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rapid Micro Biosystems Inc,4297712966,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Merrimack Pharmaceuticals Inc,5001210278,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Lavipharm SA,4295870454,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,173,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China NT Pharma Group Company Ltd,5034759579,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,173,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Indofarma Tbk PT,4295874355,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,173,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Terns Pharmaceuticals Inc,5079683393,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Terns Pharmaceuticals Inc,5079683393,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CureVac NV,5076167305,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
CureVac NV,5076167305,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Seelos Therapeutics Inc,4295914354,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Seelos Therapeutics Inc,4295914354,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CureVac NV,5076167305,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CureVac NV,5076167305,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Terns Pharmaceuticals Inc,5079683393,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biomea Fusion Inc,5079682650,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
89Bio Inc,5071508069,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Absci Corp,5041077561,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Biomea Fusion Inc,5079682650,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
89Bio Inc,5071508069,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Biomea Fusion Inc,5079682650,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Biomea Fusion Inc,5079682650,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Biomea Fusion Inc,5079682650,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Square Pharmaceuticals PLC,4295917193,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Absci Corp,5041077561,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Praxis Precision Medicines Inc,5052506535,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
TIE Kinetix NV,4295884984,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Praxis Precision Medicines Inc,5052506535,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
COFCO Biotechnology Co Ltd,4295864904,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Praxis Precision Medicines Inc,5052506535,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Enliven Therapeutics Inc,5050721453,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,169,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Calliditas Therapeutics AB,5035524063,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,169,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Enliven Therapeutics Inc,5050721453,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,169,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
NeuBase Therapeutics Inc,4295905287,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eterna Therapeutics Inc,4295904574,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
BELLUS Health Inc (Pre Merger),5037589093,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Fuji Pharma Co Ltd,4295879670,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lumos Pharma Inc,4296943235,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eterna Therapeutics Inc,4295904574,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
NeuBase Therapeutics Inc,4295905287,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
BRAIN Biotech AG,5001178117,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BRAIN Biotech AG,5001178117,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kimia Farma Tbk PT,4295874603,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Kinnate Biopharma Inc,5064597398,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kinnate Biopharma Inc,5064597398,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kinnate Biopharma Inc,5064597398,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Landos Biopharma Inc,5057796911,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Lyell Immunopharma Inc,5068932905,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Lyell Immunopharma Inc,5068932905,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Minerva Neurosciences Inc,5035525714,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Landos Biopharma Inc,5057796911,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Minerva Neurosciences Inc,5035525714,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bliss GVS Pharma Ltd,4295872849,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Law Debenture Corporation PLC,4295894011,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bliss GVS Pharma Ltd,4295872849,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Porton Pharma Solutions Ltd,5035549423,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Porton Pharma Solutions Ltd,5035549423,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cullinan Oncology Inc,5072825369,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Prelude Therapeutics Inc,5057989338,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Telesis Bio Inc,5057828183,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
PMV Pharmaceuticals Inc,5041748144,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Formosa Laboratories Inc,4297684222,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
PMV Pharmaceuticals Inc,5041748144,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Formosa Laboratories Inc,4297684222,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Telesis Bio Inc,5057828183,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Prelude Therapeutics Inc,5057989338,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cullinan Oncology Inc,5072825369,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Prelude Therapeutics Inc,5057989338,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Caribou Biosciences Inc,5044007186,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Caribou Biosciences Inc,5044007186,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cullinan Oncology Inc,5072825369,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mustang Bio Inc,5045675573,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mustang Bio Inc,5045675573,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Mustang Bio Inc,5045675573,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Finch Therapeutics Group Inc,5058533657,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,162,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Finch Therapeutics Group Inc,5058533657,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,162,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Semen Baturaja (Persero) Tbk PT,5000035952,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Janux Therapeutics Inc,5066630289,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Semen Baturaja (Persero) Tbk PT,5000035952,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Epigenomics AG,4295870322,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Dyne Therapeutics Inc,5068481524,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Semen Baturaja (Persero) Tbk PT,5000035952,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Semen Baturaja (Persero) Tbk PT,5000035952,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Epigenomics AG,4295870322,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Dyne Therapeutics Inc,5068481524,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Janux Therapeutics Inc,5066630289,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Intervacc AB,5037142061,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Deva Holding AS,4295893628,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Semen Baturaja (Persero) Tbk PT,5000035952,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Janux Therapeutics Inc,5066630289,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,161,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Oric Pharmaceuticals Inc,5047749756,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,160,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
DaShenLin Pharmaceutical Group Co Ltd,5000560542,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,160,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
DaShenLin Pharmaceutical Group Co Ltd,5000560542,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,160,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Oric Pharmaceuticals Inc,5047749756,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,160,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oric Pharmaceuticals Inc,5047749756,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,160,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oric Pharmaceuticals Inc,5047749756,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,160,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Beximco Pharmaceuticals Ltd,4295917535,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dong-A Socio Holdings Co Ltd,4295881559,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Beximco Pharmaceuticals Ltd,4295917535,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Instil Bio Inc,5071491737,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Unichem Laboratories Ltd,4295873083,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Northwest Biotherapeutics Inc,4295901912,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Pioneer Holding Ltd,5040256767,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Eris Lifesciences Ltd,5037652293,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
TCR2 Therapeutics Inc,5048737252,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eris Lifesciences Ltd,5037652293,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Spruce Biosciences Inc,5050913816,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang Medicine Co Ltd,4295864865,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Science in Sport PLC,5040055145,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Science in Sport PLC,5040055145,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Eris Lifesciences Ltd,5037652293,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Spruce Biosciences Inc,5050913816,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Spruce Biosciences Inc,5050913816,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
TCR2 Therapeutics Inc,5048737252,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
TCR2 Therapeutics Inc,5048737252,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
TCR2 Therapeutics Inc,5048737252,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ocugen Inc,4297321713,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Standard Chem & Pharm Co Ltd,4295891132,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ocugen Inc,4297321713,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Atossa Therapeutics Inc,5000707569,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Atossa Therapeutics Inc,5000707569,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Atossa Therapeutics Inc,5000707569,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
PolyPeptide Group AG,5080152257,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,156,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dong Suh Companies Inc,4295882549,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,156,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dong Suh Companies Inc,4295882549,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,156,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
PolyPeptide Group AG,5080152257,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,156,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Torii Pharmaceutical Co Ltd,4295879868,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,156,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Dong Suh Companies Inc,4295882549,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,156,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
PolyPeptide Group AG,5080152257,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,156,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GP Strategies Corp,4295904038,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
EirGenix Inc,5043462764,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
CASI Pharmaceuticals Inc(Pre-Merger),4295906369,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
IMV Inc,4297852426,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Omega Therapeutics Inc,5071401332,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biofrontera AG,4295870275,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
GP Strategies Corp,4295904038,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Verve Therapeutics Inc,5074728022,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
GP Strategies Corp,4295904038,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
EirGenix Inc,5043462764,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Omega Therapeutics Inc,5071401332,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
CASI Pharmaceuticals Inc(Pre-Merger),4295906369,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Medincell SA,5035542581,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Verve Therapeutics Inc,5074728022,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Medincell SA,5035542581,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Omega Therapeutics Inc,5071401332,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Omega Therapeutics Inc,5071401332,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,155,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Citius Pharmaceuticals Inc,5001218237,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sensei Biotherapeutics Inc,5079691095,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sensei Biotherapeutics Inc,5079691095,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Matinas BioPharma Holdings Inc,5040202545,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Matinas BioPharma Holdings Inc,5040202545,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aerovate Therapeutics Inc,5073109516,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aerovate Therapeutics Inc,5073109516,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Enorama Pharma AB,5050902994,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Matinas BioPharma Holdings Inc,5040202545,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Singular Genomics Systems Inc,5059153058,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sensei Biotherapeutics Inc,5079691095,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Citius Pharmaceuticals Inc,5001218237,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Singular Genomics Systems Inc,5059153058,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Singular Genomics Systems Inc,5059153058,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aerovate Therapeutics Inc,5073109516,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aerovate Therapeutics Inc,5073109516,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Isu Petasys Co Ltd,4295882697,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Acumen Pharmaceuticals Inc,4296014538,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Neptune Wellness Solutions Inc,4296393502,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Acumen Pharmaceuticals Inc,4296014538,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Neptune Wellness Solutions Inc,4296393502,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Isu Petasys Co Ltd,4295882697,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Acumen Pharmaceuticals Inc,4296014538,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neptune Wellness Solutions Inc,4296393502,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Neptune Wellness Solutions Inc,4296393502,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Corvus Pharmaceuticals Inc,5044197894,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,152,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Werewolf Therapeutics Inc,5067952090,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,151,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Werewolf Therapeutics Inc,5067952090,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,151,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Werewolf Therapeutics Inc,5067952090,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,151,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhejiang Xianju Pharmaceutical Co Ltd,4297898688,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,149,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aarti Drugs Ltd,4295873816,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,149,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aarti Drugs Ltd,4295873816,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,149,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sana Biotechnology Inc,5067499873,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,148,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Design Therapeutics Inc,5071512585,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,148,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Design Therapeutics Inc,5071512585,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,148,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sana Biotechnology Inc,5067499873,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,148,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sana Biotechnology Inc,5067499873,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,148,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Century Therapeutics Inc,5070761830,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Advanz Pharma Corp Ltd,5073343758,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Century Therapeutics Inc,5070761830,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nuvation Bio Inc,5074742864,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Century Therapeutics Inc,5070761830,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nuvation Bio Inc,5074742864,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Suven Pharmaceuticals Ltd,5067941170,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Arena Pharmaceuticals Inc,4295900428,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CohBar Inc,5037441109,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Arena Pharmaceuticals Inc,4295900428,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Suven Pharmaceuticals Ltd,5067941170,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CohBar Inc,5037441109,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,146,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ouro Fino Saude Animal Participacoes SA,5043460110,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nymox Pharmaceutical Corp,5052544527,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nymox Pharmaceutical Corp,5052544527,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Synmosa Biopharma Corp,4295892235,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Prometheus Biosciences Inc,5057940357,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Olema Pharmaceuticals Inc,5035547611,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Olema Pharmaceuticals Inc,5035547611,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Edgewise Therapeutics Inc,5071163582,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Olema Pharmaceuticals Inc,5035547611,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Humanigen Inc,4297292034,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Edgewise Therapeutics Inc,5071163582,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
SillaJen Inc,5040702572,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Humanigen Inc,4297292034,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Chemical & Pharmaceutical Co Ltd,4295891334,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
YungShin Global Holding Corp,5035905365,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SillaJen Inc,5040702572,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Prometheus Biosciences Inc,5057940357,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
I-Mab,5055417724,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Magenta Therapeutics Inc,5052528282,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PhaseBio Pharmaceuticals Inc,5035400506,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
I-Mab,5055417724,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
I-Mab,5055417724,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
I-Mab,5055417724,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Magenta Therapeutics Inc,5052528282,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PhaseBio Pharmaceuticals Inc,5035400506,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ContraFect Corp,5001150224,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ContraFect Corp,5001150224,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
I-Mab,5055417724,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,143,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shanghai Haohai Biological Technology Co Ltd,5037587864,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,142,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Kaleido Biosciences Inc,5051609503,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,142,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kaleido Biosciences Inc,5051609503,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,142,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kaleido Biosciences Inc,5051609503,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,142,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Anhui Anke Biotechnology Group Co Ltd,4296976195,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,142,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vera Therapeutics Inc,5079115565,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,141,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sinphar Pharmaceutical Co Ltd,4295892650,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,141,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vera Therapeutics Inc,5079115565,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,141,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Erasca Inc,5067176358,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,140,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Mayinglong Pharmaceutical Group Co Ltd,4295865408,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,140,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Erasca Inc,5067176358,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,140,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Erasca Inc,5067176358,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,140,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Il Dong Pharmaceutical Co Ltd,5041976716,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Il Dong Pharmaceutical Co Ltd,5041976716,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Panion & BF Biotech Inc,4295891914,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Henan Lingrui Pharmaceutical Co Ltd,4295863627,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,138,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dishman Carbogen Amcis Ltd,5036349504,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,138,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dishman Carbogen Amcis Ltd,5036349504,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,138,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Icosavax Inc,5071500169,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Tricida Inc,5041066023,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
9 Meters Biopharma Inc,5037627414,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cerevel Therapeutics Holdings Inc,5078356542,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
9 Meters Biopharma Inc,5037627414,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Progenics Pharmaceuticals Inc,4295907672,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oncorus Inc,5050715269,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
9 Meters Biopharma Inc,5037627414,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oncorus Inc,5050715269,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Icosavax Inc,5071500169,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cerevel Therapeutics Holdings Inc,5078356542,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cerevel Therapeutics Holdings Inc,5078356542,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oncorus Inc,5050715269,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Icosavax Inc,5071500169,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tricida Inc,5041066023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Progenics Pharmaceuticals Inc,4295907672,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,137,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Suheung Co Ltd,4295882180,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tenaya Therapeutics Inc,5052537650,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Graphite Bio Inc,5076089527,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Tenaya Therapeutics Inc,5052537650,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Suheung Co Ltd,4295882180,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tenaya Therapeutics Inc,5052537650,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Tenaya Therapeutics Inc,5052537650,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Graphite Bio Inc,5076089527,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Morepen Laboratories Ltd,4295872885,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Graphite Bio Inc,5076089527,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,136,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
AMAG Pharmaceuticals Inc,4295903284,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nacon SAS,5071563934,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oyster Point Pharma Inc,5050914678,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Greenwich Lifesciences Inc,5037125444,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
AMAG Pharmaceuticals Inc,4295903284,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Nacon SAS,5071563934,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Greenwich Lifesciences Inc,5037125444,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Oyster Point Pharma Inc,5050914678,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Immuneering Corp,5035545616,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ARS Pharmaceuticals Inc,5050718646,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ARS Pharmaceuticals Inc,5050718646,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Immuneering Corp,5035545616,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ARS Pharmaceuticals Inc,5050718646,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tyme Technologies Inc,5044009440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tyme Technologies Inc,5044009440,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Immuneering Corp,5035545616,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Momenta Pharmaceuticals Inc,4295905231,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Momenta Pharmaceuticals Inc,4295905231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Monte Rosa Therapeutics Inc,5076946858,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,133,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
GW Pharmaceuticals Ltd,4295894440,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,133,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Monte Rosa Therapeutics Inc,5076946858,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,133,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hitachi High-Tech Corp,4295878681,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,132,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sprint Bioscience AB,5001222098,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Relx NV,4295884735,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,129,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vincerx Pharma Inc,5073341405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,129,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Reneo Pharmaceuticals Inc,5045824255,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,129,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vincerx Pharma Inc,5073341405,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,129,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Reneo Pharmaceuticals Inc,5045824255,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,129,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Reneo Pharmaceuticals Inc,5045824255,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,129,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
TotalEnergies Marketing Nigeria PLC,4295885263,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,128,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Poxel SA,5000786315,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,127,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Rain Oncology Inc,5059955326,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,125,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rain Oncology Inc,5059955326,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,125,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Rain Oncology Inc,5059955326,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,125,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cyteir Therapeutics Inc,5043952888,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,124,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dong-A ST Co Ltd,5039189081,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,124,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cyteir Therapeutics Inc,5043952888,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,124,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Relief Therapeutics Holding SA,5000098134,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,120,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Relief Therapeutics Holding SA,5000098134,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,120,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Satsuma Pharmaceuticals Inc,5052544073,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,119,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Satsuma Pharmaceuticals Inc,5052544073,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,119,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Yixintang Pharmaceutical Group Co Ltd,4298345694,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,114,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Yixintang Pharmaceutical Group Co Ltd,4298345694,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,114,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Yixintang Pharmaceutical Group Co Ltd,4298345694,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,114,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Portola Pharmaceuticals LLC,4296948764,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,112,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Portola Pharmaceuticals LLC,4296948764,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,112,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
GlaxoSmithKline Consumer Healthcare Ltd,4295872411,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,112,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biovica International AB,5055421891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,112,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Stemline Therapeutics Inc,4295969989,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,110,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Stemline Therapeutics Inc,4295969989,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,110,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kindred Biosciences Inc,5037962380,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,110,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Translate Bio Inc,5064608221,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,107,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Translate Bio Inc,5064608221,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,107,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Translate Bio Inc,5064608221,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,107,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Correvio Pharma Corp,5063766186,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,106,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Correvio Pharma Corp,5063766186,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,106,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Akouos Inc,5059037223,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,103,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Akouos Inc,5059037223,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,103,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Disc Medicine Inc,5076167270,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,101,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Disc Medicine Inc,5076167270,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,101,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Disc Medicine Inc,5076167270,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,101,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Disc Medicine Inc,5076167270,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,101,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Talaris Therapeutics Inc,5019146218,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,96,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Talaris Therapeutics Inc,5019146218,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,96,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bio-On SpA,5035553307,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,89,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bio-On SpA,5035553307,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,89,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,434,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,434,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,434,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,434,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,434,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,434,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,431,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,431,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,431,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,431,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,431,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,431,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,431,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,431,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Johnson & Johnson,4295904341,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,423,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Johnson & Johnson,4295904341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,423,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Johnson & Johnson,4295904341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,423,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Johnson & Johnson,4295904341,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,423,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Johnson & Johnson,4295904341,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,423,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Johnson & Johnson,4295904341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,423,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novartis AG,4295890628,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novartis AG,4295890628,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novartis AG,4295890628,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novartis AG,4295890628,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novartis AG,4295890628,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novartis AG,4295890628,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,414,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,408,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,408,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,408,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,408,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,405,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,405,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,405,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,405,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,405,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,405,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,403,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,403,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,403,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,403,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,403,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,392,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,392,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,392,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,392,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AstraZeneca PLC,4295894341,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ALK-Abello A/S,4295866060,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ALK-Abello A/S,4295866060,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AstraZeneca PLC,4295894341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ALK-Abello A/S,4295866060,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AstraZeneca PLC,4295894341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AstraZeneca PLC,4295894341,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ALK-Abello A/S,4295866060,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AstraZeneca PLC,4295894341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ALK-Abello A/S,4295866060,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,391,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,390,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,390,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,390,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,390,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,390,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,390,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,390,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,388,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,388,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,388,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,388,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,388,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,388,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,388,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,386,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,386,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,386,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,386,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,386,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck & Co Inc,4295904886,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,385,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck & Co Inc,4295904886,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,385,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck & Co Inc,4295904886,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,385,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck & Co Inc,4295904886,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,385,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck & Co Inc,4295904886,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,385,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck & Co Inc,4295904886,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,385,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck & Co Inc,4295904886,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,385,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Corcept Therapeutics Inc,4295899705,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,384,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Corcept Therapeutics Inc,4295899705,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,384,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Corcept Therapeutics Inc,4295899705,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,384,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Corcept Therapeutics Inc,4295899705,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,384,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,383,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,383,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,383,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lonza Group AG,5000030891,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,382,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lonza Group AG,5000030891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,382,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lonza Group AG,5000030891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,382,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lonza Group AG,5000030891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,382,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lonza Group AG,5000030891,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,382,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CVS Health Corp,4295903627,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CVS Health Corp,4295903627,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CVS Health Corp,4295903627,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CVS Health Corp,4295903627,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bayer AG,4295869217,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CVS Health Corp,4295903627,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bayer AG,4295869217,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bayer AG,4295869217,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bayer AG,4295869217,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CVS Health Corp,4295903627,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,381,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ipsen SA,4295868520,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ipsen SA,4295868520,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Ipsen SA,4295868520,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ipsen SA,4295868520,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Livzon Pharmaceutical Group Inc,4295863969,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ipsen SA,4295868520,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ipsen SA,4295868520,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ipsen SA,4295868520,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,378,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GSK plc,4295895781,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GSK plc,4295895781,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aurobindo Pharma Ltd,4295872481,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GSK plc,4295895781,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GSK plc,4295895781,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,376,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,373,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,373,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,373,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,373,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,373,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,373,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biocon Ltd,4295873833,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,372,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Biocon Ltd,4295873833,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,372,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biocon Ltd,4295873833,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,372,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Biocon Ltd,4295873833,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,372,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biocon Ltd,4295873833,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,372,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Biocon Ltd,4295873833,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,372,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Biocon Ltd,4295873833,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,372,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biocon Ltd,4295873833,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,372,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Perrigo Company PLC,5040203322,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Siegfried Holding AG,5000066884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Siegfried Holding AG,5000066884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Perrigo Company PLC,5040203322,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Perrigo Company PLC,5040203322,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Perrigo Company PLC,5040203322,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Siegfried Holding AG,5000066884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Perrigo Company PLC,5040203322,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Perrigo Company PLC,5040203322,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Siegfried Holding AG,5000066884,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Siegfried Holding AG,5000066884,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,371,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eisai Co Ltd,4295876894,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eisai Co Ltd,4295876894,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eisai Co Ltd,4295876894,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eisai Co Ltd,4295876894,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,370,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,368,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ucb SA,4295859381,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CSL Ltd,4295856855,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CSL Ltd,4295856855,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CSL Ltd,4295856855,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CSL Ltd,4295856855,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CSL Ltd,4295856855,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Ucb SA,4295859381,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ucb SA,4295859381,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ucb SA,4295859381,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,367,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lupin Ltd,4295873497,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,366,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lupin Ltd,4295873497,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,366,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lupin Ltd,4295873497,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,366,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lupin Ltd,4295873497,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,366,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lupin Ltd,4295873497,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,366,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Grifols SA,4295889506,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,365,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Grifols SA,4295889506,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,365,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Grifols SA,4295889506,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,365,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Grifols SA,4295889506,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,365,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Grifols SA,4295889506,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,365,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Grifols SA,4295889506,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,365,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sino Biopharmaceutical Ltd,4295871031,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,363,S_opportunity,Biotechnology & Pharmaceuticals,2018,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Virbac SA,4295866672,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,362,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Virbac SA,4295866672,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,362,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Virbac SA,4295866672,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,362,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Virbac SA,4295866672,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,362,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Virbac SA,4295866672,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,362,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alnylam Pharmaceuticals Inc,4295916167,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Adcock Ingram Holdings Ltd,4298082482,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,360,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,359,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,359,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,359,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,359,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,359,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,359,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,359,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tsumura & Co,4295878528,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,357,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Tsumura & Co,4295878528,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,357,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Tsumura & Co,4295878528,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,357,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tsumura & Co,4295878528,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,357,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Tsumura & Co,4295878528,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,357,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Tsumura & Co,4295878528,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,357,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Evotec SE,5068477440,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Evotec SE,5068477440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orion Oyj,4295866566,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orion Oyj,4295866566,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orion Oyj,4295866566,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Evotec SE,5068477440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Evotec SE,5068477440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orion Oyj,4295866566,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orion Oyj,4295866566,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Evotec SE,5068477440,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Orion Oyj,4295866566,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orion Oyj,4295866566,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,356,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Samsung Biologics Co Ltd,5035458824,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Prestige Consumer Healthcare Inc,4295907295,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Prestige Consumer Healthcare Inc,4295907295,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Prestige Consumer Healthcare Inc,4295907295,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Prestige Consumer Healthcare Inc,4295907295,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Prestige Consumer Healthcare Inc,4295907295,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,355,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bio Rad Laboratories Inc,4295908554,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mesa Laboratories Inc,4295907138,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mesa Laboratories Inc,4295907138,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bio Rad Laboratories Inc,4295908554,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mesa Laboratories Inc,4295907138,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kalbe Farma Tbk PT,4295874370,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,354,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biomarin Pharmaceutical Inc,4295912660,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,353,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biomarin Pharmaceutical Inc,4295912660,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,353,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biomarin Pharmaceutical Inc,4295912660,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,353,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
DXP Enterprises Inc,4295906126,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
DXP Enterprises Inc,4295906126,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
DXP Enterprises Inc,4295906126,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
DXP Enterprises Inc,4295906126,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,352,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,351,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,351,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,351,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,351,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
IDEXX Laboratories Inc,4295906763,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,349,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
IDEXX Laboratories Inc,4295906763,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,349,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
IDEXX Laboratories Inc,4295906763,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,349,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Genscript Biotech Corp,5047817370,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,347,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celldex Therapeutics Inc,4297103233,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Hypera SA,4297927148,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celldex Therapeutics Inc,4297103233,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hypera SA,4297927148,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2017,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Hypera SA,4297927148,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celldex Therapeutics Inc,4297103233,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hypera SA,4297927148,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hypera SA,4297927148,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celldex Therapeutics Inc,4297103233,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Celldex Therapeutics Inc,4297103233,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Celldex Therapeutics Inc,4297103233,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Celldex Therapeutics Inc,4297103233,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hypera SA,4297927148,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,346,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,344,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,344,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,344,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,344,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ionis Pharmaceuticals Inc,4295906873,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ionis Pharmaceuticals Inc,4295906873,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ionis Pharmaceuticals Inc,4295906873,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ionis Pharmaceuticals Inc,4295906873,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ionis Pharmaceuticals Inc,4295906873,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,343,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Galapagos NV,4295859376,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,341,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Galapagos NV,4295859376,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,341,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Galapagos NV,4295859376,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,341,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Galapagos NV,4295859376,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,341,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Galapagos NV,4295859376,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,341,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Galapagos NV,4295859376,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,341,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alkermes Plc,5035456435,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,340,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alkermes Plc,5035456435,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,340,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Alkermes Plc,5035456435,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,340,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Alkermes Plc,5035456435,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,340,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Alkermes Plc,5035456435,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,340,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alkermes Plc,5035456435,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,340,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alkermes Plc,5035456435,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,340,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neurocrine Biosciences Inc,4295907381,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Merck KGaA,4295869098,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pacira Biosciences Inc,4297853578,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pacira Biosciences Inc,4297853578,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pacira Biosciences Inc,4297853578,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck KGaA,4295869098,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neurocrine Biosciences Inc,4295907381,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pacira Biosciences Inc,4297853578,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Merck KGaA,4295869098,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pacira Biosciences Inc,4297853578,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck KGaA,4295869098,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pacira Biosciences Inc,4297853578,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neurocrine Biosciences Inc,4295907381,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neurocrine Biosciences Inc,4295907381,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Merck KGaA,4295869098,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,339,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genmab A/S,4295866092,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genmab A/S,4295866092,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genmab A/S,4295866092,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genmab A/S,4295866092,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genmab A/S,4295866092,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,338,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Insight Enterprises Inc,4295906810,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Insight Enterprises Inc,4295906810,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Insight Enterprises Inc,4295906810,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Insight Enterprises Inc,4295906810,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,337,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syngene International Ltd,4298178079,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,336,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syngene International Ltd,4298178079,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,336,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syngene International Ltd,4298178079,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,336,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syngene International Ltd,4298178079,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,336,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syngene International Ltd,4298178079,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,336,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Viatris Inc,5035523437,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amicus Therapeutics Inc,4295902550,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Amicus Therapeutics Inc,4295902550,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Viatris Inc,5035523437,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amicus Therapeutics Inc,4295902550,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amicus Therapeutics Inc,4295902550,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amicus Therapeutics Inc,4295902550,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Viatris Inc,5035523437,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amicus Therapeutics Inc,4295902550,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,335,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ICON PLC,4295874891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ICON PLC,4295874891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ICON PLC,4295874891,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
ICON PLC,4295874891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Torrent Pharmaceuticals Ltd,4295872667,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ICON PLC,4295874891,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
ICON PLC,4295874891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,334,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,333,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,333,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,333,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,333,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,333,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vertex Pharmaceuticals Inc,4295908317,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,333,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,333,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
American Superconductor Corp,4295905527,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,332,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Phibro Animal Health Corp,5034074360,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,332,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
American Superconductor Corp,4295905527,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,332,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
American Superconductor Corp,4295905527,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,332,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Phibro Animal Health Corp,5034074360,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,332,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
American Superconductor Corp,4295905527,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,332,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Phibro Animal Health Corp,5034074360,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,332,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,331,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,331,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,331,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,331,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ACADIA Pharmaceuticals Inc,4295903398,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fate Therapeutics Inc,4296275166,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ACADIA Pharmaceuticals Inc,4295903398,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ACADIA Pharmaceuticals Inc,4295903398,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
ACADIA Pharmaceuticals Inc,4295903398,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Fate Therapeutics Inc,4296275166,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Fate Therapeutics Inc,4296275166,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ACADIA Pharmaceuticals Inc,4295903398,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Fate Therapeutics Inc,4296275166,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Fate Therapeutics Inc,4296275166,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ACADIA Pharmaceuticals Inc,4295903398,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,330,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bavarian Nordic A/S,4295866173,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,329,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ANI Pharmaceuticals Inc,4295902157,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,329,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Supernus Pharmaceuticals Inc,4297350707,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,329,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Supernus Pharmaceuticals Inc,4297350707,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,329,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bavarian Nordic A/S,4295866173,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,329,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Supernus Pharmaceuticals Inc,4297350707,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,329,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bavarian Nordic A/S,4295866173,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,329,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ANI Pharmaceuticals Inc,4295902157,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,329,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Wockhardt Ltd,4295873567,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,328,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Wockhardt Ltd,4295873567,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,328,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Wockhardt Ltd,4295873567,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,328,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Wockhardt Ltd,4295873567,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,328,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Wockhardt Ltd,4295873567,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,328,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Werner Enterprises Inc,4295908451,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
IPCA Laboratories Ltd,4295873554,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
IPCA Laboratories Ltd,4295873554,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Werner Enterprises Inc,4295908451,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Werner Enterprises Inc,4295908451,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Werner Enterprises Inc,4295908451,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,327,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Roche Holding AG,4295890594,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,326,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Roche Holding AG,4295890594,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,326,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Roche Holding AG,4295890594,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,326,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Roche Holding AG,4295890594,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,326,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Roche Holding AG,4295890594,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,326,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Integra Lifesciences Holdings Corp,4295906823,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,324,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Integra Lifesciences Holdings Corp,4295906823,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,324,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Integra Lifesciences Holdings Corp,4295906823,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,324,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Integra Lifesciences Holdings Corp,4295906823,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,324,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Integra Lifesciences Holdings Corp,4295906823,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,324,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Integra Lifesciences Holdings Corp,4295906823,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,324,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,323,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,323,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,323,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,323,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,323,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Quest Diagnostics Inc,4295904788,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Quest Diagnostics Inc,4295904788,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Starpharma Holdings Ltd,4295856781,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
3SBio Inc,4295863999,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Quest Diagnostics Inc,4295904788,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Quest Diagnostics Inc,4295904788,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Starpharma Holdings Ltd,4295856781,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
3SBio Inc,4295863999,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Quest Diagnostics Inc,4295904788,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Starpharma Holdings Ltd,4295856781,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Starpharma Holdings Ltd,4295856781,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Quest Diagnostics Inc,4295904788,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,322,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Blackmores Ltd,4295856664,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,321,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Blackmores Ltd,4295856664,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,321,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Blackmores Ltd,4295856664,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,321,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Blackmores Ltd,4295856664,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,321,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Omega Healthcare Investors Inc,4295904656,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Omega Healthcare Investors Inc,4295904656,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Omega Healthcare Investors Inc,4295904656,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
United Therapeutics Corp,4295915261,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
United Therapeutics Corp,4295915261,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Omega Healthcare Investors Inc,4295904656,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Omega Healthcare Investors Inc,4295904656,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Omega Healthcare Investors Inc,4295904656,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Omega Healthcare Investors Inc,4295904656,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
United Therapeutics Corp,4295915261,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,320,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amphastar Pharmaceuticals Inc,4297971432,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amphastar Pharmaceuticals Inc,4297971432,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amphastar Pharmaceuticals Inc,4297971432,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Amphastar Pharmaceuticals Inc,4297971432,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,319,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
BioCryst Pharmaceuticals Inc,4295905725,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
argenx SE,5000263797,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
BioCryst Pharmaceuticals Inc,4295905725,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang Nhu Co Ltd,4295864955,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhejiang Nhu Co Ltd,4295864955,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
BioCryst Pharmaceuticals Inc,4295905725,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang Nhu Co Ltd,4295864955,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
argenx SE,5000263797,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
BioCryst Pharmaceuticals Inc,4295905725,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhejiang Nhu Co Ltd,4295864955,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Zhejiang Nhu Co Ltd,4295864955,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Zhejiang Nhu Co Ltd,4295864955,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
argenx SE,5000263797,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
argenx SE,5000263797,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
argenx SE,5000263797,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhejiang Nhu Co Ltd,4295864955,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
argenx SE,5000263797,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
argenx SE,5000263797,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
argenx SE,5000263797,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,318,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Heron Therapeutics Inc,4295905439,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Novavax Inc,4295904633,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Novavax Inc,4295904633,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Novavax Inc,4295904633,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Novavax Inc,4295904633,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Heron Therapeutics Inc,4295905439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Heron Therapeutics Inc,4295905439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Novavax Inc,4295904633,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Luye Pharma Group Ltd,4295887822,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,316,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bachem Holding AG,5000073936,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oriola Oyj,4295866498,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pacific Biosciences of California Inc,4296988897,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oriola Oyj,4295866498,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Agenus Inc,4295912530,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Agenus Inc,4295912530,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Agenus Inc,4295912530,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bachem Holding AG,5000073936,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bachem Holding AG,5000073936,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pacific Biosciences of California Inc,4296988897,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aclaris Therapeutics Inc,5037844397,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oriola Oyj,4295866498,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,315,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rigel Pharmaceuticals Inc,4295915993,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Beigene Ltd,5046048089,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rigel Pharmaceuticals Inc,4295915993,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Denali Therapeutics Inc,5045948499,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Denali Therapeutics Inc,5045948499,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Beigene Ltd,5046048089,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Beigene Ltd,5046048089,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zydus Lifesciences Ltd,4295873709,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Denali Therapeutics Inc,5045948499,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Denali Therapeutics Inc,5045948499,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rigel Pharmaceuticals Inc,4295915993,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Beigene Ltd,5046048089,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Beigene Ltd,5046048089,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Fox Factory Holding Corp,5000166256,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Beigene Ltd,5046048089,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Denali Therapeutics Inc,5045948499,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,313,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tong Ren Tang Technologies Co Ltd,4295864045,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,312,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Ligand Pharmaceuticals Inc,4295907009,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,312,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tong Ren Tang Technologies Co Ltd,4295864045,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,312,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ligand Pharmaceuticals Inc,4295907009,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,312,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sarepta Therapeutics Inc,4295905395,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Precigen Inc,4297774183,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Precigen Inc,4297774183,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sarepta Therapeutics Inc,4295905395,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Elanco Animal Health Inc,4296365146,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Precigen Inc,4297774183,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Sarepta Therapeutics Inc,4295905395,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Precigen Inc,4297774183,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sarepta Therapeutics Inc,4295905395,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sarepta Therapeutics Inc,4295905395,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Sarepta Therapeutics Inc,4295905395,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Precigen Inc,4297774183,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sarepta Therapeutics Inc,4295905395,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,311,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Vanda Pharmaceuticals Inc,4295899966,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Vanda Pharmaceuticals Inc,4295899966,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi AppTec Co Ltd,5000217387,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Intellia Therapeutics Inc,5044066446,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vanda Pharmaceuticals Inc,4295899966,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Intellia Therapeutics Inc,5044066446,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Intellia Therapeutics Inc,5044066446,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Intellia Therapeutics Inc,5044066446,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vanda Pharmaceuticals Inc,4295899966,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,310,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Science Applications International Corp,5039584611,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
H Lundbeck A/S,4295866154,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Science Applications International Corp,5039584611,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
H Lundbeck A/S,4295866154,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Science Applications International Corp,5039584611,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
H Lundbeck A/S,4295866154,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
H Lundbeck A/S,4295866154,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Science Applications International Corp,5039584611,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
H Lundbeck A/S,4295866154,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,308,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Enanta Pharmaceuticals Inc,4296904058,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,307,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Enanta Pharmaceuticals Inc,4296904058,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,307,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Enanta Pharmaceuticals Inc,4296904058,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,307,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Fulgent Genetics Inc,5051396874,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,306,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fulgent Genetics Inc,5051396874,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,306,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fulgent Genetics Inc,5051396874,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,306,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Fulgent Genetics Inc,5051396874,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,306,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
MannKind Corp,4295903432,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,305,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
MannKind Corp,4295903432,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,305,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
MannKind Corp,4295903432,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,305,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Agios Pharmaceuticals Inc,4298032874,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Agios Pharmaceuticals Inc,4298032874,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Agios Pharmaceuticals Inc,4298032874,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,304,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mesoblast Ltd,4295858844,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mesoblast Ltd,4295858844,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mesoblast Ltd,4295858844,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Prothena Corporation PLC,5037961722,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Prothena Corporation PLC,5037961722,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Prothena Corporation PLC,5037961722,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sangamo Therapeutics Inc,4295914874,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sangamo Therapeutics Inc,4295914874,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sangamo Therapeutics Inc,4295914874,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mesoblast Ltd,4295858844,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Prothena Corporation PLC,5037961722,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Sangamo Therapeutics Inc,4295914874,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,303,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Inovio Pharmaceuticals Inc,4295901003,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,302,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Inovio Pharmaceuticals Inc,4295901003,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,302,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Inovio Pharmaceuticals Inc,4295901003,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,302,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Halozyme Therapeutics Inc,4295915674,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,302,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Halozyme Therapeutics Inc,4295915674,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,302,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Halozyme Therapeutics Inc,4295915674,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,302,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Halozyme Therapeutics Inc,4295915674,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,302,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Wolverine World Wide Inc,4295905354,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,301,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Seres Therapeutics Inc,5037639494,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,301,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Seres Therapeutics Inc,5037639494,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,301,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Wolverine World Wide Inc,4295905354,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,301,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Seres Therapeutics Inc,5037639494,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,301,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Wolverine World Wide Inc,4295905354,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,301,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Wolverine World Wide Inc,4295905354,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,301,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Wolverine World Wide Inc,4295905354,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,301,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Editas Medicine Inc,5040699642,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Collegium Pharmaceutical Inc,5045917401,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Collegium Pharmaceutical Inc,5045917401,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zealand Pharma A/S,4295989612,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Zealand Pharma A/S,4295989612,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zealand Pharma A/S,4295989612,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Editas Medicine Inc,5040699642,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Collegium Pharmaceutical Inc,5045917401,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Collegium Pharmaceutical Inc,5045917401,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Editas Medicine Inc,5040699642,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Editas Medicine Inc,5040699642,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Collegium Pharmaceutical Inc,5045917401,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,300,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eagle Pharmaceuticals Inc,4296474346,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Akebia Therapeutics Inc,4297878446,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Amneal Pharmaceuticals Inc,5062782308,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amneal Pharmaceuticals Inc,5062782308,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Apellis Pharmaceuticals Inc,5000744891,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eagle Pharmaceuticals Inc,4296474346,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eagle Pharmaceuticals Inc,4296474346,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Akebia Therapeutics Inc,4297878446,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Akebia Therapeutics Inc,4297878446,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Apellis Pharmaceuticals Inc,5000744891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Akebia Therapeutics Inc,4297878446,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Eagle Pharmaceuticals Inc,4296474346,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Akebia Therapeutics Inc,4297878446,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Apellis Pharmaceuticals Inc,5000744891,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Akebia Therapeutics Inc,4297878446,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Amneal Pharmaceuticals Inc,5062782308,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Apellis Pharmaceuticals Inc,5000744891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amneal Pharmaceuticals Inc,5062782308,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,299,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Anika Therapeutics Inc,5068320253,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Anika Therapeutics Inc,5068320253,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Anika Therapeutics Inc,5068320253,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Anika Therapeutics Inc,5068320253,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,298,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
American Vanguard Corp,4295903372,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hisamitsu Pharmaceutical Co Inc,4295877610,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hisamitsu Pharmaceutical Co Inc,4295877610,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hisamitsu Pharmaceutical Co Inc,4295877610,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
American Vanguard Corp,4295903372,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hisamitsu Pharmaceutical Co Inc,4295877610,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hanmi Pharm Co Ltd,5000805170,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,297,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Guardant Health Inc,5041079009,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Guardant Health Inc,5041079009,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Guardant Health Inc,5041079009,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Innovent Biologics Inc,5066579901,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
MorphoSys AG,4295869785,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
MorphoSys AG,4295869785,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
MorphoSys AG,4295869785,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Guardant Health Inc,5041079009,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Guardant Health Inc,5041079009,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Guardant Health Inc,5041079009,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,296,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Seagen Inc,4295901424,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,295,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Seagen Inc,4295901424,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,295,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Seagen Inc,4295901424,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,295,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Seagen Inc,4295901424,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,295,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Humanwell Healthcare Group Co Ltd,4295865648,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Myriad Genetics Inc,4295907228,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Humanwell Healthcare Group Co Ltd,4295865648,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Humanwell Healthcare Group Co Ltd,4295865648,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Nektar Therapeutics,4295906807,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nektar Therapeutics,4295906807,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Myriad Genetics Inc,4295907228,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Myriad Genetics Inc,4295907228,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Humanwell Healthcare Group Co Ltd,4295865648,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Myriad Genetics Inc,4295907228,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nektar Therapeutics,4295906807,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Humanwell Healthcare Group Co Ltd,4295865648,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Humanwell Healthcare Group Co Ltd,4295865648,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,294,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Avid Bioservices Inc,4295915112,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,293,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Avid Bioservices Inc,4295915112,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,293,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Avid Bioservices Inc,4295915112,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,293,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Knight Therapeutics Inc,5046438291,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Theravance Biopharma Inc,5040202678,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Veru Inc,4295906439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Theravance Biopharma Inc,5040202678,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Veru Inc,4295906439,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Theravance Biopharma Inc,5040202678,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Knight Therapeutics Inc,5046438291,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Knight Therapeutics Inc,5046438291,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Knight Therapeutics Inc,5046438291,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Veru Inc,4295906439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Theravance Biopharma Inc,5040202678,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Veru Inc,4295906439,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Veru Inc,4295906439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,292,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Biogaia AB,4295890085,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sosei Group Corp,4295880658,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biogaia AB,4295890085,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biogaia AB,4295890085,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sosei Group Corp,4295880658,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sosei Group Corp,4295880658,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biogaia AB,4295890085,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Yuhan Corp,4295881557,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Yuhan Corp,4295881557,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sosei Group Corp,4295880658,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biogaia AB,4295890085,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Yuhan Corp,4295881557,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Yuhan Corp,4295881557,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,291,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oxford Biomedica PLC,4295895244,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Huadong Medicine Co Ltd,4295864428,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Huadong Medicine Co Ltd,4295864428,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Huadong Medicine Co Ltd,4295864428,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Huadong Medicine Co Ltd,4295864428,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Oxford Biomedica PLC,4295895244,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oxford Biomedica PLC,4295895244,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oxford Biomedica PLC,4295895244,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Accelerate Diagnostics Inc,5038034917,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Oxford Biomedica PLC,4295895244,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oxford Biomedica PLC,4295895244,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Huadong Medicine Co Ltd,4295864428,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Accelerate Diagnostics Inc,5038034917,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Huadong Medicine Co Ltd,4295864428,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Huadong Medicine Co Ltd,4295864428,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,290,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Moderna Inc,5066596648,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Coherus BioSciences Inc,5037455589,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Moderna Inc,5066596648,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Moderna Inc,5066596648,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Coherus BioSciences Inc,5037455589,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Coherus BioSciences Inc,5037455589,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ironwood Pharmaceuticals Inc,4295940206,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Moderna Inc,5066596648,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ironwood Pharmaceuticals Inc,4295940206,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Ironwood Pharmaceuticals Inc,4295940206,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Moderna Inc,5066596648,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Moderna Inc,5066596648,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Coherus BioSciences Inc,5037455589,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Coherus BioSciences Inc,5037455589,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Moderna Inc,5066596648,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Moderna Inc,5066596648,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ironwood Pharmaceuticals Inc,4295940206,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,289,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SIGA Technologies Inc,4295914936,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
SIGA Technologies Inc,4295914936,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SIGA Technologies Inc,4295914936,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pharma Mar SA,5000066579,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Natural Grocers By Vitamin Cottage Inc,5037624117,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Pharma Mar SA,5000066579,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Natural Grocers By Vitamin Cottage Inc,5037624117,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Pharma Mar SA,5000066579,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
SIGA Technologies Inc,4295914936,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SIGA Technologies Inc,4295914936,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pharma Mar SA,5000066579,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Natural Grocers By Vitamin Cottage Inc,5037624117,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Natural Grocers By Vitamin Cottage Inc,5037624117,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Natural Grocers By Vitamin Cottage Inc,5037624117,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Natural Grocers By Vitamin Cottage Inc,5037624117,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SIGA Technologies Inc,4295914936,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,288,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Krka dd Novo Mesto,4295888307,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Krka dd Novo Mesto,4295888307,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Krka dd Novo Mesto,4295888307,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2018,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Krka dd Novo Mesto,4295888307,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,286,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Catalyst Pharmaceuticals Inc,4295902234,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Travere Therapeutics Inc,4296438961,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Arvinas Inc,5046736907,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Lineage Cell Therapeutics Inc,4295903583,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
PTC Therapeutics Inc,4296025423,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Arvinas Inc,5046736907,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Travere Therapeutics Inc,4296438961,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Lineage Cell Therapeutics Inc,4295903583,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
PTC Therapeutics Inc,4296025423,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Arvinas Inc,5046736907,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Lineage Cell Therapeutics Inc,4295903583,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lineage Cell Therapeutics Inc,4295903583,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lineage Cell Therapeutics Inc,4295903583,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
PTC Therapeutics Inc,4296025423,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Travere Therapeutics Inc,4296438961,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
PTC Therapeutics Inc,4296025423,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Catalyst Pharmaceuticals Inc,4295902234,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Catalyst Pharmaceuticals Inc,4295902234,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Catalyst Pharmaceuticals Inc,4295902234,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Catalyst Pharmaceuticals Inc,4295902234,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,285,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Jazz Pharmaceuticals PLC,4297329846,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,284,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jazz Pharmaceuticals PLC,4297329846,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,284,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Jazz Pharmaceuticals PLC,4297329846,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,284,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Jazz Pharmaceuticals PLC,4297329846,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,284,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Jazz Pharmaceuticals PLC,4297329846,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,284,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vifor Pharma AG,4295890653,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vifor Pharma AG,4295890653,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Almirall SA,4295889280,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2018,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vifor Pharma AG,4295890653,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Harrow Health Inc,4295902339,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Vifor Pharma AG,4295890653,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vaxart Inc,4295907233,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vaxart Inc,4295907233,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Almirall SA,4295889280,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vaxart Inc,4295907233,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
VBI Vaccines Inc,4295861984,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
VBI Vaccines Inc,4295861984,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Harrow Health Inc,4295902339,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
VBI Vaccines Inc,4295861984,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Harrow Health Inc,4295902339,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,283,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
WAVE Life Sciences Ltd,5041069029,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,282,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cara Therapeutics Inc,4297277386,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,282,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
WAVE Life Sciences Ltd,5041069029,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,282,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
WAVE Life Sciences Ltd,5041069029,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,282,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cara Therapeutics Inc,4297277386,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,282,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cara Therapeutics Inc,4297277386,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,282,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cara Therapeutics Inc,4297277386,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,282,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cara Therapeutics Inc,4297277386,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,282,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
XOMA Corp,5037133783,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,281,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
XOMA Corp,5037133783,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,281,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
XOMA Corp,5037133783,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,281,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
XOMA Corp,5037133783,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,281,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,280,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,280,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,280,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,280,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,280,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,280,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Boiron SA,4295867491,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Otsuka Holdings Co Ltd,5000073379,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Boiron SA,4295867491,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Proto Labs Inc,4298059665,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Puma Biotechnology Inc,4297723879,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Otsuka Holdings Co Ltd,5000073379,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Proto Labs Inc,4298059665,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
OptiNose Inc,5043339171,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Puma Biotechnology Inc,4297723879,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Proto Labs Inc,4298059665,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Otsuka Holdings Co Ltd,5000073379,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Puma Biotechnology Inc,4297723879,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
OptiNose Inc,5043339171,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Puma Biotechnology Inc,4297723879,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
OptiNose Inc,5043339171,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Boiron SA,4295867491,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Otsuka Holdings Co Ltd,5000073379,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
OptiNose Inc,5043339171,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Otsuka Holdings Co Ltd,5000073379,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Otsuka Holdings Co Ltd,5000073379,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Puma Biotechnology Inc,4297723879,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Puma Biotechnology Inc,4297723879,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
OptiNose Inc,5043339171,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,279,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Biotest AG,4295868772,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biotest AG,4295868772,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Alliance Pharma PLC,4295896230,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Revance Therapeutics Inc,4296286413,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Arbutus Biopharma Corp,5063095367,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Arbutus Biopharma Corp,5063095367,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Retail Opportunity Investments Corp,4295912075,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Biotest AG,4295868772,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Revance Therapeutics Inc,4296286413,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Retail Opportunity Investments Corp,4295912075,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Retail Opportunity Investments Corp,4295912075,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Alliance Pharma PLC,4295896230,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Retail Opportunity Investments Corp,4295912075,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biotest AG,4295868772,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
MeiraGTx Holdings PLC,5063761745,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Arbutus Biopharma Corp,5063095367,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alliance Pharma PLC,4295896230,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biotest AG,4295868772,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Retail Opportunity Investments Corp,4295912075,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alliance Pharma PLC,4295896230,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
MeiraGTx Holdings PLC,5063761745,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
MeiraGTx Holdings PLC,5063761745,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Revance Therapeutics Inc,4296286413,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Revance Therapeutics Inc,4296286413,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Arbutus Biopharma Corp,5063095367,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
MeiraGTx Holdings PLC,5063761745,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Arbutus Biopharma Corp,5063095367,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,278,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Taisho Pharmaceutical Holdings Co Ltd,5035303233,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,277,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Taisho Pharmaceutical Holdings Co Ltd,5035303233,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,277,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Twist Bioscience Corp,5040185976,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,277,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Twist Bioscience Corp,5040185976,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,277,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Royalty Pharma PLC,5031889023,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,276,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Royalty Pharma PLC,5031889023,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,276,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Royalty Pharma PLC,5031889023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,276,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Royalty Pharma PLC,5031889023,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,276,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Royalty Pharma PLC,5031889023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,276,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Royalty Pharma PLC,5031889023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,276,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Revolution Medicines Inc,5044506598,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Organogenesis Holdings Inc,5067949286,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Revolution Medicines Inc,5044506598,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Revolution Medicines Inc,5044506598,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Revolution Medicines Inc,5044506598,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Organogenesis Holdings Inc,5067949286,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Revolution Medicines Inc,5044506598,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Revolution Medicines Inc,5044506598,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Revolution Medicines Inc,5044506598,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Organogenesis Holdings Inc,5067949286,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,274,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Intra-Cellular Therapies Inc,5038989170,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Intra-Cellular Therapies Inc,5038989170,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Intra-Cellular Therapies Inc,5038989170,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
EyePoint Pharmaceuticals Inc,4295857066,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Camurus AB,5035523580,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Intra-Cellular Therapies Inc,5038989170,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Camurus AB,5035523580,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Intra-Cellular Therapies Inc,5038989170,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Supply_Chain_Integrity
Camurus AB,5035523580,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Camurus AB,5035523580,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Camurus AB,5035523580,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,273,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Probi AB,4295890448,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Core Laboratories NV,4295884861,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Indivior PLC,5044066242,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Probi AB,4295890448,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Indivior PLC,5044066242,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Probi AB,4295890448,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Core Laboratories NV,4295884861,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Core Laboratories NV,4295884861,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Probi AB,4295890448,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Indivior PLC,5044066242,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Core Laboratories NV,4295884861,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Probi AB,4295890448,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Core Laboratories NV,4295884861,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Probi AB,4295890448,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Indivior PLC,5044066242,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,272,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Meridian Bioscience Inc,4295907136,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Deciphera Pharmaceuticals Inc,5057832486,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Meridian Bioscience Inc,4295907136,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vir Biotechnology Inc,5052795509,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Deciphera Pharmaceuticals Inc,5057832486,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vir Biotechnology Inc,5052795509,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Deciphera Pharmaceuticals Inc,5057832486,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Deciphera Pharmaceuticals Inc,5057832486,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vir Biotechnology Inc,5052795509,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Vir Biotechnology Inc,5052795509,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vir Biotechnology Inc,5052795509,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vir Biotechnology Inc,5052795509,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Vir Biotechnology Inc,5052795509,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,271,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Axsome Therapeutics Inc,5039864624,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Horizon Therapeutics PLC,5037276891,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Lifecore Biomedical Inc,4295906967,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Axsome Therapeutics Inc,5039864624,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Axsome Therapeutics Inc,5039864624,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Axsome Therapeutics Inc,5039864624,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Horizon Therapeutics PLC,5037276891,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Axsome Therapeutics Inc,5039864624,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Axsome Therapeutics Inc,5039864624,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Lifecore Biomedical Inc,4295906967,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lifecore Biomedical Inc,4295906967,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Axsome Therapeutics Inc,5039864624,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Axsome Therapeutics Inc,5039864624,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,270,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Harvard Bioscience Inc,4295902196,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aquestive Therapeutics Inc,5031994451,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aquestive Therapeutics Inc,5031994451,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Harvard Bioscience Inc,4295902196,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Harvard Bioscience Inc,4295902196,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Harvard Bioscience Inc,4295902196,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aquestive Therapeutics Inc,5031994451,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,269,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Acrux Ltd,4295858548,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,268,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Acrux Ltd,4295858548,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,268,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Acrux Ltd,4295858548,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,268,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Acrux Ltd,4295858548,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,268,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Acrux Ltd,4295858548,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,268,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
TG Therapeutics Inc,4295912581,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Marker Therapeutics Inc,5066581785,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Celltrion Inc,5000076514,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Celltrion Inc,5000076514,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Marker Therapeutics Inc,5066581785,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Marker Therapeutics Inc,5066581785,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
TG Therapeutics Inc,4295912581,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Celltrion Inc,5000076514,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Marker Therapeutics Inc,5066581785,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celltrion Inc,5000076514,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,267,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
G1 Therapeutics Inc,5035526162,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Endo International PLC,5040791002,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Mallinckrodt PLC,5038068684,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Polynovo Ltd,4295857937,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Endo International PLC,5040791002,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Polynovo Ltd,4295857937,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mallinckrodt PLC,5038068684,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mallinckrodt PLC,5038068684,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Mallinckrodt PLC,5038068684,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mallinckrodt PLC,5038068684,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
G1 Therapeutics Inc,5035526162,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Protagonist Therapeutics Inc,5037933405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Endo International PLC,5040791002,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mallinckrodt PLC,5038068684,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Polynovo Ltd,4295857937,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
G1 Therapeutics Inc,5035526162,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Protagonist Therapeutics Inc,5037933405,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Polynovo Ltd,4295857937,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Polynovo Ltd,4295857937,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Mallinckrodt PLC,5038068684,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,266,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zai Lab Ltd,5057819640,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Benchmark Holdings PLC,5003638730,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
STADA Arzneimittel AG,4295869543,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alaunos Therapeutics Inc,4295902600,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Benchmark Holdings PLC,5003638730,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
STADA Arzneimittel AG,4295869543,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zai Lab Ltd,5057819640,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
STADA Arzneimittel AG,4295869543,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alaunos Therapeutics Inc,4295902600,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ibio Inc,4298054794,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Benchmark Holdings PLC,5003638730,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zai Lab Ltd,5057819640,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zai Lab Ltd,5057819640,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Benchmark Holdings PLC,5003638730,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ibio Inc,4298054794,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zai Lab Ltd,5057819640,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alaunos Therapeutics Inc,4295902600,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,265,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Voyager Therapeutics Inc,5041076755,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hansa Biopharma AB,4298014997,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Voyager Therapeutics Inc,5041076755,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Redcare Pharmacy NV,5052123270,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Redcare Pharmacy NV,5052123270,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Voyager Therapeutics Inc,5041076755,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Redcare Pharmacy NV,5052123270,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Redcare Pharmacy NV,5052123270,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Redcare Pharmacy NV,5052123270,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,264,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Reata Pharmaceuticals Inc,5000090491,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Syneos Health Inc,5040258481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Reata Pharmaceuticals Inc,5000090491,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Celltrion Pharm Inc,4295882372,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Midsona AB,4295890221,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Midsona AB,4295890221,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celltrion Pharm Inc,4295882372,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Midsona AB,4295890221,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syneos Health Inc,5040258481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celltrion Pharm Inc,4295882372,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Pieris Pharmaceuticals Inc,5040241774,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Syneos Health Inc,5040258481,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celltrion Pharm Inc,4295882372,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Syneos Health Inc,5040258481,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Midsona AB,4295890221,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pieris Pharmaceuticals Inc,5040241774,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Midsona AB,4295890221,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syneos Health Inc,5040258481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Midsona AB,4295890221,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celltrion Pharm Inc,4295882372,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Reata Pharmaceuticals Inc,5000090491,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Celltrion Pharm Inc,4295882372,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Celltrion Pharm Inc,4295882372,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syneos Health Inc,5040258481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,263,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Faes Farma SA,4295889471,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AcelRx Pharmaceuticals Inc,4297543075,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cellectis SA,4295868150,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cellectis SA,4295868150,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
AcelRx Pharmaceuticals Inc,4297543075,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cellectis SA,4295868150,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cellectis SA,4295868150,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Faes Farma SA,4295889471,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
AcelRx Pharmaceuticals Inc,4297543075,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Faes Farma SA,4295889471,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Faes Farma SA,4295889471,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,262,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Karyopharm Therapeutics Inc,5001437822,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,261,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Karyopharm Therapeutics Inc,5001437822,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,261,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
SSY Group Ltd,4295865393,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,261,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SSY Group Ltd,4295865393,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,261,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Karyopharm Therapeutics Inc,5001437822,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,261,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SSY Group Ltd,4295865393,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,261,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Ascendis Pharma A/S,4297931709,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Syros Pharmaceuticals Inc,5037818300,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ascendis Pharma A/S,4297931709,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ascendis Pharma A/S,4297931709,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Syros Pharmaceuticals Inc,5037818300,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ascendis Pharma A/S,4297931709,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syros Pharmaceuticals Inc,5037818300,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syros Pharmaceuticals Inc,5037818300,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ascendis Pharma A/S,4297931709,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Syros Pharmaceuticals Inc,5037818300,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,260,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cosmo Pharmaceuticals NV,5051001094,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,259,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,259,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,259,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,259,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cosmo Pharmaceuticals NV,5051001094,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,259,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cosmo Pharmaceuticals NV,5051001094,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,259,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cosmo Pharmaceuticals NV,5051001094,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,259,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Evolus Inc,5038792215,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
NGM Biopharmaceuticals Inc,4297800748,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Evolus Inc,5038792215,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
NGM Biopharmaceuticals Inc,4297800748,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CanSino Biologics Inc,5037456309,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
NGM Biopharmaceuticals Inc,4297800748,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Urogen Pharma Ltd,5035535486,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Urogen Pharma Ltd,5035535486,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Castle Biosciences Inc,5000451463,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Castle Biosciences Inc,5000451463,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aurinia Pharmaceuticals Inc,5000451880,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
vTv Therapeutics Inc,5046056658,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Evolus Inc,5038792215,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Castle Biosciences Inc,5000451463,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
vTv Therapeutics Inc,5046056658,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aurinia Pharmaceuticals Inc,5000451880,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aurinia Pharmaceuticals Inc,5000451880,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Castle Biosciences Inc,5000451463,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CorMedix Inc,5000592140,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
vTv Therapeutics Inc,5046056658,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
NGM Biopharmaceuticals Inc,4297800748,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aurinia Pharmaceuticals Inc,5000451880,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Evolus Inc,5038792215,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CorMedix Inc,5000592140,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CorMedix Inc,5000592140,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aurinia Pharmaceuticals Inc,5000451880,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,258,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
BioNTech SE,5071170280,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Curis Inc,4295906080,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Arrowhead Pharmaceuticals Inc,4295913831,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
BioNTech SE,5071170280,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BioNTech SE,5071170280,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Arrowhead Pharmaceuticals Inc,4295913831,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Curis Inc,4295906080,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
BioNTech SE,5071170280,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Curis Inc,4295906080,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Arrowhead Pharmaceuticals Inc,4295913831,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Vetoquinol SA,4298441722,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,257,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Madrigal Pharmaceuticals Inc,4295899733,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Valneva SE,4297009143,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ECO Animal Health Group PLC,4295895203,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Madrigal Pharmaceuticals Inc,4295899733,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ECO Animal Health Group PLC,4295895203,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Supply_Chain_Integrity
ECO Animal Health Group PLC,4295895203,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Valneva SE,4297009143,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ECO Animal Health Group PLC,4295895203,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ECO Animal Health Group PLC,4295895203,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Supply_Chain_Integrity
ECO Animal Health Group PLC,4295895203,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Valneva SE,4297009143,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
ECO Animal Health Group PLC,4295895203,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Valneva SE,4297009143,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Madrigal Pharmaceuticals Inc,4295899733,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Madrigal Pharmaceuticals Inc,4295899733,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ECO Animal Health Group PLC,4295895203,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Valneva SE,4297009143,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,256,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Harmony Biosciences Holdings Inc,5076167827,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Harmony Biosciences Holdings Inc,5076167827,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Harmony Biosciences Holdings Inc,5076167827,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Sutro Biopharma Inc,5017515126,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sutro Biopharma Inc,5017515126,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Idorsia Ltd,5056400072,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sutro Biopharma Inc,5017515126,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Idorsia Ltd,5056400072,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Idorsia Ltd,5056400072,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Harmony Biosciences Holdings Inc,5076167827,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Harmony Biosciences Holdings Inc,5076167827,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Idorsia Ltd,5056400072,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,255,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zentiva SA,4296393146,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Alector Inc,5066605183,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zentiva SA,4296393146,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Medigene AG,4295869325,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zentiva SA,4296393146,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zentiva SA,4296393146,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Alector Inc,5066605183,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alector Inc,5066605183,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Medigene AG,4295869325,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Alector Inc,5066605183,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Medigene AG,4295869325,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,254,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Mersana Therapeutics Inc,4298068040,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lotus Pharmaceutical Co Ltd,4295892568,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fortress Biotech Inc,5035420209,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Scandi Standard AB (publ),5040249601,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lotus Pharmaceutical Co Ltd,4295892568,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Atara Biotherapeutics Inc,5037937603,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mersana Therapeutics Inc,4298068040,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mersana Therapeutics Inc,4298068040,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Fortress Biotech Inc,5035420209,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Scandi Standard AB (publ),5040249601,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Inotiv Inc,4295905723,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mersana Therapeutics Inc,4298068040,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Scandi Standard AB (publ),5040249601,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Atara Biotherapeutics Inc,5037937603,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Scandi Standard AB (publ),5040249601,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fortress Biotech Inc,5035420209,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Inotiv Inc,4295905723,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Mersana Therapeutics Inc,4298068040,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Atara Biotherapeutics Inc,5037937603,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Inotiv Inc,4295905723,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Scandi Standard AB (publ),5040249601,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,253,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Addex Therapeutics Ltd,4295890551,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Mithra Pharmaceuticals SA,5000960352,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Albioma SAS,4295866947,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Albioma SAS,4295866947,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Albioma SAS,4295866947,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mithra Pharmaceuticals SA,5000960352,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Addex Therapeutics Ltd,4295890551,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Addex Therapeutics Ltd,4295890551,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mithra Pharmaceuticals SA,5000960352,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
AddLife AB,5050647517,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CytomX Therapeutics Inc,5040944268,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
AddLife AB,5050647517,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AddLife AB,5050647517,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Addex Therapeutics Ltd,4295890551,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Albioma SAS,4295866947,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CytomX Therapeutics Inc,5040944268,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Addex Therapeutics Ltd,4295890551,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AddLife AB,5050647517,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mithra Pharmaceuticals SA,5000960352,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CytomX Therapeutics Inc,5040944268,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,252,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Walvax Biotechnology Co Ltd,5001170754,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Walvax Biotechnology Co Ltd,5001170754,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Pharming Group NV,4295884868,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Walvax Biotechnology Co Ltd,5001170754,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Molecular Templates Inc,4295908364,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Pharming Group NV,4295884868,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pharming Group NV,4295884868,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CEL-SCI Corp,4295903677,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CEL-SCI Corp,4295903677,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Adaptive Biotechnologies Corp,5000627106,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Molecular Templates Inc,4295908364,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Pharming Group NV,4295884868,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Molecular Templates Inc,4295908364,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Walvax Biotechnology Co Ltd,5001170754,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Adaptive Biotechnologies Corp,5000627106,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CEL-SCI Corp,4295903677,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Walvax Biotechnology Co Ltd,5001170754,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pharming Group NV,4295884868,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Molecular Templates Inc,4295908364,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,251,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Arcturus Therapeutics Holdings Inc,5068339275,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cue Biopharma Inc,5046434620,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cue Biopharma Inc,5046434620,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cue Biopharma Inc,5046434620,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Beam Therapeutics Inc,5063164263,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sanofi India Ltd,4295872276,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sanofi India Ltd,4295872276,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Beam Therapeutics Inc,5063164263,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Arcturus Therapeutics Holdings Inc,5068339275,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cue Biopharma Inc,5046434620,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Beam Therapeutics Inc,5063164263,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Arcturus Therapeutics Holdings Inc,5068339275,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Beam Therapeutics Inc,5063164263,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,250,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Lexicon Pharmaceuticals Inc,4295914055,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kala Pharmaceuticals Inc,5000621507,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lexicon Pharmaceuticals Inc,4295914055,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Orexo AB,4295890191,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kala Pharmaceuticals Inc,5000621507,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Orexo AB,4295890191,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orexo AB,4295890191,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kala Pharmaceuticals Inc,5000621507,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orexo AB,4295890191,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orexo AB,4295890191,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Crinetics Pharmaceuticals Inc,5037611560,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lexicon Pharmaceuticals Inc,4295914055,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kala Pharmaceuticals Inc,5000621507,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Crinetics Pharmaceuticals Inc,5037611560,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kala Pharmaceuticals Inc,5000621507,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Lexicon Pharmaceuticals Inc,4295914055,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Crinetics Pharmaceuticals Inc,5037611560,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,249,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Precision BioSciences Inc,5035539845,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,248,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cardiff Oncology Inc,4296438979,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,248,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cardiff Oncology Inc,4296438979,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,248,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Precision BioSciences Inc,5035539845,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,248,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Precision BioSciences Inc,5035539845,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,248,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kaken Pharmaceutical Co Ltd,4295878524,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,248,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Assembly Biosciences Inc,5001158603,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Intercept Pharmaceuticals Inc,4296966741,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Assembly Biosciences Inc,5001158603,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Esperion Therapeutics Inc,4295900449,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Assembly Biosciences Inc,5001158603,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
MaxCyte Inc,4297024126,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Personalis Inc,5037652668,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Assembly Biosciences Inc,5001158603,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Intercept Pharmaceuticals Inc,4296966741,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Assembly Biosciences Inc,5001158603,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Scholar Rock Holding Corp,5060509019,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Personalis Inc,5037652668,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Assembly Biosciences Inc,5001158603,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Esperion Therapeutics Inc,4295900449,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Intercept Pharmaceuticals Inc,4296966741,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
MaxCyte Inc,4297024126,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Assembly Biosciences Inc,5001158603,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
MaxCyte Inc,4297024126,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Scholar Rock Holding Corp,5060509019,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Esperion Therapeutics Inc,4295900449,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Esperion Therapeutics Inc,4295900449,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Personalis Inc,5037652668,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Scholar Rock Holding Corp,5060509019,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
MEI Pharma Inc,4295899598,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Viridian Therapeutics Inc,5034847971,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syndax Pharmaceuticals Inc,4297793633,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Syndax Pharmaceuticals Inc,4297793633,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
MEI Pharma Inc,4295899598,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kiniksa Pharmaceuticals Ltd,5063731859,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Viridian Therapeutics Inc,5034847971,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Syndax Pharmaceuticals Inc,4297793633,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Viridian Therapeutics Inc,5034847971,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Morphic Holding Inc,5066537246,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Viridian Therapeutics Inc,5034847971,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Syndax Pharmaceuticals Inc,4297793633,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CK Life Sciences Intl (Holdings) Inc,5000036103,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CK Life Sciences Intl (Holdings) Inc,5000036103,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
MEI Pharma Inc,4295899598,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Morphic Holding Inc,5066537246,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Syndax Pharmaceuticals Inc,4297793633,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Morphic Holding Inc,5066537246,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Syndax Pharmaceuticals Inc,4297793633,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kiniksa Pharmaceuticals Ltd,5063731859,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kiniksa Pharmaceuticals Ltd,5063731859,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kiniksa Pharmaceuticals Ltd,5063731859,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,246,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oxurion NV,4295859470,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oxurion NV,4295859470,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
CRISPR Therapeutics AG,5042268704,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Hemas Holdings PLC,4295889739,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CRISPR Therapeutics AG,5042268704,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Clinuvel Pharmaceuticals Ltd,4295856451,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hemas Holdings PLC,4295889739,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BioArctic AB,5035561399,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CRISPR Therapeutics AG,5042268704,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Clinuvel Pharmaceuticals Ltd,4295856451,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Oxurion NV,4295859470,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Clinuvel Pharmaceuticals Ltd,4295856451,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CRISPR Therapeutics AG,5042268704,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Kura Oncology Inc,5044341506,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
BioArctic AB,5035561399,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CRISPR Therapeutics AG,5042268704,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hemas Holdings PLC,4295889739,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CRISPR Therapeutics AG,5042268704,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Clinuvel Pharmaceuticals Ltd,4295856451,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,245,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Betta Pharmaceuticals Co Ltd,5000768225,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Betta Pharmaceuticals Co Ltd,5000768225,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Beijing Tiantan Biological Products Corp Ltd,4295865264,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Betta Pharmaceuticals Co Ltd,5000768225,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Betta Pharmaceuticals Co Ltd,5000768225,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cyclerion Therapeutics Inc,5067843831,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Betta Pharmaceuticals Co Ltd,5000768225,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Betta Pharmaceuticals Co Ltd,5000768225,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Beijing Tiantan Biological Products Corp Ltd,4295865264,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cyclerion Therapeutics Inc,5067843831,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cyclerion Therapeutics Inc,5067843831,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Beijing Tiantan Biological Products Corp Ltd,4295865264,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Betta Pharmaceuticals Co Ltd,5000768225,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cyclerion Therapeutics Inc,5067843831,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,244,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
OBI Pharma Inc,5000693472,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Ajanta Pharma Ltd,4295874157,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orgenesis Inc,4298422934,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Orgenesis Inc,4298422934,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Orgenesis Inc,4298422934,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kalvista Pharmaceuticals Inc,4297340254,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
OBI Pharma Inc,5000693472,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ajanta Pharma Ltd,4295874157,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Exagen Inc,4296127863,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Exagen Inc,4296127863,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kalvista Pharmaceuticals Inc,4297340254,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kalvista Pharmaceuticals Inc,4297340254,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ajanta Pharma Ltd,4295874157,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
OBI Pharma Inc,5000693472,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Y-mAbs Therapeutics Inc,5051611538,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Y-mAbs Therapeutics Inc,5051611538,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Y-mAbs Therapeutics Inc,5051611538,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,243,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Inhibrx Inc,5063750249,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Corbus Pharmaceuticals Holdings Inc,5040943458,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Sorrento Therapeutics Inc,4296491271,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Corbus Pharmaceuticals Holdings Inc,5040943458,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sorrento Therapeutics Inc,4296491271,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Corbus Pharmaceuticals Holdings Inc,5040943458,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Corbus Pharmaceuticals Holdings Inc,5040943458,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Corbus Pharmaceuticals Holdings Inc,5040943458,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Corbus Pharmaceuticals Holdings Inc,5040943458,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sorrento Therapeutics Inc,4296491271,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Sorrento Therapeutics Inc,4296491271,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Inhibrx Inc,5063750249,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Inhibrx Inc,5063750249,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,242,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Essex Bio-Technology Ltd,4295871189,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,241,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Taro Pharmaceutical Industries Ltd,4295875212,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,241,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Taro Pharmaceutical Industries Ltd,4295875212,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,241,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Taro Pharmaceutical Industries Ltd,4295875212,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,241,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Taro Pharmaceutical Industries Ltd,4295875212,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,241,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
RVL Pharmaceuticals PLC,5065379339,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,241,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
RVL Pharmaceuticals PLC,5065379339,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,241,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Essex Bio-Technology Ltd,4295871189,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,241,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Yunnan Baiyao Group Co Ltd,4295864051,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Abeona Therapeutics Inc,4295911990,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cidara Therapeutics Inc,5042263702,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cidara Therapeutics Inc,5042263702,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Abeona Therapeutics Inc,4295911990,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cidara Therapeutics Inc,5042263702,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oramed Pharmaceuticals Inc,5037660929,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ADMA Biologics Inc,4297548856,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Abeona Therapeutics Inc,4295911990,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ADMA Biologics Inc,4297548856,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Oramed Pharmaceuticals Inc,5037660929,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cidara Therapeutics Inc,5042263702,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Yunnan Baiyao Group Co Ltd,4295864051,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ADMA Biologics Inc,4297548856,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ADMA Biologics Inc,4297548856,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Yunnan Baiyao Group Co Ltd,4295864051,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Yunnan Baiyao Group Co Ltd,4295864051,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cidara Therapeutics Inc,5042263702,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,240,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Apeloa Pharmaceutical Co Ltd,4295863743,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Jounce Therapeutics Inc,5038067073,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Affimed NV,5043318185,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Affimed NV,5043318185,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BridgeBio Pharma Inc,5052793334,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
BridgeBio Pharma Inc,5052793334,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jounce Therapeutics Inc,5038067073,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
BridgeBio Pharma Inc,5052793334,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
AB Science SA,5000727830,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Affimed NV,5043318185,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
AB Science SA,5000727830,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Apeloa Pharmaceutical Co Ltd,4295863743,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Affimed NV,5043318185,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Apeloa Pharmaceutical Co Ltd,4295863743,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Jounce Therapeutics Inc,5038067073,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Affimed NV,5043318185,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang Huahai Pharmaceutical Co Ltd,4295864835,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jounce Therapeutics Inc,5038067073,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Apeloa Pharmaceutical Co Ltd,4295863743,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhejiang Huahai Pharmaceutical Co Ltd,4295864835,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zhejiang Huahai Pharmaceutical Co Ltd,4295864835,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Assertio Holdings Inc,5073962717,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
AB Science SA,5000727830,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
BridgeBio Pharma Inc,5052793334,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Assertio Holdings Inc,5073962717,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Assertio Holdings Inc,5073962717,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang Huahai Pharmaceutical Co Ltd,4295864835,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,239,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Clearside Biomedical Inc,5037247054,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,238,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Rhythm Pharmaceuticals Inc,5043464231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,238,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Clearside Biomedical Inc,5037247054,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,238,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rhythm Pharmaceuticals Inc,5043464231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,238,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Rhythm Pharmaceuticals Inc,5043464231,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,238,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Clearside Biomedical Inc,5037247054,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,238,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Rhythm Pharmaceuticals Inc,5043464231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,238,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Clearside Biomedical Inc,5037247054,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,238,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Trulieve Cannabis Corp,4296507565,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Viracta Therapeutics Inc,4295912556,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Viracta Therapeutics Inc,4295912556,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Mayne Pharma Group Ltd,4295858866,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mayne Pharma Group Ltd,4295858866,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Viracta Therapeutics Inc,4295912556,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Trulieve Cannabis Corp,4296507565,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Trulieve Cannabis Corp,4296507565,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cogent Biosciences Inc,5043324118,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Viracta Therapeutics Inc,4295912556,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Cogent Biosciences Inc,5043324118,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Trulieve Cannabis Corp,4296507565,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Viracta Therapeutics Inc,4295912556,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,237,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
HOOKIPA Pharma Inc,5067945220,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mirati Therapeutics Inc,5039800567,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Krystal Biotech Inc,5057764486,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mirati Therapeutics Inc,5039800567,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Krystal Biotech Inc,5057764486,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
HOOKIPA Pharma Inc,5067945220,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
HOOKIPA Pharma Inc,5067945220,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mirati Therapeutics Inc,5039800567,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,236,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Pliant Therapeutics Inc,5046715672,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Iovance Biotherapeutics Inc,5056411750,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Pliant Therapeutics Inc,5046715672,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bionano Genomics Inc,4296225077,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Pliant Therapeutics Inc,5046715672,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Iovance Biotherapeutics Inc,5056411750,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bionano Genomics Inc,4296225077,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bionano Genomics Inc,4296225077,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bionano Genomics Inc,4296225077,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Iovance Biotherapeutics Inc,5056411750,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,235,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
bluebird bio Inc,5035523656,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Molecular Partners AG,4297804675,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aptinyx Inc,5046706152,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Paratek Pharmaceuticals Inc,4295902313,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aptinyx Inc,5046706152,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
bluebird bio Inc,5035523656,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
bluebird bio Inc,5035523656,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aptinyx Inc,5046706152,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
bluebird bio Inc,5035523656,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Molecular Partners AG,4297804675,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Paratek Pharmaceuticals Inc,4295902313,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Paratek Pharmaceuticals Inc,4295902313,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Paratek Pharmaceuticals Inc,4295902313,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Molecular Partners AG,4297804675,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,234,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aeglea Bio Therapeutics Inc,5038915440,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Microbio Co Ltd,4295891098,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aurora Cannabis Inc,4297776358,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Microbio Co Ltd,4295891098,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aurora Cannabis Inc,4297776358,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aurora Cannabis Inc,4297776358,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Microbio Co Ltd,4295891098,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aeglea Bio Therapeutics Inc,5038915440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Microbio Co Ltd,4295891098,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aeglea Bio Therapeutics Inc,5038915440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aeglea Bio Therapeutics Inc,5038915440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,233,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CStone Pharmaceuticals,5066609443,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Innate Pharma SA,4295866723,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Innate Pharma SA,4295866723,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Immutep Ltd,4295857055,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Innate Pharma SA,4295866723,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Immutep Ltd,4295857055,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Immutep Ltd,4295857055,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
CStone Pharmaceuticals,5066609443,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Innate Pharma SA,4295866723,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,232,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cassava Sciences Inc,4295915956,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Acorda Therapeutics Inc,4295909042,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cassava Sciences Inc,4295915956,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Seegene Inc,5000846840,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Acorda Therapeutics Inc,4295909042,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Synlogic Inc,5000782315,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Synlogic Inc,5000782315,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Synlogic Inc,5000782315,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Synlogic Inc,5000782315,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Synlogic Inc,5000782315,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Seegene Inc,5000846840,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Seegene Inc,5000846840,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Acorda Therapeutics Inc,4295909042,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Seegene Inc,5000846840,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Acorda Therapeutics Inc,4295909042,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Seegene Inc,5000846840,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,231,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Joinn Laboratories China Co Ltd,5037992901,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
C4 Therapeutics Inc,5048904801,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Joinn Laboratories China Co Ltd,5037992901,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Joinn Laboratories China Co Ltd,5037992901,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Champions Oncology Inc,4295912832,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
C4 Therapeutics Inc,5048904801,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Akero Therapeutics Inc,5064611248,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Champions Oncology Inc,4295912832,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Akero Therapeutics Inc,5064611248,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Joinn Laboratories China Co Ltd,5037992901,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Joinn Laboratories China Co Ltd,5037992901,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
C4 Therapeutics Inc,5048904801,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Akero Therapeutics Inc,5064611248,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Joinn Laboratories China Co Ltd,5037992901,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Akero Therapeutics Inc,5064611248,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,230,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Homology Medicines Inc,5046317196,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Solid Biosciences Inc,5040932912,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Aravive Inc,4298508493,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Solid Biosciences Inc,5040932912,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Solid Biosciences Inc,5040932912,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Solid Biosciences Inc,5040932912,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Solid Biosciences Inc,5040932912,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Aravive Inc,4298508493,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aravive Inc,4298508493,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Homology Medicines Inc,5046317196,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,229,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astrazeneca Pharma India Ltd,4295873481,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astrazeneca Pharma India Ltd,4295873481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kymera Therapeutics Inc,5076089513,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Fulcrum Therapeutics Inc,5051602622,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rocket Pharmaceuticals Inc,4297060461,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rocket Pharmaceuticals Inc,4297060461,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fulcrum Therapeutics Inc,5051602622,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Fulcrum Therapeutics Inc,5051602622,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Astrazeneca Pharma India Ltd,4295873481,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fulcrum Therapeutics Inc,5051602622,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Fulcrum Therapeutics Inc,5051602622,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Astrazeneca Pharma India Ltd,4295873481,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kymera Therapeutics Inc,5076089513,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kymera Therapeutics Inc,5076089513,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,228,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Selecta Biosciences Inc,4298128957,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SAGE Therapeutics Inc,5036384269,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SAGE Therapeutics Inc,5036384269,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SAGE Therapeutics Inc,5036384269,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Selecta Biosciences Inc,4298128957,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Harpoon Therapeutics Inc,5046317800,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SAGE Therapeutics Inc,5036384269,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Harpoon Therapeutics Inc,5046317800,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SAGE Therapeutics Inc,5036384269,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Harpoon Therapeutics Inc,5046317800,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Selecta Biosciences Inc,4298128957,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SAGE Therapeutics Inc,5036384269,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Selecta Biosciences Inc,4298128957,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,227,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Gritstone bio Inc,5046716076,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Gritstone bio Inc,5046716076,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Gritstone bio Inc,5046716076,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
UNITY Biotechnology Inc,5042242039,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Gritstone bio Inc,5046716076,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Relay Therapeutics Inc,5051787387,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
UNITY Biotechnology Inc,5042242039,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,226,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Maravai LifeSciences Holdings Inc,5078367609,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Maravai LifeSciences Holdings Inc,5078367609,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Atreca Inc,5037061527,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
IDEAYA Biosciences Inc,5046317163,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
IDEAYA Biosciences Inc,5046317163,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Atreca Inc,5037061527,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Maravai LifeSciences Holdings Inc,5078367609,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Atreca Inc,5037061527,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Maravai LifeSciences Holdings Inc,5078367609,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Maravai LifeSciences Holdings Inc,5078367609,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,225,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Avidity Biosciences Inc,5041069348,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
DermTech Inc,5071164163,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Arcutis Biotherapeutics Inc,5071515336,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aytu Biopharma Inc,5046048674,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
DermTech Inc,5071164163,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Arcutis Biotherapeutics Inc,5071515336,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Avidity Biosciences Inc,5041069348,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
DermTech Inc,5071164163,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Avidity Biosciences Inc,5041069348,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,224,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Photocure ASA,4295885687,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,223,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Duopharma Biotech Bhd,4295883043,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,223,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Photocure ASA,4295885687,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,223,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Duopharma Biotech Bhd,4295883043,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,223,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,223,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Photocure ASA,4295885687,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,223,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
NextCure Inc,5048904889,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,222,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
NextCure Inc,5048904889,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,222,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
NextCure Inc,5048904889,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,222,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
NextCure Inc,5048904889,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,222,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
X4 Pharmaceuticals Inc,5001432321,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Replimune Group Inc,5064609639,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Athenex Inc,4297156651,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
X4 Pharmaceuticals Inc,5001432321,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
X4 Pharmaceuticals Inc,5001432321,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
X4 Pharmaceuticals Inc,5001432321,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Replimune Group Inc,5064609639,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Replimune Group Inc,5064609639,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Athenex Inc,4297156651,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Athenex Inc,4297156651,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Athenex Inc,4297156651,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,221,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Medipharm Labs Corp,5057974133,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,220,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Medipharm Labs Corp,5057974133,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,220,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Medipharm Labs Corp,5057974133,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,220,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Fennec Pharmaceuticals Inc,4295862881,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,220,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Theratechnologies Inc,4295861528,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,220,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Fennec Pharmaceuticals Inc,4295862881,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,220,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cronos Group Inc,5052536942,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Outlook Therapeutics Inc,5034864632,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Outlook Therapeutics Inc,5034864632,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cronos Group Inc,5052536942,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jilin Aodong Pharmaceutical Group Co Ltd,4295864286,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Allogene Therapeutics Inc,5063310679,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
IGM Biosciences Inc,5000837249,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Outlook Therapeutics Inc,5034864632,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Avalo Therapeutics Inc,5036216067,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Avalo Therapeutics Inc,5036216067,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Allogene Therapeutics Inc,5063310679,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Avalo Therapeutics Inc,5036216067,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
IGM Biosciences Inc,5000837249,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Allogene Therapeutics Inc,5063310679,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
IGM Biosciences Inc,5000837249,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jilin Aodong Pharmaceutical Group Co Ltd,4295864286,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Allogene Therapeutics Inc,5063310679,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Jilin Aodong Pharmaceutical Group Co Ltd,4295864286,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,219,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hualan Biological Engineering Inc,4295865475,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vistagen Therapeutics Inc,4296274076,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Strides Pharma Science Ltd,4295873295,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sinovac Biotech Ltd,4295863966,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hualan Biological Engineering Inc,4295865475,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Strides Pharma Science Ltd,4295873295,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ovid Therapeutics Inc,5045853309,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hualan Biological Engineering Inc,4295865475,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Strides Pharma Science Ltd,4295873295,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vistagen Therapeutics Inc,4296274076,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,218,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Marinus Pharmaceuticals Inc,4296927359,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Avecho Biotechnology Ltd,4295858250,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Beijing Tongrentang Co Ltd,4295865333,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Beijing Tongrentang Co Ltd,4295865333,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Beijing SL Pharmaceutical Co Ltd,4295865485,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
China Resources Double-Crane Pharmaceutical Co Ltd,4295864997,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
China Resources Double-Crane Pharmaceutical Co Ltd,4295864997,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Beijing SL Pharmaceutical Co Ltd,4295865485,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Marinus Pharmaceuticals Inc,4296927359,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Avecho Biotechnology Ltd,4295858250,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Marinus Pharmaceuticals Inc,4296927359,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Marinus Pharmaceuticals Inc,4296927359,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Beijing Tongrentang Co Ltd,4295865333,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,217,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dong-E-E-Jiao Co Ltd,4295864992,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Recursion Pharmaceuticals Inc,5042238812,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Karuna Therapeutics Inc,5036220029,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Karuna Therapeutics Inc,5036220029,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nkarta Inc,5061699475,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dong-E-E-Jiao Co Ltd,4295864992,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dong-E-E-Jiao Co Ltd,4295864992,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Karuna Therapeutics Inc,5036220029,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nkarta Inc,5061699475,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Recursion Pharmaceuticals Inc,5042238812,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,216,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Xeris Pharmaceuticals Inc,4297260021,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kodiak Sciences Inc,4298009606,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kodiak Sciences Inc,4298009606,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Xeris Pharmaceuticals Inc,4297260021,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Guangzhou Kingmed Diagnostics Group Co Ltd,5043415350,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Guangzhou Kingmed Diagnostics Group Co Ltd,5043415350,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,214,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Forte Biosciences Inc,4297884814,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Beyondspring Inc,5052143727,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Beyondspring Inc,5052143727,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Altimmune Inc,4295902506,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Altimmune Inc,4295902506,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Forte Biosciences Inc,4297884814,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Forte Biosciences Inc,4297884814,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,213,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dbv Technologies SA,4295983024,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dbv Technologies SA,4295983024,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Dbv Technologies SA,4295983024,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Dbv Technologies SA,4295983024,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Dbv Technologies SA,4295983024,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Lee's Pharmaceutical Holdings Ltd,4295871517,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Dbv Technologies SA,4295983024,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,212,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Catalyst Biosciences Inc,4295899884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,211,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Catalyst Biosciences Inc,4295899884,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,211,S_opportunity,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Supply_Chain_Integrity
Catalyst Biosciences Inc,4295899884,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,211,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Lyra Therapeutics Inc,5000454023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,211,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Lyra Therapeutics Inc,5000454023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,211,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lyra Therapeutics Inc,5000454023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,211,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Lyra Therapeutics Inc,5000454023,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,211,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Catalyst Biosciences Inc,4295899884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,211,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Allergy Therapeutics PLC,4295894147,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang CONBA Pharmaceutical Co Ltd,4295865378,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Savara Inc,4295915685,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Allergy Therapeutics PLC,4295894147,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kangmei Pharmaceutical Co Ltd,4295865533,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Poseida Therapeutics Inc,5048023521,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chembio Diagnostics Inc,4295900231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang CONBA Pharmaceutical Co Ltd,4295865378,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhejiang CONBA Pharmaceutical Co Ltd,4295865378,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Savara Inc,4295915685,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Allergy Therapeutics PLC,4295894147,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Allergy Therapeutics PLC,4295894147,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BioXcel Therapeutics Inc,5059088690,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kangmei Pharmaceutical Co Ltd,4295865533,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Chembio Diagnostics Inc,4295900231,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
BioXcel Therapeutics Inc,5059088690,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zhejiang CONBA Pharmaceutical Co Ltd,4295865378,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Savara Inc,4295915685,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Kangmei Pharmaceutical Co Ltd,4295865533,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Chembio Diagnostics Inc,4295900231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Poseida Therapeutics Inc,5048023521,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,210,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Centogene NV,5068331881,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Agile Therapeutics Inc,4295990208,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Spectrum Pharmaceuticals Inc,4295907365,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Agile Therapeutics Inc,4295990208,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Spectrum Pharmaceuticals Inc,4295907365,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Centogene NV,5068331881,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Spectrum Pharmaceuticals Inc,4295907365,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Agile Therapeutics Inc,4295990208,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Stoke Therapeutics Inc,5044099417,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Stoke Therapeutics Inc,5044099417,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Centogene NV,5068331881,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Stoke Therapeutics Inc,5044099417,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,209,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Nanjing King-friend Biochemical Pharmaceutical Co Ltd,5000520341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aerie Pharmaceuticals Inc,4297213141,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
SpringWorks Therapeutics Inc,5068659971,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aerie Pharmaceuticals Inc,4297213141,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nurix Therapeutics Inc,5037639007,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Viking Therapeutics Inc,5042933582,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Nanjing King-friend Biochemical Pharmaceutical Co Ltd,5000520341,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Viking Therapeutics Inc,5042933582,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nurix Therapeutics Inc,5037639007,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nurix Therapeutics Inc,5037639007,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Ctp NV,5076163128,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Transgene SA,4295868038,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ctp NV,5076163128,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Nanjing King-friend Biochemical Pharmaceutical Co Ltd,5000520341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SpringWorks Therapeutics Inc,5068659971,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Viking Therapeutics Inc,5042933582,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Transgene SA,4295868038,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ctp NV,5076163128,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,208,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Medical Developments International Ltd,4295857325,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
PDS Biotechnology Corp,5000474462,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Opthea Ltd,4295857664,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bioatla Inc,5076111023,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Medical Developments International Ltd,4295857325,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Medical Developments International Ltd,4295857325,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bioatla Inc,5076111023,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
PDS Biotechnology Corp,5000474462,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Opthea Ltd,4295857664,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hexo Corp,5043460552,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hexo Corp,5043460552,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
PDS Biotechnology Corp,5000474462,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Opthea Ltd,4295857664,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PDS Biotechnology Corp,5000474462,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,207,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cytek Biosciences Inc,5051007061,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cytek Biosciences Inc,5051007061,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
TaiMed Biologics Inc,4298124682,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
TaiMed Biologics Inc,4298124682,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tonghua Dongbao Pharmaceutical Co Ltd,4295865440,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
TaiMed Biologics Inc,4298124682,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
TaiMed Biologics Inc,4298124682,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cytek Biosciences Inc,5051007061,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tonghua Dongbao Pharmaceutical Co Ltd,4295865440,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Merus NV,4297392913,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bellicum Pharmaceuticals Inc,5000448724,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,206,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BB Biotech AG,4295890616,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Rapt Therapeutics Inc,5046047686,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rapt Therapeutics Inc,5046047686,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Pulse Biosciences Inc,5064601827,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shanghai RAAS Blood Products Co Ltd,4298025328,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Adicet Bio Inc,5055941844,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Adicet Bio Inc,5055941844,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shenzhen Salubris Pharmaceuticals Co Ltd,4298150679,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shenzhen Salubris Pharmaceuticals Co Ltd,4298150679,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Rapt Therapeutics Inc,5046047686,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Adicet Bio Inc,5055941844,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shenzhen Salubris Pharmaceuticals Co Ltd,4298150679,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Adicet Bio Inc,5055941844,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BB Biotech AG,4295890616,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,205,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Alpine Immune Sciences Inc,5035525548,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Relmada Therapeutics Inc,5037949940,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Mirum Pharmaceuticals Inc,5066605934,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
T2 Biosystems Inc,5000751904,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
T2 Biosystems Inc,5000751904,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
T2 Biosystems Inc,5000751904,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Mirum Pharmaceuticals Inc,5066605934,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Alpine Immune Sciences Inc,5035525548,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Relmada Therapeutics Inc,5037949940,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Relmada Therapeutics Inc,5037949940,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alpine Immune Sciences Inc,5035525548,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alpine Immune Sciences Inc,5035525548,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Organovo Holdings Inc,5037282896,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
T2 Biosystems Inc,5000751904,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,204,S_opportunity,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Supply_Chain_Integrity
Ascletis Pharma Inc,5037651630,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tarsus Pharmaceuticals Inc,5070510044,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Foghorn Therapeutics Inc.,5050713856,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Ascletis Pharma Inc,5037651630,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Foghorn Therapeutics Inc.,5050713856,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
IVERIC bio Inc,4297721792,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tarsus Pharmaceuticals Inc,5070510044,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tarsus Pharmaceuticals Inc,5070510044,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tarsus Pharmaceuticals Inc,5070510044,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,203,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Checkpoint Therapeutics Inc,4296562024,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Telix Pharmaceuticals Ltd,5053083994,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Checkpoint Therapeutics Inc,4296562024,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Telix Pharmaceuticals Ltd,5053083994,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Iteos Therapeutics Inc,5073964452,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Iteos Therapeutics Inc,5073964452,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alligator Bioscience AB,4295976193,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Checkpoint Therapeutics Inc,4296562024,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Telix Pharmaceuticals Ltd,5053083994,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Alligator Bioscience AB,4295976193,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,202,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Spero Therapeutics Inc,5042250852,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Spero Therapeutics Inc,5042250852,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ergomed PLC,5042964908,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ergomed PLC,5042964908,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Spero Therapeutics Inc,5042250852,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Spero Therapeutics Inc,5042250852,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,201,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
scPharmaceuticals Inc,5042230367,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,200,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
scPharmaceuticals Inc,5042230367,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,200,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
scPharmaceuticals Inc,5042230367,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,200,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Exicure Inc,5055416070,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Exicure Inc,5055416070,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Exicure Inc,5055416070,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Exicure Inc,5055416070,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,199,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Clovis Oncology Inc,4298504105,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,198,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Clovis Oncology Inc,4298504105,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,198,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
SQZ Biotechnologies Co,5042254800,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,198,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Clovis Oncology Inc,4298504105,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,198,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Liminal BioSciences Inc,4295861739,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,197,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shandong Buchang Pharmaceuticals Co Ltd,5000560344,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,197,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Adaptimmune Therapeutics PLC,5045847548,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,197,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shandong Buchang Pharmaceuticals Co Ltd,5000560344,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,197,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Adaptimmune Therapeutics PLC,5045847548,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,197,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Liminal BioSciences Inc,4295861739,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,197,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shandong Buchang Pharmaceuticals Co Ltd,5000560344,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,197,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Liminal BioSciences Inc,4295861739,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,197,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Applied Therapeutics Inc,5053942137,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,196,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Applied Therapeutics Inc,5053942137,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,196,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eton Pharmaceuticals Inc,5064704765,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,196,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Gossamer Bio Inc,5060473928,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,196,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Gossamer Bio Inc,5060473928,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,196,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Gossamer Bio Inc,5060473928,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,196,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Etex NV,5000023330,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,196,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eton Pharmaceuticals Inc,5064704765,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,196,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shilpa Medicare Ltd,4295873197,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,195,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shilpa Medicare Ltd,4295873197,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,195,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Infinity Pharmaceuticals Inc,4295915855,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Surface Oncology Inc,5044199583,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Surface Oncology Inc,5044199583,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Amarin Corporation PLC,4295897405,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Surface Oncology Inc,5044199583,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Infinity Pharmaceuticals Inc,4295915855,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Amarin Corporation PLC,4295897405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genprex Inc,5036210734,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Genprex Inc,5036210734,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Genprex Inc,5036210734,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Genprex Inc,5036210734,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Amarin Corporation PLC,4295897405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aldeyra Therapeutics Inc,4297349911,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Infinity Pharmaceuticals Inc,4295915855,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,194,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tasly Pharmaceutical Group Co Ltd,4295865148,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Guizhou Bailing Group Pharmaceutical Co Ltd,4298345796,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Keros Therapeutics Inc,5050915513,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kezar Life Sciences Inc,5046058924,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Kezar Life Sciences Inc,5046058924,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
AVROBIO Inc,5050307187,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Guizhou Bailing Group Pharmaceutical Co Ltd,4298345796,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Eloxx Pharmaceuticals Inc,4295914898,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tasly Pharmaceutical Group Co Ltd,4295865148,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Kezar Life Sciences Inc,5046058924,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Xenon Pharmaceuticals Inc,4295968711,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tasly Pharmaceutical Group Co Ltd,4295865148,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eloxx Pharmaceuticals Inc,4295914898,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Keros Therapeutics Inc,5050915513,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
CymaBay Therapeutics Inc,4297588727,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eloxx Pharmaceuticals Inc,4295914898,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Guizhou Bailing Group Pharmaceutical Co Ltd,4298345796,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
AVROBIO Inc,5050307187,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
CymaBay Therapeutics Inc,4297588727,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
CymaBay Therapeutics Inc,4297588727,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,192,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Antares Pharma Inc,4295914166,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
CTI Biopharma Corp,5060588775,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aligos Therapeutics Inc,5065980352,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aligos Therapeutics Inc,5065980352,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jinyu Bio-Technology Co Ltd,4295864704,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jinyu Bio-Technology Co Ltd,4295864704,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Antares Pharma Inc,4295914166,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Jinyu Bio-Technology Co Ltd,4295864704,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
CTI Biopharma Corp,5060588775,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Antares Pharma Inc,4295914166,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,191,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Curaleaf Holdings Inc,5045851306,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,190,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zentalis Pharmaceuticals Inc,5072818884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,190,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Co-Diagnostics Inc,5040195339,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,190,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zentalis Pharmaceuticals Inc,5072818884,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,190,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Co-Diagnostics Inc,5040195339,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,190,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Curaleaf Holdings Inc,5045851306,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,190,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Burning Rock Biotech Ltd,5074555179,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Generation Bio Co,5060500613,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Generation Bio Co,5060500613,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Burning Rock Biotech Ltd,5074555179,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Burning Rock Biotech Ltd,5074555179,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,189,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Albireo Pharma Inc,4295904266,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Soleno Therapeutics Inc,4297184240,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Allakos Inc,5037990289,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Soleno Therapeutics Inc,4297184240,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Bionomics Ltd,4295856352,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Albireo Pharma Inc,4295904266,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Phathom Pharmaceuticals Inc,5069405688,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
PDL BioPharma Inc,4295907681,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bionomics Ltd,4295856352,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Allakos Inc,5037990289,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
PDL BioPharma Inc,4295907681,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PDL BioPharma Inc,4295907681,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Albireo Pharma Inc,4295904266,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Phathom Pharmaceuticals Inc,5069405688,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,188,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oncternal Therapeutics Inc,4295908396,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Evofem Biosciences Inc,4297632572,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Protara Therapeutics Inc,4296048186,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Black Diamond Therapeutics Inc,5044168456,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
La Jolla Pharmaceutical Co,4295906958,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
AC Immune SA,4297285623,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Protara Therapeutics Inc,4296048186,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oncternal Therapeutics Inc,4295908396,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Black Diamond Therapeutics Inc,5044168456,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
La Jolla Pharmaceutical Co,4295906958,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Evofem Biosciences Inc,4297632572,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Evofem Biosciences Inc,4297632572,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Black Diamond Therapeutics Inc,5044168456,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Protara Therapeutics Inc,4296048186,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Black Diamond Therapeutics Inc,5044168456,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Protara Therapeutics Inc,4296048186,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Evofem Biosciences Inc,4297632572,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
BGI Genomics Co Ltd,5043316839,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
BGI Genomics Co Ltd,5043316839,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
BGI Genomics Co Ltd,5043316839,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Anavex Life Sciences Corp,4295899501,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Yifan Pharmaceutical Co Ltd,4295865353,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Shinpoong Pharmaceutical Co Ltd,4295881859,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shinpoong Pharmaceutical Co Ltd,4295881859,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Yifan Pharmaceutical Co Ltd,4295865353,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Towa Pharmaceutical Co Ltd,4295879059,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Anavex Life Sciences Corp,4295899501,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Shinpoong Pharmaceutical Co Ltd,4295881859,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Yifan Pharmaceutical Co Ltd,4295865353,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Anavex Life Sciences Corp,4295899501,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,185,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eiger BioPharmaceuticals Inc,4297271351,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Global Blood Therapeutics Inc,5037622915,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Global Blood Therapeutics Inc,5037622915,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eiger BioPharmaceuticals Inc,4297271351,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Global Blood Therapeutics Inc,5037622915,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,183,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Xbrane Biopharma AB,5035526276,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Xbrane Biopharma AB,5035526276,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,182,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Arix Bioscience PLC,5050720127,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd,5035524971,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd,5035524971,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Arix Bioscience PLC,5050720127,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd,5035524971,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,181,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cabaletta Bio Inc,5066607195,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Sichuan Languang Development Co Ltd,4295863639,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Sichuan Languang Development Co Ltd,4295863639,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cabaletta Bio Inc,5066607195,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cabaletta Bio Inc,5066607195,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cabaletta Bio Inc,5066607195,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cabaletta Bio Inc,5066607195,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,180,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Verrica Pharmaceuticals Inc,5045389384,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,178,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Verrica Pharmaceuticals Inc,5045389384,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,178,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Verrica Pharmaceuticals Inc,5045389384,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,178,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Verrica Pharmaceuticals Inc,5045389384,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,178,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Enochian Biosciences Inc,5036384219,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Enochian Biosciences Inc,5036384219,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,177,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Taysha Gene Therapies Inc,5074235329,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,176,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Taysha Gene Therapies Inc,5074235329,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,176,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Calithera Biosciences Inc,5000784443,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hanmi Science Co Ltd,4295882141,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Turning Point Therapeutics Inc,5068346529,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Hanmi Science Co Ltd,4295882141,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Turning Point Therapeutics Inc,5068346529,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Calithera Biosciences Inc,5000784443,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hanmi Science Co Ltd,4295882141,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Calithera Biosciences Inc,5000784443,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Turning Point Therapeutics Inc,5068346529,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Paradigm Biopharmaceuticals Ltd,5044166860,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Paradigm Biopharmaceuticals Ltd,5044166860,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Paradigm Biopharmaceuticals Ltd,5044166860,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biohaven Pharmaceutical Holding Company Ltd,5040932194,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Biohaven Pharmaceutical Holding Company Ltd,5040932194,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Biohaven Pharmaceutical Holding Company Ltd,5040932194,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Rubius Therapeutics Inc,5045880503,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,172,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vyne Therapeutics Inc,5038045986,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Wuhu Token Sciences Co Ltd,5000539211,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Vyne Therapeutics Inc,5038045986,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Wuhu Token Sciences Co Ltd,5000539211,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Passage Bio Inc,5065980347,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Passage Bio Inc,5065980347,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Evelo Biosciences Inc,5047108020,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Tianjin Chase Sun Pharmaceutical Co Ltd,5000446260,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Tianjin Chase Sun Pharmaceutical Co Ltd,5000446260,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Evelo Biosciences Inc,5047108020,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Passage Bio Inc,5065980347,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Evelo Biosciences Inc,5047108020,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tianjin Chase Sun Pharmaceutical Co Ltd,5000446260,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Acceleron Pharma Inc,4296015497,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,169,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Acceleron Pharma Inc,4296015497,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,169,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Acceleron Pharma Inc,4296015497,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,169,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oncopeptides AB,4298493813,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neoleukin Therapeutics Inc,4296262694,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neoleukin Therapeutics Inc,4296262694,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Galera Therapeutics Inc,5037989344,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Frequency Therapeutics Inc,5052794794,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Frequency Therapeutics Inc,5052794794,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Oncopeptides AB,4298493813,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Galera Therapeutics Inc,5037989344,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oncopeptides AB,4298493813,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Frequency Therapeutics Inc,5052794794,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Neoleukin Therapeutics Inc,4296262694,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Frequency Therapeutics Inc,5052794794,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Frequency Therapeutics Inc,5052794794,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,168,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Axcella Health Inc,5046040911,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Axcella Health Inc,5046040911,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Helixmith Co Ltd,4295881620,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Helixmith Co Ltd,4295881620,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Devoteam SAS,4295868217,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Alteogen Inc,5035522960,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Alteogen Inc,5035522960,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Alteogen Inc,5035522960,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Devoteam SAS,4295868217,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,164,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Provention Bio Inc,5056411135,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Provention Bio Inc,5056411135,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Neurobo Pharmaceuticals Inc,5045853684,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Provention Bio Inc,5056411135,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,159,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Concert Pharmaceuticals Inc,4297543586,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Concert Pharmaceuticals Inc,4297543586,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Concert Pharmaceuticals Inc,4297543586,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aveo Pharmaceuticals Inc,4297278257,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aveo Pharmaceuticals Inc,4297278257,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aveo Pharmaceuticals Inc,4297278257,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
LogicBio Therapeutics Inc,5049432034,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,152,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Strongbridge Biopharma plc,5046703828,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Strongbridge Biopharma plc,5046703828,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Carisma Therapeutics Inc,5000661021,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Carisma Therapeutics Inc,5000661021,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Carisma Therapeutics Inc,5000661021,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Dicerna Pharmaceuticals Inc,5034137552,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dicerna Pharmaceuticals Inc,5034137552,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dicerna Pharmaceuticals Inc,5034137552,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Adamas Pharmaceuticals Inc,4297309035,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Adamas Pharmaceuticals Inc,4297309035,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,135,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Flexion Therapeutics Inc,4297906483,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Flexion Therapeutics Inc,4297906483,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,187,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Imeik Technology Development Co Ltd,5056432599,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Imeik Technology Development Co Ltd,5056432599,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Imeik Technology Development Co Ltd,5056432599,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Imeik Technology Development Co Ltd,5056432599,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Imeik Technology Development Co Ltd,5056432599,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,184,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Simcere Pharmaceutical Group Ltd,5059956980,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Simcere Pharmaceutical Group Ltd,5059956980,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,179,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
GoTo Gojek Tokopedia PT Tbk,5081055647,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
GoTo Gojek Tokopedia PT Tbk,5081055647,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GoTo Gojek Tokopedia PT Tbk,5081055647,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GoTo Gojek Tokopedia PT Tbk,5081055647,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,174,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Philogen SpA,5000011164,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Philogen SpA,5000011164,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,171,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Gan & Lee Pharmaceuticals,5000745370,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,170,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shanghai Medicilon Inc,4297884856,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,157,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Ocumension Therapeutics,5066605178,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,151,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Ocumension Therapeutics,5066605178,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,151,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Ocumension Therapeutics,5066605178,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,151,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Ocumension Therapeutics,5066605178,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,151,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ocumension Therapeutics,5066605178,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,151,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Kintor Pharmaceutical Ltd,5072811065,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,140,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Kancera AB,5001436678,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Neuren Pharmaceuticals Ltd,4295858589,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,138,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Novacyt SA,5035542125,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Aino Health AB (publ),5052541224,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,132,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aino Health AB (publ),5052541224,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,132,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cyxone AB,5050718180,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cyxone AB,5050718180,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Cyxone AB,5050718180,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Hero AG,4295890921,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Cyxone AB,5050718180,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cyxone AB,5050718180,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
AcedrA Pharmaceutical Co,5076114133,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,118,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
AcedrA Pharmaceutical Co,5076114133,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,118,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PharmaBlock Sciences Nanjing Inc,5052792291,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,112,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mind Medicine (MindMed) Inc,5001198706,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,111,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Mind Medicine (MindMed) Inc,5001198706,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,111,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Center Laboratories Inc,4295892655,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,105,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhaoke Ophthalmology Ltd,5076909548,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,104,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zynerba Pharmaceuticals Inc,4296164911,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,95,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Zynerba Pharmaceuticals Inc,4296164911,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,95,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
TRG Pakistan Ltd,4297081341,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,88,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
TRG Pakistan Ltd,4297081341,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,88,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Tanvex BioPharma Inc,5046457659,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,85,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Tanvex BioPharma Inc,5046457659,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,85,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GlaxoSmithKline SAE,4295866204,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,81,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bob Evans Farms Inc,4295905749,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,81,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Melinta Therapeutics Inc,4298504748,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,81,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bob Evans Farms Inc,4295905749,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,81,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bergenbio ASA,5035526218,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,78,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Constellation Pharmaceuticals Inc,4296153489,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,75,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Constellation Pharmaceuticals Inc,4296153489,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,75,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Array BioPharma Inc,4295901644,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,73,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Array BioPharma Inc,4295901644,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,73,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Medicines Co,4295900476,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,72,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Aimmune Therapeutics Inc,5040059297,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,71,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aimmune Therapeutics Inc,5040059297,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,71,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aprea Therapeutics Inc,5071168699,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,69,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aprea Therapeutics Inc,5071168699,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,69,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Keryx Biopharmaceuticals Inc,4295900456,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,67,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Keryx Biopharmaceuticals Inc,4295900456,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,67,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Imago BioSciences Inc,5044017757,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,66,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Imago BioSciences Inc,5044017757,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,66,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Spark Therapeutics Inc,5040271210,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,63,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Spark Therapeutics Inc,5040271210,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,63,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Somalogic Inc,5079707680,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,62,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Foundation Medicine Inc,5000714889,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,61,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Diplomat Pharmacy Inc,4297771046,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,60,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Diplomat Pharmacy Inc,4297771046,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,60,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Cassiopea SpA,5035325252,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,57,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Cassiopea SpA,5035325252,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,57,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Lundbeck Seattle Biopharmaceuticals Inc,4296032231,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,55,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Lundbeck Seattle Biopharmaceuticals Inc,4296032231,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,55,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Dova Pharmaceuticals Inc,5052128613,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,53,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Dova Pharmaceuticals Inc,5052128613,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,53,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Synthorx Inc,5042373556,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,52,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Synthorx Inc,5042373556,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,52,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Audentes Therapeutics Inc,5040171536,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,49,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Audentes Therapeutics Inc,5040171536,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,49,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Majid Al Futtaim Holding LLC,5000030405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Majid Al Futtaim Holding LLC,5000030405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Majid Al Futtaim Holding LLC,5000030405,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Majid Al Futtaim Holding LLC,5000030405,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,247,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Santhera Pharmaceuticals Holding AG,4295890728,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Santhera Pharmaceuticals Holding AG,4295890728,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Santhera Pharmaceuticals Holding AG,4295890728,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Santhera Pharmaceuticals Holding AG,4295890728,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Santhera Pharmaceuticals Holding AG,4295890728,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,186,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Oryzon Genomics SA,4297159438,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,175,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hua Medicine,5046653844,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,173,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
ADC Therapeutics SA,5037362072,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ADC Therapeutics SA,5037362072,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
ADC Therapeutics SA,5037362072,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
ADC Therapeutics SA,5037362072,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,167,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Gensight Biologics SA,5039191405,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Gensight Biologics SA,5039191405,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Gensight Biologics SA,5039191405,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Gensight Biologics SA,5039191405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Gensight Biologics SA,5039191405,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,166,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Equillium Inc,5065627715,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Equillium Inc,5065627715,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Bora Pharmaceuticals Co Ltd,5044006942,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bora Pharmaceuticals Co Ltd,5044006942,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,165,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Medigen Biotechnology Corp,4295892209,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Saniona AB,5041982010,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Saniona AB,5041982010,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Medigen Biotechnology Corp,4295892209,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Saniona AB,5041982010,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Saniona AB,5041982010,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Saniona AB,5041982010,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Saniona AB,5041982010,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,163,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Zhong Jia Guo Xin Holdings Co Ltd,4295871820,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,162,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Zhong Jia Guo Xin Holdings Co Ltd,4295871820,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,162,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Blau Farmaceutica SA,5037838687,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,158,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GT Biopharma Inc,4295907505,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Suven Life Sciences Ltd,4295873926,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Suven Life Sciences Ltd,4295873926,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
GT Biopharma Inc,4295907505,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Heidelberg Pharma AG,5057984015,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,154,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Diamyd Medical AB,5035530036,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,153,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
InnoCare Pharma Ltd,5071511883,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,150,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rana Gruber ASA,4297660032,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,150,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
InnoCare Pharma Ltd,5071511883,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,150,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Rana Gruber ASA,4297660032,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,150,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Karolinska Development AB,4298129740,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,147,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Oxford Biodynamics PLC,5035548501,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Celyad Oncology SA,5000454045,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,145,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
4Sc AG,4295870097,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
4Sc AG,4295870097,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,144,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Tonix Pharmaceuticals Holding Corp,4297915579,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,142,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Allovir Inc,5044174285,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,141,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Allovir Inc,5044174285,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,141,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nuvalent Inc,5071514083,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
PCI Biotech Holding ASA,4298025346,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nuvalent Inc,5071514083,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
PCI Biotech Holding ASA,4298025346,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PCI Biotech Holding ASA,4298025346,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,139,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Solara Active Pharma Sciences Ltd,5063388054,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Solara Active Pharma Sciences Ltd,5063388054,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Solara Active Pharma Sciences Ltd,5063388054,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Solara Active Pharma Sciences Ltd,5063388054,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,134,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vor Biopharma Inc,5050921121,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,133,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Vor Biopharma Inc,5050921121,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,133,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Vor Biopharma Inc,5050921121,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,133,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
ATAI Life Sciences NV,5080054459,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,132,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Day One Biopharmaceuticals Inc,5079901024,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Day One Biopharmaceuticals Inc,5079901024,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,130,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Neximmune Inc,5037275804,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,128,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Neximmune Inc,5037275804,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,128,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Nykode Therapeutics ASA,5035525105,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,127,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Nykode Therapeutics ASA,5035525105,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,127,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Bioventix PLC,4296127814,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,125,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Shield Therapeutics PLC,5046664318,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,124,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
M Cash Integrasi Tbk PT,5057939443,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,122,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
M Cash Integrasi Tbk PT,5057939443,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,122,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Aileron Therapeutics Inc,4297864562,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,120,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Aileron Therapeutics Inc,4297864562,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,120,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Aileron Therapeutics Inc,4297864562,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,120,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Okomu Oil Palm Company PLC,4295986151,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,119,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Inventiva SA,5037845589,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,0.0,116,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
ESSA Pharma Inc,5037363591,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,115,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Elicio Therapeutics Inc,5000644263,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,113,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Elicio Therapeutics Inc,5000644263,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,113,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Gamida Cell Ltd,4296875405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,113,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Gamida Cell Ltd,4296875405,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,113,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Elicio Therapeutics Inc,5000644263,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,113,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Forma Therapeutics Holdings Inc,5037435569,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,107,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Forma Therapeutics Holdings Inc,5037435569,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,107,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Celgene Corp,4295905897,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,99,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
INSYS Therapeutics Inc,5035155013,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,99,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Celgene Corp,4295905897,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,99,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
INSYS Therapeutics Inc,5035155013,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,99,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Allena Pharmaceuticals Inc,5036777605,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,98,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Allena Pharmaceuticals Inc,5036777605,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,98,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Eidos Therapeutics Inc,5055476555,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,94,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Eidos Therapeutics Inc,5055476555,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,94,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Forty Seven Inc,5005164140,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,93,S_opportunity,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Supply_Chain_Integrity
Forty Seven Inc,5005164140,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,93,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Forty Seven Inc,5005164140,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,93,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
"Codiak BioSciences, Inc.",5047640766,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,93,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
"Codiak BioSciences, Inc.",5047640766,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,93,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
F-Star Therapeutics Inc,5035561393,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,91,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Principia Biopharma Inc,5034759295,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,91,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Principia Biopharma Inc,5034759295,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,91,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
F-Star Therapeutics Inc,5035561393,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,91,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Immunic Inc,4295983152,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,90,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Immunic Inc,4295983152,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,90,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Impel Pharmaceuticals Inc,4298072043,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,88,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Impel Pharmaceuticals Inc,4298072043,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,88,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Impel Pharmaceuticals Inc,4298072043,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,88,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Active Fine Chemicals Ltd,5001218171,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,86,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
MyoKardia Inc,5037638327,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,80,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
MyoKardia Inc,5037638327,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,80,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Akcea Therapeutics Inc,5046039618,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,78,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Akcea Therapeutics Inc,5046039618,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,78,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ra Pharmaceuticals Inc,5000662981,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,73,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Ra Pharmaceuticals Inc,5000662981,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,73,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ECC Pharm Ltd,4295856905,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,67,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
ECC Pharm Ltd,4295856905,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,67,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Hamburger Sparkasse AG,4296880258,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,127,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Hamburger Sparkasse AG,4296880258,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,127,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Biophytis SA,5035564282,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,89,S_opportunity,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Supply_Chain_Integrity
Biophytis SA,5035564282,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,89,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Supply_Chain_Integrity
Biophytis SA,5035564282,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,89,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Supply_Chain_Integrity
Biophytis SA,5035564282,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,89,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Supply_Chain_Integrity
Biophytis SA,5035564282,quantitative,CALCULATED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,0.0,89,S_opportunity,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Supply_Chain_Integrity
Piramal Pharma Ltd,5074845229,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,63,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Piramal Pharma Ltd,5074845229,quantitative,REPORTED,Does the company have a due diligence process in place to prevent/ act upon human right abuses? Both in its operations and suppliers’ operations?,HUMAN_RIGHTS_POLICY_DUEDILIGENCE,1.0,63,S_opportunity,Biotechnology & Pharmaceuticals,2024,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mizuho International PLC,4296699872,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,53,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Mizuho International PLC,4296699872,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,53,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
KK M&A Research Institute,5071570715,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,46,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Greenlight Biosciences Holdings PBC,5079236516,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,17,S_opportunity,Biotechnology & Pharmaceuticals,2023,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Greenlight Biosciences Holdings PBC,5079236516,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,17,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Catalent Pharma Solutions Inc,4295911386,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,16,S_opportunity,Biotechnology & Pharmaceuticals,2022,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
Teva Pharmaceutical Finance IV BV,5036348599,quantitative,REPORTED,Does the company report or show to use human rights criteria in the selection or monitoring process of its suppliers or sourcing partners?,HUMAN_RIGHTS_CONTRACTOR,1.0,7,S_opportunity,Biotechnology & Pharmaceuticals,2019,0.4149377593360995,0.6931471805599453,Supply_Chain_Integrity
PharmaSGP Holding SE,5074558504,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
PharmaSGP Holding SE,5074558504,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Immunocore Holdings PLC,5079691460,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aziyo Biologics Inc,5047231061,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,156,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
2Seventy Bio Inc,5081079448,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Amylyx Pharmaceuticals Inc,5044011252,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Amylyx Pharmaceuticals Inc,5044011252,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Amylyx Pharmaceuticals Inc,5044011252,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Amylyx Pharmaceuticals Inc,5044011252,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,146,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Shenzhen New Industries Biomedical Engineering Co Ltd,5041976582,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.71,146,S_risk,Biotechnology & Pharmaceuticals,2022,0.284,0.5364933705145685,Drug_Safety
Afyren SAS,5047106998,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Afyren SAS,5047106998,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Afyren SAS,5047106998,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Afyren SAS,5047106998,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Afyren SAS,5047106998,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Afyren SAS,5047106998,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Afyren SAS,5047106998,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Loxam SAS,4297463274,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,136,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Loxam SAS,4297463274,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Loxam SAS,4297463274,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Geneuro SA,5035525137,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,133,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Athora Netherlands NV,4296558856,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,131,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Abivax SA,5041076826,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,128,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Genor Biopharma Holdings Ltd,5064614344,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,124,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Genor Biopharma Holdings Ltd,5064614344,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,124,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ama Corporation PLC,5080040632,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,118,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Ama Corporation PLC,5080040632,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,118,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ama Corporation PLC,5080040632,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,118,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Ama Corporation PLC,5080040632,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,118,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Ama Corporation PLC,5080040632,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,118,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Prime Medicine Inc,5079223028,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,118,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Anhui Huaheng Biotechnology Co Ltd,5043319507,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.48,115,S_risk,Biotechnology & Pharmaceuticals,2023,0.592,0.9082585601768908,Drug_Safety
Anhui Huaheng Biotechnology Co Ltd,5043319507,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,115,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Anhui Huaheng Biotechnology Co Ltd,5043319507,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,115,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
SciClone Pharmaceuticals (Holdings) Ltd,5076693566,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,109,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kim Forest Enterprise Co Ltd,5044674796,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,105,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Genetron Holdings Ltd,5071553510,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,104,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Genetron Holdings Ltd,5071553510,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,104,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Genetron Holdings Ltd,5071553510,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,104,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Biora Therapeutics Inc,5044195095,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,103,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shree Ganesh Remedies Ltd,5057777372,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
FYI Resources Ltd,4295857627,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
FYI Resources Ltd,4295857627,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
FYI Resources Ltd,4295857627,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Workforce_Development
FYI Resources Ltd,4295857627,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
FYI Resources Ltd,4295857627,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,102,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
FYI Resources Ltd,4295857627,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Workforce_Development
FYI Resources Ltd,4295857627,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Wuhan Keqian Biology Co Ltd,5038069872,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
BrightGene Bio-Medical Technology Co Ltd,5040263043,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS,5034802731,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,98,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS,5034802731,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Jacobio Pharmaceuticals Group Co Ltd,5077892545,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,97,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Jacobio Pharmaceuticals Group Co Ltd,5077892545,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,97,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Jacobio Pharmaceuticals Group Co Ltd,5077892545,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,97,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Jacobio Pharmaceuticals Group Co Ltd,5077892545,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,97,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Jacobio Pharmaceuticals Group Co Ltd,5077892545,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,97,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Beijing Wantai Biological Pharmacy Enterprise Co Ltd,5035525611,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,94,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Medicenna Therapeutics Corp,5045915928,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,94,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Beijing Wantai Biological Pharmacy Enterprise Co Ltd,5035525611,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,94,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Jiangsu Bioperfectus Technologies Co Ltd,5043324074,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,93,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Pure Biologics SA,5064585830,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,93,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Pure Biologics SA,5064585830,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,93,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Jiangsu Bioperfectus Technologies Co Ltd,5043324074,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,93,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jiangsu Lihua Animal Husbandry Co Ltd,5050703084,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,91,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aegirbio AB,5073157453,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,91,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Aegirbio AB,5073157453,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,91,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aegirbio AB,5073157453,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,91,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Aegirbio AB,5073157453,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,91,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
SMS Lifesciences India Ltd,5036193996,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,89,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shanghai Haoyuan Chemexpress Co Ltd,5053083973,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,89,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shanghai Haoyuan Chemexpress Co Ltd,5053083973,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,89,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Shanghai Haoyuan Chemexpress Co Ltd,5053083973,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,89,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Compass Therapeutics Inc.,5064570789,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,88,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Immunome Inc,5000458922,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,88,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Immunome Inc,5000458922,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,88,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CellSource Co Ltd,5071396634,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Auro Laboratories Ltd,4296008176,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,87,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Advent Pharma Ltd,5060541390,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,86,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PepGen Inc,5079227040,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,86,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ambrx Biopharma Cayman Inc,5064030388,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,85,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Ambrx Biopharma Cayman Inc,5064030388,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,85,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Ambrx Biopharma Cayman Inc,5064030388,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,85,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Living Technologies Inc,5069413572,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,84,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jetema Co Ltd,5050912648,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,83,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhejiang Orient Gene Biotech Co Ltd,5068319044,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,81,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
AMI Organics Ltd,5038066181,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,80,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
AMI Organics Ltd,5038066181,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,80,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
AMI Organics Ltd,5038066181,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,80,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
TOT BIOPHARM International Co Ltd,5035255038,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,76,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Ultimovacs ASA,5038062852,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,75,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ultimovacs ASA,5038062852,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,75,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Vanta Bioscience Ltd,5056410133,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,74,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Summit Therapeutics Ltd,4295894441,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,69,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
MiLOC Group Ltd,5000835814,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,68,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Adagio Therapeutics Inc,5076161534,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,67,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Adagio Therapeutics Inc,5076161534,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,67,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aether Industries Ltd,5064581591,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,67,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Abionyx Pharma SA,4297177308,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,62,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Immunotech Biopharm Ltd,5064592404,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,61,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Immunotech Biopharm Ltd,5064592404,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,61,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Immunotech Biopharm Ltd,5064592404,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,61,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Immunotech Biopharm Ltd,5064592404,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,61,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Predilife SA,5035544919,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,60,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ReNeuron Group PLC,4295894218,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,59,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Biogend Therapeutics Co Ltd,5057860206,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,59,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sansure Biotech Inc,5046056662,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,56,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Calidus Resources Ltd,4295858042,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,55,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Glenmark Life Sciences Ltd,5071163514,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,55,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Glenmark Life Sciences Ltd,5071163514,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,55,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Glenmark Life Sciences Ltd,5071163514,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,55,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
MedPacto Inc,5041082008,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,54,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Infant Bacterial Therapeutics AB,5040202605,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,54,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
MedPacto Inc,5041082008,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,54,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
MedPacto Inc,5041082008,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,54,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Exact Therapeutics AS,5043372331,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,53,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Exact Therapeutics AS,5043372331,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,53,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Exact Therapeutics AS,5043372331,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,53,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Portage Biotech Inc,5040245430,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,52,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Synergy Pharmaceuticals LLC,5037621320,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,50,S_risk,Biotechnology & Pharmaceuticals,2017,0.4,0.6931471805599453,Business_Ethics
Sunshine Guojian Pharmaceutical Shanghai Co Ltd,5035901064,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,49,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sunshine Guojian Pharmaceutical Shanghai Co Ltd,5035901064,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,49,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Sunshine Guojian Pharmaceutical Shanghai Co Ltd,5035901064,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,49,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Arqit Quantum Inc,5080167774,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,47,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Arqit Quantum Inc,5080167774,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,47,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
OliPass Corp,5035547409,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,46,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Celularity Inc,5068933591,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,46,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
InflaRx NV,5057951351,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,41,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
InflaRx NV,5057951351,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,41,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Makedonijaturist AD Skopje,4296211730,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,38,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
POINT Biopharma Global Inc,5074783900,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,28,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Uni Pharma Co Ltd,5035561501,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,18,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Accenture SAS,4298161238,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,16,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Rohto Pharmaceutical Co Ltd,4295877894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,251,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Rohto Pharmaceutical Co Ltd,4295877894,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,251,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
SK Biopharmaceuticals Co Ltd,5036772845,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Akeso Inc,5004716215,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Akeso Inc,5004716215,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Akeso Inc,5004716215,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Akeso Inc,5004716215,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Akeso Inc,5004716215,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Akeso Inc,5004716215,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Akeso Inc,5004716215,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Akeso Inc,5004716215,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Akeso Inc,5004716215,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Akeso Inc,5004716215,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Akeso Inc,5004716215,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Akeso Inc,5004716215,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Akeso Inc,5004716215,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
United Company RUSAL Plc,5000619007,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
United Company RUSAL Plc,5000619007,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.05,242,S_risk,Biotechnology & Pharmaceuticals,2023,0.42,0.7178397931503169,Drug_Safety
United Company RUSAL Plc,5000619007,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
United Company RUSAL Plc,5000619007,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
United Company RUSAL Plc,5000619007,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
United Company RUSAL Plc,5000619007,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.35,242,S_risk,Biotechnology & Pharmaceuticals,2021,0.54,0.8544153281560676,Drug_Safety
Certara Inc,5078554280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
RaySearch Laboratories AB (publ),4295889885,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
RaySearch Laboratories AB (publ),4295889885,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
RaySearch Laboratories AB (publ),4295889885,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Immunitybio Inc,5046045471,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Immunitybio Inc,5046045471,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Immunitybio Inc,5046045471,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Certara Inc,5078554280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
RaySearch Laboratories AB (publ),4295889885,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Rapid Nutrition PLC,5042944492,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,236,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,231,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,231,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.75,231,S_risk,Biotechnology & Pharmaceuticals,2023,0.3,0.5596157879354227,Drug_Safety
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,231,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Zhejiang Jiuzhou Pharmaceutical Co Ltd,4298151119,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,231,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Mochida Pharmaceutical Co Ltd,4295877793,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
VIVA Biotech Holdings,5064663384,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
VIVA Biotech Holdings,5064663384,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,227,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
VIVA Biotech Holdings,5064663384,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,227,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
VIVA Biotech Holdings,5064663384,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,227,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
VIVA Biotech Holdings,5064663384,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,227,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
VIVA Biotech Holdings,5064663384,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
VIVA Biotech Holdings,5064663384,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,227,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
VIVA Biotech Holdings,5064663384,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,227,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
PharmaEngine Inc,5035255012,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
PharmaEngine Inc,5035255012,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
PharmaEngine Inc,5035255012,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Grand Pharmaceutical Group Ltd,4295871045,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
PharmaEngine Inc,5035255012,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
PharmaEngine Inc,5035255012,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
PharmaEngine Inc,5035255012,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.1,217,S_risk,Biotechnology & Pharmaceuticals,2022,0.04,0.0953101798043248,Drug_Safety
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
PharmaEngine Inc,5035255012,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
PharmaEngine Inc,5035255012,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
PharmaEngine Inc,5035255012,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Grand Pharmaceutical Group Ltd,4295871045,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Grand Pharmaceutical Group Ltd,4295871045,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,216,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,216,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Procter & Gamble Hygiene and Health Care Ltd,4295872700,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,216,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Procter & Gamble Hygiene and Health Care Ltd,4295872700,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.63,216,S_risk,Biotechnology & Pharmaceuticals,2024,0.252,0.4885800148186709,Drug_Safety
Hikal Ltd,4295873814,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,215,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hikal Ltd,4295873814,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.13,215,S_risk,Biotechnology & Pharmaceuticals,2023,0.052,0.1222176327242492,Drug_Safety
Hikal Ltd,4295873814,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,215,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Hikal Ltd,4295873814,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,215,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Hikal Ltd,4295873814,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,215,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Hikal Ltd,4295873814,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,215,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Vaxcyte Inc,5040942643,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,215,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Vaxcyte Inc,5040942643,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,215,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Neuland Laboratories Ltd,4295872314,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,214,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Neuland Laboratories Ltd,4295872314,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Neuland Laboratories Ltd,4295872314,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,214,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Neuland Laboratories Ltd,4295872314,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Neuland Laboratories Ltd,4295872314,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,214,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,213,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Shanghai Junshi Biosciences Co Ltd,5044196366,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,213,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shanghai Junshi Biosciences Co Ltd,5044196366,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,213,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,213,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Shanghai Junshi Biosciences Co Ltd,5044196366,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,213,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Shanghai Junshi Biosciences Co Ltd,5044196366,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,213,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Summit Therapeutics Inc,5076940644,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,212,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shandong Xinhua Pharmaceutical Co Ltd,4295864184,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,209,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shandong Xinhua Pharmaceutical Co Ltd,4295864184,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ascentage Pharma Group International,5071509965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ascentage Pharma Group International,5071509965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Ascentage Pharma Group International,5071509965,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ascentage Pharma Group International,5071509965,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ascentage Pharma Group International,5071509965,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Ascentage Pharma Group International,5071509965,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Ascentage Pharma Group International,5071509965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ascentage Pharma Group International,5071509965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Ascentage Pharma Group International,5071509965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Sun Pharma Advanced Research Co Ltd,4295872154,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Sun Pharma Advanced Research Co Ltd,4295872154,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sun Pharma Advanced Research Co Ltd,4295872154,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,205,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Sun Pharma Advanced Research Co Ltd,4295872154,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,205,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Hofseth Biocare ASA,5035906262,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,204,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Silence Therapeutics PLC,4295895614,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hofseth Biocare ASA,5035906262,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hofseth Biocare ASA,5035906262,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hofseth Biocare ASA,5035906262,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,204,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Hofseth Biocare ASA,5035906262,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Jacobson Pharma Corporation Ltd,5050900566,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jacobson Pharma Corporation Ltd,5050900566,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Jacobson Pharma Corporation Ltd,5050900566,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Kuros Biosciences AG,4295890889,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Medivir AB,4295890107,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,201,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Medivir AB,4295890107,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,201,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Medivir AB,4295890107,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,201,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Orchid Pharma Ltd,4295872729,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,201,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Orchid Pharma Ltd,4295872729,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,201,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Orchid Pharma Ltd,4295872729,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,201,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.48,200,S_risk,Biotechnology & Pharmaceuticals,2023,0.192,0.3920420877760237,Drug_Safety
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.5,200,S_risk,Biotechnology & Pharmaceuticals,2021,0.2,0.4054651081081644,Drug_Safety
SK Bioscience Co Ltd,5064623101,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,200,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.35,200,S_risk,Biotechnology & Pharmaceuticals,2018,0.94,1.208960345836975,Drug_Safety
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,200,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,200,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,200,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,200,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,200,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,200,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
SK Bioscience Co Ltd,5064623101,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,200,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Legend Biotech Corp,5056412290,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,199,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shattuck Labs Inc,5051773339,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,199,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shattuck Labs Inc,5051773339,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,199,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Immunovant Inc,5068663165,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,198,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Immunovant Inc,5068663165,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,198,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Immunovant Inc,5068663165,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,198,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
JCR Pharmaceuticals Co Ltd,4295877033,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.9,195,S_risk,Biotechnology & Pharmaceuticals,2021,0.76,1.0647107369924282,Workforce_Development
JCR Pharmaceuticals Co Ltd,4295877033,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,195,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
JCR Pharmaceuticals Co Ltd,4295877033,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.8,195,S_risk,Biotechnology & Pharmaceuticals,2019,0.72,1.0296194171811583,Workforce_Development
Fine Foods & Pharmaceuticals NTM SpA,5052128850,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Abbott India Ltd,4295873246,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Pembangunan Perumahan (Persero) Tbk PT,4295933662,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Newron Pharmaceuticals SpA,4295875695,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pembangunan Perumahan (Persero) Tbk PT,4295933662,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Fine Foods & Pharmaceuticals NTM SpA,5052128850,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Pembangunan Perumahan (Persero) Tbk PT,4295933662,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Fine Foods & Pharmaceuticals NTM SpA,5052128850,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Pembangunan Perumahan (Persero) Tbk PT,4295933662,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Pembangunan Perumahan (Persero) Tbk PT,4295933662,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Fine Foods & Pharmaceuticals NTM SpA,5052128850,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Fine Foods & Pharmaceuticals NTM SpA,5052128850,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pembangunan Perumahan (Persero) Tbk PT,4295933662,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Newron Pharmaceuticals SpA,4295875695,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Annexon Inc,5038791948,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Annexon Inc,5038791948,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pembangunan Perumahan (Persero) Tbk PT,4295933662,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,194,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Abbott India Ltd,4295873246,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Chunghwa Chemical Synthesis & Biotech Co Ltd,4297933413,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,193,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Chunghwa Chemical Synthesis & Biotech Co Ltd,4297933413,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,193,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Seer Inc,5060207077,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,193,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Chunghwa Chemical Synthesis & Biotech Co Ltd,4297933413,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,193,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
ALX Oncology Holdings Inc,5074847748,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alterity Therapeutics Ltd,4295857196,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Wakamoto Pharmaceutical Co Ltd,4295878544,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,192,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ALX Oncology Holdings Inc,5074847748,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Miko NV,4295859478,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Marksans Pharma Ltd,4295873633,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Marksans Pharma Ltd,4295873633,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,191,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Novartis India Ltd,4295872270,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Sigilon Therapeutics Inc,5055943391,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Sigilon Therapeutics Inc,5055943391,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Marksans Pharma Ltd,4295873633,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,191,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Novartis India Ltd,4295872270,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Marksans Pharma Ltd,4295873633,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,191,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Marksans Pharma Ltd,4295873633,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,191,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Miko NV,4295859478,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
PharmaEssentia Corp,4297703294,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,190,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
PharmaEssentia Corp,4297703294,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,190,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PharmaEssentia Corp,4297703294,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,190,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aptose Biosciences Inc,4295861982,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Taiwan FamilyMart Co Ltd,4295892674,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Taiwan FamilyMart Co Ltd,4295892674,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,189,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Taiwan FamilyMart Co Ltd,4295892674,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.61,189,S_risk,Biotechnology & Pharmaceuticals,2021,0.244,0.4762341789963716,Drug_Safety
Aptose Biosciences Inc,4295861982,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Taiwan FamilyMart Co Ltd,4295892674,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,189,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Taiwan FamilyMart Co Ltd,4295892674,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.35,189,S_risk,Biotechnology & Pharmaceuticals,2023,0.1399999999999999,0.300104592450338,Drug_Safety
Aptose Biosciences Inc,4295861982,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Taiwan FamilyMart Co Ltd,4295892674,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Taiwan FamilyMart Co Ltd,4295892674,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.75,189,S_risk,Biotechnology & Pharmaceuticals,2022,0.3,0.5596157879354227,Drug_Safety
Taiwan FamilyMart Co Ltd,4295892674,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Organon & Co,5080031678,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.9,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.36,0.6418538861723948,Drug_Safety
Bolt Biotherapeutics Inc,5057818417,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Antibiotice SA,4296440714,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Indoco Remedies Ltd,4295873905,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Indoco Remedies Ltd,4295873905,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Bolt Biotherapeutics Inc,5057818417,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Indoco Remedies Ltd,4295873905,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Antibiotice SA,4296440714,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Antibiotice SA,4296440714,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Organon & Co,5080031678,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Antibiotice SA,4296440714,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Astria Therapeutics Inc,4298140380,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Indoco Remedies Ltd,4295873905,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Astria Therapeutics Inc,4298140380,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
BioInvent International AB,4295889923,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Alpha Teknova Inc,5002454841,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
BioInvent International AB,4295889923,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Organon & Co,5080031678,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
BioInvent International AB,4295889923,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Organon & Co,5080031678,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Organon & Co,5080031678,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Indoco Remedies Ltd,4295873905,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alpha Teknova Inc,5002454841,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Indoco Remedies Ltd,4295873905,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
4D Molecular Therapeutics Inc,5046652758,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
4D Molecular Therapeutics Inc,5046652758,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Inozyme Pharma Inc,5052794383,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,186,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Inozyme Pharma Inc,5052794383,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,186,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Inozyme Pharma Inc,5052794383,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,186,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Granules India Ltd,4295873932,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,184,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ikena Oncology Inc,5059957115,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Granules India Ltd,4295873932,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Granules India Ltd,4295873932,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.11,184,S_risk,Biotechnology & Pharmaceuticals,2024,0.044,0.1043600153242427,Drug_Safety
Kronos Bio Inc,5064284477,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Kronos Bio Inc,5064284477,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,184,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Kronos Bio Inc,5064284477,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Ikena Oncology Inc,5059957115,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,184,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ikena Oncology Inc,5059957115,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Granules India Ltd,4295873932,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,184,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Ikena Oncology Inc,5059957115,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kronos Bio Inc,5064284477,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Atea Pharmaceuticals Inc,5040791368,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Atea Pharmaceuticals Inc,5040791368,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sawai Group Holdings Co Ltd,5079209190,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Zevra Therapeutics Inc,5044167023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Zevra Therapeutics Inc,5044167023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
ProQR Therapeutics NV,5038906661,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Avenue Therapeutics Inc,5045106861,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,182,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Akoya Biosciences Inc,5056728883,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Akoya Biosciences Inc,5056728883,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Avenue Therapeutics Inc,5045106861,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,182,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Avenue Therapeutics Inc,5045106861,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,182,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Quince Therapeutics Inc,5042946656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Jiangsu Nhwa Pharmaceutical Co Ltd,4298052371,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Jiangsu Nhwa Pharmaceutical Co Ltd,4298052371,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,182,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Akoya Biosciences Inc,5056728883,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Quince Therapeutics Inc,5042946656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Quince Therapeutics Inc,5042946656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
ProQR Therapeutics NV,5038906661,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,182,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Athira Pharma Inc,5057940063,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,181,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Galectin Therapeutics Inc,4295908397,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,181,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Athira Pharma Inc,5057940063,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,181,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Athira Pharma Inc,5057940063,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,181,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Galectin Therapeutics Inc,4295908397,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,181,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Imugene Ltd,4295858255,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,180,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Imugene Ltd,4295858255,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,180,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Ampio Pharmaceuticals Inc,5000686554,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,180,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Imugene Ltd,4295858255,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,180,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Imugene Ltd,4295858255,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,180,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Ampio Pharmaceuticals Inc,5000686554,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,180,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Ampio Pharmaceuticals Inc,5000686554,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,180,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Imugene Ltd,4295858255,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,180,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Imugene Ltd,4295858255,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,180,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Kyorin Pharmaceutical Co Ltd,4295880327,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.29,179,S_risk,Biotechnology & Pharmaceuticals,2024,0.516,0.8285518175661483,Drug_Safety
Kyorin Pharmaceutical Co Ltd,4295880327,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,179,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Brainstorm Cell Therapeutics Inc,4295899439,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Brainstorm Cell Therapeutics Inc,4295899439,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Brainstorm Cell Therapeutics Inc,4295899439,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Brainstorm Cell Therapeutics Inc,4295899439,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,179,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Actinium Pharmaceuticals Inc,5039585048,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,179,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Brainstorm Cell Therapeutics Inc,4295899439,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,179,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Navamedic ASA,4297516229,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,177,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Austar Lifesciences Ltd,5044029401,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,177,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Chongkundang Holdings Corp,4295880919,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,177,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Navamedic ASA,4297516229,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,177,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Chongkundang Holdings Corp,4295880919,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.15,177,S_risk,Biotechnology & Pharmaceuticals,2022,0.06,0.1397619423751586,Drug_Safety
Chongkundang Holdings Corp,4295880919,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,177,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Austar Lifesciences Ltd,5044029401,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,177,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Chongkundang Holdings Corp,4295880919,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.72,177,S_risk,Biotechnology & Pharmaceuticals,2023,0.288,0.5423242908253617,Drug_Safety
SeQuent Scientific Ltd,4295873850,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,176,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
SeQuent Scientific Ltd,4295873850,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,176,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
SeQuent Scientific Ltd,4295873850,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,176,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Daito Pharmaceutical Co Ltd,4296616956,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,176,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
SeQuent Scientific Ltd,4295873850,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,176,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
SeQuent Scientific Ltd,4295873850,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.28,176,S_risk,Biotechnology & Pharmaceuticals,2023,0.112,0.2468600779315258,Drug_Safety
Frontage Holdings Corp,5068328255,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,176,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Frontage Holdings Corp,5068328255,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,176,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Frontage Holdings Corp,5068328255,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,176,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Nanobiotix SA,4297696426,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,175,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Caplin Point Laboratories Ltd,4296008194,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.29,175,S_risk,Biotechnology & Pharmaceuticals,2023,0.1159999999999999,0.2546422183735807,Drug_Safety
Adimmune Corp,4296974440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,175,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Nanobiotix SA,4297696426,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,175,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Adimmune Corp,4296974440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,175,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Caplin Point Laboratories Ltd,4296008194,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,175,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Caplin Point Laboratories Ltd,4296008194,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,175,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Merrimack Pharmaceuticals Inc,5001210278,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,174,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Merrimack Pharmaceuticals Inc,5001210278,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,174,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Rapid Micro Biosystems Inc,4297712966,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,174,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Rapid Micro Biosystems Inc,4297712966,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,174,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Merrimack Pharmaceuticals Inc,5001210278,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,174,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Merrimack Pharmaceuticals Inc,5001210278,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,174,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lavipharm SA,4295870454,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.64,173,S_risk,Biotechnology & Pharmaceuticals,2023,0.6559999999999999,0.9707789171582248,Drug_Safety
China NT Pharma Group Company Ltd,5034759579,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,173,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
China NT Pharma Group Company Ltd,5034759579,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,173,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Lavipharm SA,4295870454,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,173,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Indofarma Tbk PT,4295874355,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,173,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
China NT Pharma Group Company Ltd,5034759579,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,173,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lavipharm SA,4295870454,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,173,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Indofarma Tbk PT,4295874355,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,173,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Enad Global 7 AB (publ),5058529334,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Seelos Therapeutics Inc,4295914354,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CureVac NV,5076167305,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CureVac NV,5076167305,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Terns Pharmaceuticals Inc,5079683393,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,172,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Terns Pharmaceuticals Inc,5079683393,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,172,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Enad Global 7 AB (publ),5058529334,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Yield10 Bioscience Inc,4295907348,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Terns Pharmaceuticals Inc,5079683393,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,172,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Seelos Therapeutics Inc,4295914354,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Terns Pharmaceuticals Inc,5079683393,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Biomea Fusion Inc,5079682650,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,171,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Biomea Fusion Inc,5079682650,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,171,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
89Bio Inc,5071508069,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,171,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Absci Corp,5041077561,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,171,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
89Bio Inc,5071508069,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,171,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Square Pharmaceuticals PLC,4295917193,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,171,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Absci Corp,5041077561,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,171,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
COFCO Biotechnology Co Ltd,4295864904,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,170,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
TIE Kinetix NV,4295884984,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,170,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Praxis Precision Medicines Inc,5052506535,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,170,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Praxis Precision Medicines Inc,5052506535,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,170,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Calliditas Therapeutics AB,5035524063,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,169,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Enliven Therapeutics Inc,5050721453,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,169,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Calliditas Therapeutics AB,5035524063,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,169,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Enliven Therapeutics Inc,5050721453,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,169,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
BELLUS Health Inc (Pre Merger),5037589093,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,168,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
NeuBase Therapeutics Inc,4295905287,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Animalcare Group PLC,4295894891,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,168,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Eterna Therapeutics Inc,4295904574,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
NeuBase Therapeutics Inc,4295905287,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Fuji Pharma Co Ltd,4295879670,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,168,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lumos Pharma Inc,4296943235,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
BELLUS Health Inc (Pre Merger),5037589093,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,168,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Kimia Farma Tbk PT,4295874603,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
BRAIN Biotech AG,5001178117,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Shanghai Henlius Biotech Inc,5035931646,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kimia Farma Tbk PT,4295874603,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shanghai Henlius Biotech Inc,5035931646,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Kimia Farma Tbk PT,4295874603,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.75,167,S_risk,Biotechnology & Pharmaceuticals,2020,0.7,1.01160091167848,Drug_Safety
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Shanghai Henlius Biotech Inc,5035931646,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Lyell Immunopharma Inc,5068932905,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,166,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Kinnate Biopharma Inc,5064597398,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,166,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Lyell Immunopharma Inc,5068932905,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,166,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Landos Biopharma Inc,5057796911,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,166,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Landos Biopharma Inc,5057796911,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,166,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Landos Biopharma Inc,5057796911,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,166,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kinnate Biopharma Inc,5064597398,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,166,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Kinnate Biopharma Inc,5064597398,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,166,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Porton Pharma Solutions Ltd,5035549423,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,165,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Law Debenture Corporation PLC,4295894011,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,165,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bliss GVS Pharma Ltd,4295872849,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,165,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Porton Pharma Solutions Ltd,5035549423,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,165,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Seikagaku Corp,4295877088,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,165,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bliss GVS Pharma Ltd,4295872849,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,165,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Porton Pharma Solutions Ltd,5035549423,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,165,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Telesis Bio Inc,5057828183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Formosa Laboratories Inc,4297684222,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cullinan Oncology Inc,5072825369,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,164,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Prelude Therapeutics Inc,5057989338,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Caribou Biosciences Inc,5044007186,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Caribou Biosciences Inc,5044007186,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cullinan Oncology Inc,5072825369,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,164,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Telesis Bio Inc,5057828183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cullinan Oncology Inc,5072825369,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,164,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Formosa Laboratories Inc,4297684222,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
PMV Pharmaceuticals Inc,5041748144,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Prelude Therapeutics Inc,5057989338,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Mustang Bio Inc,5045675573,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,163,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Mustang Bio Inc,5045675573,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,163,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Mustang Bio Inc,5045675573,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,163,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Mustang Bio Inc,5045675573,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,163,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Finch Therapeutics Group Inc,5058533657,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,162,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Finch Therapeutics Group Inc,5058533657,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,162,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Janux Therapeutics Inc,5066630289,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Epigenomics AG,4295870322,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,161,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Dyne Therapeutics Inc,5068481524,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Abcellera Biologics Inc,5049432057,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Dyne Therapeutics Inc,5068481524,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Deva Holding AS,4295893628,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dyne Therapeutics Inc,5068481524,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Bicycle Therapeutics PLC,5068933601,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Bicycle Therapeutics PLC,5068933601,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,161,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Intervacc AB,5037142061,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,161,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Abcellera Biologics Inc,5049432057,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Semen Baturaja (Persero) Tbk PT,5000035952,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Intervacc AB,5037142061,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,161,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Epigenomics AG,4295870322,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,161,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
DaShenLin Pharmaceutical Group Co Ltd,5000560542,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,160,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Oric Pharmaceuticals Inc,5047749756,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,160,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Oric Pharmaceuticals Inc,5047749756,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,160,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alexion Pharmaceuticals Inc (Pre-Merger),4295905466,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,160,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
DaShenLin Pharmaceutical Group Co Ltd,5000560542,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,160,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Beximco Pharmaceuticals Ltd,4295917535,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,159,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Instil Bio Inc,5071491737,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shanghai Pioneer Holding Ltd,5040256767,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Dong-A Socio Holdings Co Ltd,4295881559,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Northwest Biotherapeutics Inc,4295901912,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Unichem Laboratories Ltd,4295873083,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,159,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Beximco Pharmaceuticals Ltd,4295917535,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,159,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Unichem Laboratories Ltd,4295873083,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,159,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Unichem Laboratories Ltd,4295873083,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Shanghai Pioneer Holding Ltd,5040256767,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,159,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Instil Bio Inc,5071491737,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dong-A Socio Holdings Co Ltd,4295881559,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shanghai Pioneer Holding Ltd,5040256767,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Northwest Biotherapeutics Inc,4295901912,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Science in Sport PLC,5040055145,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Eris Lifesciences Ltd,5037652293,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
TCR2 Therapeutics Inc,5048737252,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Spruce Biosciences Inc,5050913816,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Science in Sport PLC,5040055145,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ocugen Inc,4297321713,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Atossa Therapeutics Inc,5000707569,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Atossa Therapeutics Inc,5000707569,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Standard Chem & Pharm Co Ltd,4295891132,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Atossa Therapeutics Inc,5000707569,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ocugen Inc,4297321713,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Standard Chem & Pharm Co Ltd,4295891132,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Torii Pharmaceutical Co Ltd,4295879868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,156,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
PolyPeptide Group AG,5080152257,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,156,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
PolyPeptide Group AG,5080152257,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,156,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Torii Pharmaceutical Co Ltd,4295879868,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,156,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
CASI Pharmaceuticals Inc(Pre-Merger),4295906369,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Medincell SA,5035542581,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,155,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Biofrontera AG,4295870275,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,155,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
IMV Inc,4297852426,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Omega Therapeutics Inc,5071401332,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Biofrontera AG,4295870275,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,155,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Medincell SA,5035542581,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Alkaloid AD Skopje,4297979819,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
IMV Inc,4297852426,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Nippon Chemiphar Co Ltd,4295877828,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Bioporto A/S,4295866112,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Verve Therapeutics Inc,5074728022,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Omega Therapeutics Inc,5071401332,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Verve Therapeutics Inc,5074728022,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
EirGenix Inc,5043462764,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Medincell SA,5035542581,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,155,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Verve Therapeutics Inc,5074728022,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Nippon Chemiphar Co Ltd,4295877828,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Alkaloid AD Skopje,4297979819,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,155,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
EirGenix Inc,5043462764,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,155,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bioporto A/S,4295866112,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,155,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Matinas BioPharma Holdings Inc,5040202545,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Singular Genomics Systems Inc,5059153058,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sensei Biotherapeutics Inc,5079691095,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Citius Pharmaceuticals Inc,5001218237,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Citius Pharmaceuticals Inc,5001218237,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sensei Biotherapeutics Inc,5079691095,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Aerovate Therapeutics Inc,5073109516,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Enorama Pharma AB,5050902994,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Enorama Pharma AB,5050902994,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Aerovate Therapeutics Inc,5073109516,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Enorama Pharma AB,5050902994,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Aerovate Therapeutics Inc,5073109516,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Citius Pharmaceuticals Inc,5001218237,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Acumen Pharmaceuticals Inc,4296014538,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,153,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Isu Petasys Co Ltd,4295882697,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.29,153,S_risk,Biotechnology & Pharmaceuticals,2022,0.1159999999999999,0.2546422183735807,Drug_Safety
Isu Petasys Co Ltd,4295882697,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,153,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Isu Petasys Co Ltd,4295882697,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,153,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Isu Petasys Co Ltd,4295882697,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,153,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Corvus Pharmaceuticals Inc,5044197894,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,152,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Corvus Pharmaceuticals Inc,5044197894,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,152,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Werewolf Therapeutics Inc,5067952090,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Werewolf Therapeutics Inc,5067952090,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Werewolf Therapeutics Inc,5067952090,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Werewolf Therapeutics Inc,5067952090,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,151,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Larimar Therapeutics Inc,4296190853,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,150,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Larimar Therapeutics Inc,4296190853,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,150,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
AnGes Inc,4295876807,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,150,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Merkur Privatbank KGaA,4295869733,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,149,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aarti Drugs Ltd,4295873816,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,149,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Aarti Drugs Ltd,4295873816,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,149,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Aarti Drugs Ltd,4295873816,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,149,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aarti Drugs Ltd,4295873816,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,149,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Aarti Drugs Ltd,4295873816,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,149,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Zhejiang Xianju Pharmaceutical Co Ltd,4297898688,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,149,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Merkur Privatbank KGaA,4295869733,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,149,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Zeria Pharmaceutical Co Ltd,4295878660,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,148,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sana Biotechnology Inc,5067499873,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,148,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sana Biotechnology Inc,5067499873,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,148,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Fuso Pharmaceutical Industries Ltd,4295878912,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,148,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Design Therapeutics Inc,5071512585,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,148,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Design Therapeutics Inc,5071512585,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,148,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Century Therapeutics Inc,5070761830,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Century Therapeutics Inc,5070761830,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Century Therapeutics Inc,5070761830,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Century Therapeutics Inc,5070761830,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,147,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Savior Lifetec Corp,5034749574,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Formycon AG,5037846418,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Advanz Pharma Corp Ltd,5073343758,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,147,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Formycon AG,5037846418,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Advanz Pharma Corp Ltd,5073343758,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,147,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Formycon AG,5037846418,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Formycon AG,5037846418,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Savior Lifetec Corp,5034749574,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,147,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Nuvation Bio Inc,5074742864,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,147,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Savior Lifetec Corp,5034749574,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Nuvation Bio Inc,5074742864,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,147,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CohBar Inc,5037441109,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Suven Pharmaceuticals Ltd,5067941170,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.16,146,S_risk,Biotechnology & Pharmaceuticals,2023,0.064,0.1484200051182732,Drug_Safety
Arena Pharmaceuticals Inc,4295900428,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,146,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
CohBar Inc,5037441109,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Suven Pharmaceuticals Ltd,5067941170,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,146,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Arena Pharmaceuticals Inc,4295900428,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Suven Pharmaceuticals Ltd,5067941170,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
CohBar Inc,5037441109,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Arena Pharmaceuticals Inc,4295900428,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Suven Pharmaceuticals Ltd,5067941170,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.34,146,S_risk,Biotechnology & Pharmaceuticals,2024,0.136,0.29266961396282,Drug_Safety
Arena Pharmaceuticals Inc,4295900428,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,146,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Ouro Fino Saude Animal Participacoes SA,5043460110,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,145,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Nymox Pharmaceutical Corp,5052544527,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,145,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Nymox Pharmaceutical Corp,5052544527,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,145,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Synmosa Biopharma Corp,4295892235,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,145,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ouro Fino Saude Animal Participacoes SA,5043460110,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.0,145,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
Edgewise Therapeutics Inc,5071163582,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Humanigen Inc,4297292034,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
YungShin Global Holding Corp,5035905365,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
China Chemical & Pharmaceutical Co Ltd,4295891334,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Prometheus Biosciences Inc,5057940357,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Humanigen Inc,4297292034,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Humanigen Inc,4297292034,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Olema Pharmaceuticals Inc,5035547611,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Olema Pharmaceuticals Inc,5035547611,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Prometheus Biosciences Inc,5057940357,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
AIM ImmunoTech Inc,4295904158,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Prometheus Biosciences Inc,5057940357,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Humanigen Inc,4297292034,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Edgewise Therapeutics Inc,5071163582,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
YungShin Global Holding Corp,5035905365,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Prometheus Biosciences Inc,5057940357,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PhaseBio Pharmaceuticals Inc,5035400506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Magenta Therapeutics Inc,5052528282,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
SCI Pharmtech Inc,4295892340,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
I-Mab,5055417724,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
SCI Pharmtech Inc,4295892340,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
ContraFect Corp,5001150224,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
PhaseBio Pharmaceuticals Inc,5035400506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
I-Mab,5055417724,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,143,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Magenta Therapeutics Inc,5052528282,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
I-Mab,5055417724,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,143,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Nichi-Iko Pharmaceutical Co Ltd,4295876492,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kaleido Biosciences Inc,5051609503,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,142,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shanghai Haohai Biological Technology Co Ltd,5037587864,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Shanghai Haohai Biological Technology Co Ltd,5037587864,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,142,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Caregen Co Ltd,5000740643,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Anhui Anke Biotechnology Group Co Ltd,4296976195,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
SanBio Co Ltd,5045504969,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Caregen Co Ltd,5000740643,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Shanghai Haohai Biological Technology Co Ltd,5037587864,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,142,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Caregen Co Ltd,5000740643,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
SanBio Co Ltd,5045504969,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
SanBio Co Ltd,5045504969,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Vera Therapeutics Inc,5079115565,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,141,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sinphar Pharmaceutical Co Ltd,4295892650,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,141,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Vera Therapeutics Inc,5079115565,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,141,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Vera Therapeutics Inc,5079115565,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,141,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Repare Therapeutics Inc,5056409976,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,140,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Repare Therapeutics Inc,5056409976,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,140,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Erasca Inc,5067176358,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,140,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd,4295865060,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Panion & BF Biotech Inc,4295891914,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,139,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Il Dong Pharmaceutical Co Ltd,5041976716,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,139,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Panion & BF Biotech Inc,4295891914,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
PKU HealthCare Corp Ltd,4295863923,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Panion & BF Biotech Inc,4295891914,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.8,139,S_risk,Biotechnology & Pharmaceuticals,2023,0.72,1.0296194171811583,Drug_Safety
Tus Pharmaceutical Group Co Ltd,4295865337,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Nabriva Therapeutics PLC,5055466588,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,138,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aurora Optoelectronics Co Ltd,4295865357,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Dishman Carbogen Amcis Ltd,5036349504,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Dishman Carbogen Amcis Ltd,5036349504,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd,4295863618,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
GuangYuYuan Chinese Herbal Medicine Co Ltd,4295864099,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Harbin Pharmaceutical Group Co Ltd,4295863954,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Dishman Carbogen Amcis Ltd,5036349504,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hainan Haiyao Co Ltd,4295865495,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Henan Lingrui Pharmaceutical Co Ltd,4295863627,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Nabriva Therapeutics PLC,5055466588,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd,4295863943,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Icosavax Inc,5071500169,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,137,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tricida Inc,5041066023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,137,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd,4295863943,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
9 Meters Biopharma Inc,5037627414,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,137,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Cerevel Therapeutics Holdings Inc,5078356542,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,137,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
North China Pharmaceutical Co Ltd,4295864330,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd,4295863943,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Cerevel Therapeutics Holdings Inc,5078356542,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,137,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd,4295863943,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Oncorus Inc,5050715269,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,137,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
9 Meters Biopharma Inc,5037627414,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,137,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Oncorus Inc,5050715269,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,137,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Morepen Laboratories Ltd,4295872885,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,136,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Tenaya Therapeutics Inc,5052537650,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Suheung Co Ltd,4295882180,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,136,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Graphite Bio Inc,5076089527,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dhg Pharmaceutical Joint-Stock Co,4297791350,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
SymBio Pharmaceuticals Ltd,5000693593,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,136,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Dhg Pharmaceutical Joint-Stock Co,4297791350,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,136,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Suheung Co Ltd,4295882180,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Graphite Bio Inc,5076089527,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Morepen Laboratories Ltd,4295872885,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.8,136,S_risk,Biotechnology & Pharmaceuticals,2024,0.32,0.5877866649021191,Drug_Safety
Suheung Co Ltd,4295882180,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,136,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Morepen Laboratories Ltd,4295872885,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Dhg Pharmaceutical Joint-Stock Co,4297791350,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,136,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Tenaya Therapeutics Inc,5052537650,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,136,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Carna Biosciences Inc,4295879043,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,136,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Oyster Point Pharma Inc,5050914678,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,135,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Greenwich Lifesciences Inc,5037125444,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,135,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Greenwich Lifesciences Inc,5037125444,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Evolva Holding SA,4295890719,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tianda Pharmaceuticals Ltd,4295871112,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Nacon SAS,5071563934,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,135,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Oyster Point Pharma Inc,5050914678,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd,4295865606,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Greenwich Lifesciences Inc,5037125444,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Greenwich Lifesciences Inc,5037125444,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Anhui Fengyuan Pharmaceutical Co Ltd,4295864716,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Enzychem Lifesciences Corp,5000831295,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Jiangsu Lianhuan Pharmaceutical Co Ltd,4295864011,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Northeast Pharmaceutical Group Co Ltd,5000026707,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jinling Pharmaceutical Co Ltd,4295863702,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Henan Taloph Pharmaceutical Stock Co Ltd,4295865647,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Enzychem Lifesciences Corp,5000831295,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,135,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Fuan Pharmaceutical Group Co Ltd,5001217525,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tyme Technologies Inc,5044009440,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Renhe Pharmacy Co Ltd,4295864111,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Gpro Titanium Industry Co Ltd,4295863691,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ARS Pharmaceuticals Inc,5050718646,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,134,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
ARS Pharmaceuticals Inc,5050718646,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ARS Pharmaceuticals Inc,5050718646,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Tyme Technologies Inc,5044009440,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hunan Jingfeng Pharmaceutical Co Ltd,4295865313,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Immuneering Corp,5035545616,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,134,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tyme Technologies Inc,5044009440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Pierrel SpA,4295875554,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
OncoTherapy Science Inc,4295875918,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PT Sentul City Tbk,4295874675,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,133,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shandong Wohua Pharmaceutical Co Ltd,4295865023,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Komipharm International Co Ltd,4295882344,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jiuzhitang Co Ltd,4295865206,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Pak Fah Yeow International Ltd,4295859603,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Medinet Co Ltd,4295879014,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Huapont Life Sciences Co Ltd,4295865040,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Monte Rosa Therapeutics Inc,5076946858,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,133,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hubei Guangji Pharmaceutical Co Ltd,4295864663,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Monte Rosa Therapeutics Inc,5076946858,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,133,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Wai Yuen Tong Medicine Holdings Ltd,4295871641,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,133,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Renata Ltd,4295941152,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,132,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jiangsu Kanion Pharmaceutical Co Ltd,4295864665,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,132,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Guangdong Jiaying Pharmaceutical Co Ltd,4295863600,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,132,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hitachi High-Tech Corp,4295878681,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.11,132,S_risk,Biotechnology & Pharmaceuticals,2017,0.844,1.1346227261911428,Drug_Safety
Hitachi High-Tech Corp,4295878681,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,132,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hybio Pharmaceutical Co Ltd,4297870669,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,132,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hitachi High-Tech Corp,4295878681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,132,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Lanzhou Foci Pharmaceutical Co Ltd,5000567710,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,131,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
GlaxoSmithKline Pakistan Ltd,4295885858,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,131,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Guizhou Yibai Pharmaceutical Co Ltd,4295863597,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,131,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
HeiLongJiang ZBD Pharmaceutical Co Ltd,5000556950,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,131,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Haisco Pharmaceutical Group Co Ltd,5036352884,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,131,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shandong Lukang Pharmaceutical Co Ltd,4295865118,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sprint Bioscience AB,5001222098,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
D.Western Therapeutics Institute Inc,5000263284,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hebei Changshan Biochemical Pharmaceutical Co Ltd,4297162240,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Honz Pharmaceutical Co Ltd,5000730289,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sprint Bioscience AB,5001222098,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sprint Bioscience AB,5001222098,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Reneo Pharmaceuticals Inc,5045824255,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Chongqing Lummy Pharmaceutical Co Ltd,5000364567,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,129,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Daewoong Pharma,4295882473,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Tianjin Ringpu Bio-Technology Co Ltd,5000846863,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,129,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Taigen Biopharmaceuticals Holdings Ltd,5000863630,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Vincerx Pharma Inc,5073341405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Relx NV,4295884735,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Yuyu Pharma Inc,4295881267,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,129,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Taigen Biopharmaceuticals Holdings Ltd,5000863630,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Relx NV,4295884735,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Guilin Sanjin Pharmaceutical Co Ltd,5000038600,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,129,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd,4295864580,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,129,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Relx NV,4295884735,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.3,129,S_risk,Biotechnology & Pharmaceuticals,2017,0.12,0.262364264467491,Drug_Safety
Daewoong Pharma,4295882473,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,129,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Uni-Bio Science Group Ltd,4295871411,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,129,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Vincerx Pharma Inc,5073341405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Taigen Biopharmaceuticals Holdings Ltd,5000863630,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Flanigan's Enterprises Inc,4295904002,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Chiome Bioscience Inc,4298046688,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
HARBIN GLORIA PHARMACEUTICALS Co Ltd,5000553946,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Guangdong Taiantang Pharmaceutical Co Ltd,5000519913,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
TotalEnergies Marketing Nigeria PLC,4295885263,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hainan Shuangcheng Pharmaceuticals Co Ltd,5037346679,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Japan Tissue Engineering Co Ltd,4295880249,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
TotalEnergies Marketing Nigeria PLC,4295885263,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Ginwa Enterprise Group Inc,4295864564,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hunan Hansen Pharmaceutical Co Ltd,5000545423,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
RaQualia Pharma Inc,4298032666,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jilin Jian Yisheng Pharmaceutical Co Ltd,5000518228,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Poxel SA,5000786315,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
MDxHealth SA,4295859547,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Changzhou Qianhong Biopharma Co Ltd,5000475644,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,126,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Phong Phu Pharmaceutical JSC,5000495358,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,126,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Inner Mongolia Furui Medical Science Co Ltd,5000617745,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,126,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhejiang Xinguang Pharmaceutical Co Ltd,5000552900,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,126,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Oncolys Biopharma Inc,5001546120,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,126,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Phong Phu Pharmaceutical JSC,5000495358,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,126,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jinhe Biotechnology Co Ltd,5000465025,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,126,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PuraPharm Corp Ltd,5046279547,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Fujian Cosunter Pharmaceutical Co Ltd,5035560316,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Rain Oncology Inc,5059955326,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,125,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
3-D Matrix Ltd,5035457143,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PT Temas Tbk,4295874360,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,125,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Solasia Pharma KK,5035525095,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Makers Laboratories Ltd,4296410632,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tiansheng Pharmaceutical Group Co Ltd,5000505704,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Rain Oncology Inc,5059955326,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,125,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hunan Fangsheng Pharmaceutical Co Ltd,5001564312,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Phapros Tbk PT,5000019883,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Phapros Tbk PT,5000019883,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
New Journey Health Technology Group Co Ltd,4295864433,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
SMS Pharmaceuticals Ltd,4295873975,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jiangsu Sihuan Bioengineering Co Ltd,4295864899,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Cyteir Therapeutics Inc,5043952888,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,124,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dong-A ST Co Ltd,5039189081,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Xinjiang Bai Hua Cun Pharma Tech Co Ltd,4295865458,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kunming Longjin Pharmaceutical Co Ltd,5000544050,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sunflower Pharmaceutical Group Co Ltd,5037355566,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,123,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jilin Zixin Pharmaceutical Industrial Co Ltd,4295865326,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,123,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ReproCell Inc,5000421097,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,123,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Guilin Layn Natural Ingredients Corp,4295865322,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,123,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kyungdong Pharm,4295882493,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lionco Pharmaceutical Group Co Ltd,5043318825,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Beihai Gofar Chuanshan Biological Co Ltd,4295865062,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tissue Regenix Group PLC,4295899009,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Tissue Regenix Group PLC,4295899009,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Regent Pacific Group Ltd,4295871755,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,121,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Human Metabolome Technologies Inc,4297703285,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,121,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Relief Therapeutics Holding SA,5000098134,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,120,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
ST Pharm Co Ltd,5035512921,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,120,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jinghua Pharmaceutical Group Co Ltd,5000627984,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,120,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jaguar Health Inc,5040693204,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,120,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Qianjiang Yongan Pharmaceutical Co Ltd,5000642768,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Charm Care Corp,5037359932,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
BEACON Pharmaceutical Ltd,5001151981,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Satsuma Pharmaceuticals Inc,5052544073,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,119,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tianjin Lisheng Pharmaceutical Co Ltd,5000438501,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PhoenixBio Co Ltd,5000938481,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Taiko Pharmaceutical Co Ltd,4297469734,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Guizhou Xinbang Pharmaceutical Co Ltd,5000682400,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,118,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Pharma Foods International Co Ltd,4295876847,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,118,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Central Pharmaceutical JSC No3,5046317614,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,118,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhejiang Starry Pharmaceutical Co Ltd,5000569538,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,117,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ImmuPharma PLC,4295896943,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,117,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Corline Biomedical AB,5046041193,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,117,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ImmuPharma PLC,4295896943,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,117,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Guangdong Zhongsheng Pharmaceutical Co Ltd,5000587733,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,117,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Acousort AB,5039189432,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Mercury Laboratories Ltd,4296689152,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sarimelati Kencana Tbk PT,5063723200,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Acousort AB,5039189432,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhejiang Ausun Pharmaceutical Co Ltd,5040253094,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Yixintang Pharmaceutical Group Co Ltd,4298345694,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,114,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Realcan Pharmaceutical Group Co Ltd,4298155644,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,114,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Genetic Signatures Ltd,5035532216,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,114,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
EuBiologics Co Ltd,5037930235,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,114,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
China Health Group Inc,4295871097,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,113,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hainan Poly Pharm Co Ltd,5035551331,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lifecome Biochemistry Co Ltd,5042951109,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Biovica International AB,5055421891,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
GlaxoSmithKline Consumer Healthcare Ltd,4295872411,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
GlaxoSmithKline Consumer Healthcare Ltd,4295872411,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,112,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hyphens Pharma International Ltd,5063729045,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Otsuka Pakistan Ltd,4295924007,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,111,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
FUREN Group Pharmaceutical Co Ltd,4295865105,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,111,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hunan Er-Kang Pharmaceutical Co Ltd,5000503801,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,111,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
GNI Group Ltd,4295880850,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,110,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lansen Pharmaceutical Holdings Ltd,5000728517,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,110,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Egyptian International Pharmaceutical Industries Company SAE,4295866246,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,109,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Denis Chem Lab Ltd,4296384924,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,109,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Biofermin Pharmaceutical Co Ltd,4295876171,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,109,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Gulf Pharmaceutical Industries PSC,4296092528,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,108,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ChemPartner PharmaTech Co Ltd,5001223202,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,108,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
IBN SINA Pharmaceutical Industry Ltd,4295940753,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,107,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Rhinomed Ltd,4295858181,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,107,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Translate Bio Inc,5064608221,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,107,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Mcnulty Korea Co Ltd,5001325921,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,107,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Yong Pyong Resort Corp,4297227188,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,106,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Akouos Inc,5059037223,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Minapharm Pharmaceuticals SAE,4297293802,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Akouos Inc,5059037223,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Disc Medicine Inc,5076167270,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,101,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Disc Medicine Inc,5076167270,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,101,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Disc Medicine Inc,5076167270,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,101,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Titan Pharmaceuticals Inc,4295905095,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,96,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Talaris Therapeutics Inc,5019146218,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,96,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Talaris Therapeutics Inc,5019146218,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,96,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Unrivaled Brands Inc,4297388027,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,92,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Orchard Therapeutics Ltd,5066542950,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,90,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bio-On SpA,5035553307,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,89,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bio-On SpA,5035553307,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,89,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,434,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,434,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,434,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,434,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,434,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Aspen Pharmacare Holdings Ltd,4295888632,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,434,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,434,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,434,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,434,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,434,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,434,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,434,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Aspen Pharmacare Holdings Ltd,4295888632,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,434,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.22,431,S_risk,Biotechnology & Pharmaceuticals,2024,0.088,0.1988508587451652,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,431,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.16,431,S_risk,Biotechnology & Pharmaceuticals,2022,0.064,0.1484200051182732,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,431,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,431,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,431,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,431,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,431,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,431,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.18,431,S_risk,Biotechnology & Pharmaceuticals,2021,0.072,0.1655144384775733,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.15,431,S_risk,Biotechnology & Pharmaceuticals,2019,0.06,0.1397619423751586,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,431,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,431,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dr Reddy's Laboratories Ltd,4295872868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,431,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,431,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.18,431,S_risk,Biotechnology & Pharmaceuticals,2020,0.072,0.1655144384775733,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,431,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,431,S_risk,Biotechnology & Pharmaceuticals,2018,0.4,0.6931471805599453,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.27,431,S_risk,Biotechnology & Pharmaceuticals,2023,0.108,0.2390169004704999,Drug_Safety
Dr Reddy's Laboratories Ltd,4295872868,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.23,431,S_risk,Biotechnology & Pharmaceuticals,2018,0.092,0.2070141693843261,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,423,S_risk,Biotechnology & Pharmaceuticals,2016,0.4,0.6931471805599453,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,423,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.55,423,S_risk,Biotechnology & Pharmaceuticals,2019,0.62,0.9360933591703348,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,423,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,423,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,423,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.23,423,S_risk,Biotechnology & Pharmaceuticals,2022,0.092,0.2070141693843261,Drug_Safety
Johnson & Johnson,4295904341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,423,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Johnson & Johnson,4295904341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,423,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.2,423,S_risk,Biotechnology & Pharmaceuticals,2020,0.48,0.7884573603642702,Drug_Safety
Johnson & Johnson,4295904341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,423,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Johnson & Johnson,4295904341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,423,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.05,423,S_risk,Biotechnology & Pharmaceuticals,2018,0.82,1.1151415906193205,Drug_Safety
Johnson & Johnson,4295904341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,423,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Johnson & Johnson,4295904341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.4,423,S_risk,Biotechnology & Pharmaceuticals,2023,0.5599999999999999,0.8754687373538999,Drug_Safety
Johnson & Johnson,4295904341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,423,S_risk,Biotechnology & Pharmaceuticals,2021,0.6,0.9162907318741552,Drug_Safety
Novartis AG,4295890628,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.9,414,S_risk,Biotechnology & Pharmaceuticals,2018,0.76,1.0647107369924282,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.31,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.124,0.2700271372130601,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,414,S_risk,Biotechnology & Pharmaceuticals,2023,0.52,0.832909122935104,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Shionogi & Co Ltd,4295876951,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Novartis AG,4295890628,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.2,414,S_risk,Biotechnology & Pharmaceuticals,2022,0.08,0.1823215567939546,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.39,414,S_risk,Biotechnology & Pharmaceuticals,2018,0.156,0.3293037471426004,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.4,414,S_risk,Biotechnology & Pharmaceuticals,2017,0.5599999999999999,0.8754687373538999,Workforce_Development
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.9,414,S_risk,Biotechnology & Pharmaceuticals,2018,0.76,1.0647107369924282,Workforce_Development
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.21,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.484,0.7929925155296614,Drug_Safety
Novartis AG,4295890628,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Novartis AG,4295890628,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Novartis AG,4295890628,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Novartis AG,4295890628,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.55,414,S_risk,Biotechnology & Pharmaceuticals,2022,0.62,0.9360933591703348,Drug_Safety
Novartis AG,4295890628,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.25,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.5,0.8109302162163288,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Shionogi & Co Ltd,4295876951,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Novartis AG,4295890628,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.6,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.64,0.9555114450274363,Workforce_Development
Novartis AG,4295890628,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.34,414,S_risk,Biotechnology & Pharmaceuticals,2019,0.136,0.29266961396282,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.81,414,S_risk,Biotechnology & Pharmaceuticals,2019,0.324,0.5933268452777344,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.6,414,S_risk,Biotechnology & Pharmaceuticals,2019,0.64,0.9555114450274363,Workforce_Development
Shionogi & Co Ltd,4295876951,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.19,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.076,0.173953307123438,Drug_Safety
Novartis AG,4295890628,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shionogi & Co Ltd,4295876951,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Teva Pharmaceutical Industries Ltd,4295875158,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.9,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.76,1.0647107369924282,Workforce_Development
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.19,414,S_risk,Biotechnology & Pharmaceuticals,2021,0.076,0.173953307123438,Drug_Safety
Teva Pharmaceutical Industries Ltd,4295875158,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Novartis AG,4295890628,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.15,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.4599999999999999,0.7654678421395714,Drug_Safety
Novartis AG,4295890628,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.65,414,S_risk,Biotechnology & Pharmaceuticals,2023,0.6599999999999999,0.9745596399981308,Drug_Safety
Novartis AG,4295890628,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2017,0.4,0.6931471805599453,Drug_Safety
Shionogi & Co Ltd,4295876951,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.4,414,S_risk,Biotechnology & Pharmaceuticals,2016,0.5599999999999999,0.8754687373538999,Workforce_Development
Teva Pharmaceutical Industries Ltd,4295875158,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Teva Pharmaceutical Industries Ltd,4295875158,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,414,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Novartis AG,4295890628,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,414,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Takeda Pharmaceutical Co Ltd,4295877353,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,408,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Takeda Pharmaceutical Co Ltd,4295877353,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,408,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Takeda Pharmaceutical Co Ltd,4295877353,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,408,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,408,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,408,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Takeda Pharmaceutical Co Ltd,4295877353,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,408,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,408,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Takeda Pharmaceutical Co Ltd,4295877353,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,408,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Takeda Pharmaceutical Co Ltd,4295877353,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,408,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Takeda Pharmaceutical Co Ltd,4295877353,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,408,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,405,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.43,405,S_risk,Biotechnology & Pharmaceuticals,2018,0.172,0.3576744442718159,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,405,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.19,405,S_risk,Biotechnology & Pharmaceuticals,2023,0.076,0.173953307123438,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,405,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,405,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,405,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.2,405,S_risk,Biotechnology & Pharmaceuticals,2022,0.08,0.1823215567939546,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,405,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.4,405,S_risk,Biotechnology & Pharmaceuticals,2019,0.5599999999999999,0.8754687373538999,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.36,405,S_risk,Biotechnology & Pharmaceuticals,2021,0.144,0.3074846997479606,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,405,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,405,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.49,405,S_risk,Biotechnology & Pharmaceuticals,2020,0.196,0.3987761199573678,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,405,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,405,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,405,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shanghai Fosun Pharmaceutical Group Co Ltd,4295863746,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,405,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.33,403,S_risk,Biotechnology & Pharmaceuticals,2021,0.132,0.2851789422336624,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.33,403,S_risk,Biotechnology & Pharmaceuticals,2022,0.132,0.2851789422336624,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.55,403,S_risk,Biotechnology & Pharmaceuticals,2019,0.22,0.4382549309311553,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,403,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,403,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,403,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,403,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,403,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.18,403,S_risk,Biotechnology & Pharmaceuticals,2020,0.072,0.1655144384775733,Drug_Safety
Astellas Pharma Inc,4295876965,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,403,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.66,403,S_risk,Biotechnology & Pharmaceuticals,2024,0.264,0.5068176023684519,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,403,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,403,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,403,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Astellas Pharma Inc,4295876965,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,403,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,403,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.32,403,S_risk,Biotechnology & Pharmaceuticals,2018,0.128,0.2776317365982795,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,403,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Astellas Pharma Inc,4295876965,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.57,403,S_risk,Biotechnology & Pharmaceuticals,2023,0.2279999999999999,0.4510756193602167,Drug_Safety
Daiichi Sankyo Co Ltd,4295880584,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,392,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Daiichi Sankyo Co Ltd,4295880584,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,392,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,392,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.01,392,S_risk,Biotechnology & Pharmaceuticals,2020,0.404,0.6981347220709844,Drug_Safety
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,392,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Daiichi Sankyo Co Ltd,4295880584,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,392,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Daiichi Sankyo Co Ltd,4295880584,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,392,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.11,392,S_risk,Biotechnology & Pharmaceuticals,2022,0.444,0.7466879474879752,Drug_Safety
Daiichi Sankyo Co Ltd,4295880584,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.01,392,S_risk,Biotechnology & Pharmaceuticals,2021,0.404,0.6981347220709844,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
ALK-Abello A/S,4295866060,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,391,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
AstraZeneca PLC,4295894341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.49,391,S_risk,Biotechnology & Pharmaceuticals,2022,0.196,0.3987761199573678,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,391,S_risk,Biotechnology & Pharmaceuticals,2021,0.8,1.0986122886681098,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
ALK-Abello A/S,4295866060,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.12,391,S_risk,Biotechnology & Pharmaceuticals,2019,0.448,0.7514160886839212,Drug_Safety
ALK-Abello A/S,4295866060,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
ALK-Abello A/S,4295866060,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.8,391,S_risk,Biotechnology & Pharmaceuticals,2020,0.72,1.0296194171811583,Drug_Safety
ALK-Abello A/S,4295866060,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,391,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
ALK-Abello A/S,4295866060,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.7,391,S_risk,Biotechnology & Pharmaceuticals,2022,0.6799999999999999,0.9932517730102832,Drug_Safety
AstraZeneca PLC,4295894341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,391,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
ALK-Abello A/S,4295866060,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.63,391,S_risk,Biotechnology & Pharmaceuticals,2020,0.252,0.4885800148186709,Drug_Safety
ALK-Abello A/S,4295866060,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.3,391,S_risk,Biotechnology & Pharmaceuticals,2021,0.12,0.262364264467491,Drug_Safety
ALK-Abello A/S,4295866060,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
ALK-Abello A/S,4295866060,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,391,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
AstraZeneca PLC,4295894341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.32,391,S_risk,Biotechnology & Pharmaceuticals,2018,0.528,0.8415671856782186,Drug_Safety
AstraZeneca PLC,4295894341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,391,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
ALK-Abello A/S,4295866060,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,391,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
AstraZeneca PLC,4295894341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.72,391,S_risk,Biotechnology & Pharmaceuticals,2023,0.288,0.5423242908253617,Drug_Safety
ALK-Abello A/S,4295866060,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.8,391,S_risk,Biotechnology & Pharmaceuticals,2023,0.32,0.5877866649021191,Drug_Safety
AstraZeneca PLC,4295894341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,391,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
AstraZeneca PLC,4295894341,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,391,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
AstraZeneca PLC,4295894341,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.56,391,S_risk,Biotechnology & Pharmaceuticals,2021,0.224,0.4446858212614457,Drug_Safety
ALK-Abello A/S,4295866060,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,391,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.02,390,S_risk,Biotechnology & Pharmaceuticals,2024,0.008,0.0198026272961797,Drug_Safety
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.7,390,S_risk,Biotechnology & Pharmaceuticals,2021,0.2799999999999999,0.5306282510621704,Drug_Safety
Sun Pharmaceutical Industries Ltd,4295873594,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,390,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,390,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.44,390,S_risk,Biotechnology & Pharmaceuticals,2023,0.176,0.3646431135879092,Drug_Safety
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,390,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sun Pharmaceutical Industries Ltd,4295873594,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,390,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,390,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Sun Pharmaceutical Industries Ltd,4295873594,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,390,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Sun Pharmaceutical Industries Ltd,4295873594,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,390,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,390,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Sun Pharmaceutical Industries Ltd,4295873594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.55,390,S_risk,Biotechnology & Pharmaceuticals,2020,0.22,0.4382549309311553,Drug_Safety
Aneka Tambang Tbk PT,4295874596,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,388,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,388,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Drug_Safety
Aneka Tambang Tbk PT,4295874596,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,388,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,388,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.08,388,S_risk,Biotechnology & Pharmaceuticals,2017,0.032,0.0769610411361283,Workforce_Development
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,388,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.15,388,S_risk,Biotechnology & Pharmaceuticals,2019,0.4599999999999999,0.7654678421395714,Workforce_Development
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.81,388,S_risk,Biotechnology & Pharmaceuticals,2018,0.324,0.5933268452777344,Workforce_Development
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.15,388,S_risk,Biotechnology & Pharmaceuticals,2021,0.06,0.1397619423751586,Drug_Safety
Aneka Tambang Tbk PT,4295874596,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,388,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.12,388,S_risk,Biotechnology & Pharmaceuticals,2023,0.048,0.1133286853070031,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,388,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,388,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Aneka Tambang Tbk PT,4295874596,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,388,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,388,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.19,388,S_risk,Biotechnology & Pharmaceuticals,2022,0.076,0.173953307123438,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.15,388,S_risk,Biotechnology & Pharmaceuticals,2018,0.06,0.1397619423751586,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.05,388,S_risk,Biotechnology & Pharmaceuticals,2020,0.02,0.048790164169432,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.17,388,S_risk,Biotechnology & Pharmaceuticals,2019,0.068,0.1570037488096647,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,2.2,388,S_risk,Biotechnology & Pharmaceuticals,2022,0.8800000000000001,1.1631508098056809,Workforce_Development
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,388,S_risk,Biotechnology & Pharmaceuticals,2016,0.4,0.6931471805599453,Drug_Safety
Aneka Tambang Tbk PT,4295874596,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,388,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Aneka Tambang Tbk PT,4295874596,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,388,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,386,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,386,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.25,386,S_risk,Biotechnology & Pharmaceuticals,2020,0.9,1.1786549963416462,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,386,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,386,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,386,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Regeneron Pharmaceuticals Inc,4295907752,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,386,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Regeneron Pharmaceuticals Inc,4295907752,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,386,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Regeneron Pharmaceuticals Inc,4295907752,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,386,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,386,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,386,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,386,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Regeneron Pharmaceuticals Inc,4295907752,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,386,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,385,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,385,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,385,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Merck & Co Inc,4295904886,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,385,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Merck & Co Inc,4295904886,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.8,385,S_risk,Biotechnology & Pharmaceuticals,2020,0.32,0.5877866649021191,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,385,S_risk,Biotechnology & Pharmaceuticals,2022,0.52,0.832909122935104,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.07,385,S_risk,Biotechnology & Pharmaceuticals,2021,0.428,0.7275486072772778,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,385,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,385,S_risk,Biotechnology & Pharmaceuticals,2018,0.8,1.0986122886681098,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.4,385,S_risk,Biotechnology & Pharmaceuticals,2023,0.5599999999999999,0.8754687373538999,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,385,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Merck & Co Inc,4295904886,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,385,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Merck & Co Inc,4295904886,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,385,S_risk,Biotechnology & Pharmaceuticals,2018,0.6,0.9162907318741552,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,385,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
Merck & Co Inc,4295904886,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,385,S_risk,Biotechnology & Pharmaceuticals,2019,0.6,0.9162907318741552,Drug_Safety
Merck & Co Inc,4295904886,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,385,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Merck & Co Inc,4295904886,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,385,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Merck & Co Inc,4295904886,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,385,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Corcept Therapeutics Inc,4295899705,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,384,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Corcept Therapeutics Inc,4295899705,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,384,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Corcept Therapeutics Inc,4295899705,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,384,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.56,383,S_risk,Biotechnology & Pharmaceuticals,2024,0.224,0.4446858212614457,Drug_Safety
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,383,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,383,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Santen Pharmaceutical Co Ltd,4295877908,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,383,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Santen Pharmaceutical Co Ltd,4295877908,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,383,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.38,383,S_risk,Biotechnology & Pharmaceuticals,2022,0.5519999999999999,0.8671004876833833,Drug_Safety
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,383,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Santen Pharmaceutical Co Ltd,4295877908,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,383,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,382,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.4,382,S_risk,Biotechnology & Pharmaceuticals,2019,0.96,1.2237754316221157,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,382,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.5,382,S_risk,Biotechnology & Pharmaceuticals,2022,1.0,1.252762968495368,Drug_Safety
Lonza Group AG,5000030891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,382,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Lonza Group AG,5000030891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,382,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Lonza Group AG,5000030891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,382,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Lonza Group AG,5000030891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,382,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Lonza Group AG,5000030891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,382,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,382,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,382,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.62,382,S_risk,Biotechnology & Pharmaceuticals,2020,0.248,0.4824261492442927,Drug_Safety
Lonza Group AG,5000030891,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.4,382,S_risk,Biotechnology & Pharmaceuticals,2023,0.96,1.2237754316221157,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Drug_Safety
CVS Health Corp,4295903627,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bayer AG,4295869217,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.0,381,S_risk,Biotechnology & Pharmaceuticals,2018,0.8,1.0986122886681098,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,381,S_risk,Biotechnology & Pharmaceuticals,2021,0.8,1.0986122886681098,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,381,S_risk,Biotechnology & Pharmaceuticals,2020,0.8,1.0986122886681098,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.85,381,S_risk,Biotechnology & Pharmaceuticals,2022,0.74,1.0473189942805592,Drug_Safety
CVS Health Corp,4295903627,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,381,S_risk,Biotechnology & Pharmaceuticals,2022,0.8,1.0986122886681098,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,381,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.42,381,S_risk,Biotechnology & Pharmaceuticals,2023,0.1679999999999999,0.3506568716131693,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,381,S_risk,Biotechnology & Pharmaceuticals,2016,0.8,1.0986122886681098,Drug_Safety
Bayer AG,4295869217,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,381,S_risk,Biotechnology & Pharmaceuticals,2018,0.8,1.0986122886681098,Drug_Safety
Bayer AG,4295869217,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CVS Health Corp,4295903627,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Bayer AG,4295869217,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CVS Health Corp,4295903627,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Bayer AG,4295869217,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.37,381,S_risk,Biotechnology & Pharmaceuticals,2021,0.148,0.3148107398400335,Drug_Safety
CVS Health Corp,4295903627,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Bayer AG,4295869217,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.3,381,S_risk,Biotechnology & Pharmaceuticals,2019,0.92,1.1939224684724346,Drug_Safety
CVS Health Corp,4295903627,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,381,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Bayer AG,4295869217,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.6,381,S_risk,Biotechnology & Pharmaceuticals,2020,0.64,0.9555114450274363,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Ipsen SA,4295868520,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ipsen SA,4295868520,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ipsen SA,4295868520,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.71,378,S_risk,Biotechnology & Pharmaceuticals,2019,0.284,0.5364933705145685,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.52,378,S_risk,Biotechnology & Pharmaceuticals,2023,0.208,0.418710334858185,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Ipsen SA,4295868520,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ipsen SA,4295868520,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Ipsen SA,4295868520,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.4,378,S_risk,Biotechnology & Pharmaceuticals,2021,0.16,0.3364722366212129,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ipsen SA,4295868520,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.33,378,S_risk,Biotechnology & Pharmaceuticals,2022,0.132,0.2851789422336624,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.26,378,S_risk,Biotechnology & Pharmaceuticals,2022,0.104,0.2311117209633866,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ipsen SA,4295868520,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Ipsen SA,4295868520,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ipsen SA,4295868520,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.45,378,S_risk,Biotechnology & Pharmaceuticals,2018,0.58,0.8960880245566356,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.61,378,S_risk,Biotechnology & Pharmaceuticals,2020,0.244,0.4762341789963716,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.24,378,S_risk,Biotechnology & Pharmaceuticals,2020,0.096,0.2151113796169455,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.13,378,S_risk,Biotechnology & Pharmaceuticals,2023,0.052,0.1222176327242492,Drug_Safety
Ipsen SA,4295868520,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,378,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Livzon Pharmaceutical Group Inc,4295863969,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,378,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
GSK plc,4295895781,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.3,376,S_risk,Biotechnology & Pharmaceuticals,2019,0.92,1.1939224684724346,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
GSK plc,4295895781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.6,376,S_risk,Biotechnology & Pharmaceuticals,2022,0.64,0.9555114450274363,Drug_Safety
GSK plc,4295895781,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.02,376,S_risk,Biotechnology & Pharmaceuticals,2023,0.008,0.0198026272961797,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2017,0.4,0.6931471805599453,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Drug_Safety
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.06,376,S_risk,Biotechnology & Pharmaceuticals,2024,0.024,0.0582689081239757,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.54,376,S_risk,Biotechnology & Pharmaceuticals,2019,0.216,0.4317824164255378,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.05,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.02,0.048790164169432,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.4,376,S_risk,Biotechnology & Pharmaceuticals,2023,0.96,1.2237754316221157,Drug_Safety
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.5,376,S_risk,Biotechnology & Pharmaceuticals,2023,0.2,0.4054651081081644,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.7,376,S_risk,Biotechnology & Pharmaceuticals,2020,0.6799999999999999,0.9932517730102832,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.3,376,S_risk,Biotechnology & Pharmaceuticals,2018,0.92,1.1939224684724346,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.29,376,S_risk,Biotechnology & Pharmaceuticals,2020,0.1159999999999999,0.2546422183735807,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.09,376,S_risk,Biotechnology & Pharmaceuticals,2022,0.436,0.7371640659767197,Drug_Safety
Aurobindo Pharma Ltd,4295872481,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
China Shineway Pharmaceutical Group Ltd,4295872000,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Aurobindo Pharma Ltd,4295872481,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
GSK plc,4295895781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.6,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.64,0.9555114450274363,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2016,0.4,0.6931471805599453,Drug_Safety
GSK plc,4295895781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,376,S_risk,Biotechnology & Pharmaceuticals,2020,0.8,1.0986122886681098,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
GSK plc,4295895781,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aurobindo Pharma Ltd,4295872481,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,376,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
China Shineway Pharmaceutical Group Ltd,4295872000,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.19,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.076,0.173953307123438,Drug_Safety
GSK plc,4295895781,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,376,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,373,S_risk,Biotechnology & Pharmaceuticals,2020,0.52,0.832909122935104,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,373,S_risk,Biotechnology & Pharmaceuticals,2021,0.52,0.832909122935104,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,373,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,373,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,373,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
Novo Nordisk A/S,4295865996,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,373,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,373,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.4,373,S_risk,Biotechnology & Pharmaceuticals,2018,0.96,1.2237754316221157,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,373,S_risk,Biotechnology & Pharmaceuticals,2022,0.6,0.9162907318741552,Drug_Safety
Novo Nordisk A/S,4295865996,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,373,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.2,373,S_risk,Biotechnology & Pharmaceuticals,2019,0.8800000000000001,1.1631508098056809,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,373,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Drug_Safety
Novo Nordisk A/S,4295865996,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,373,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,373,S_risk,Biotechnology & Pharmaceuticals,2022,0.8,1.0986122886681098,Drug_Safety
Novo Nordisk A/S,4295865996,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,373,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,373,S_risk,Biotechnology & Pharmaceuticals,2023,0.6,0.9162907318741552,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,373,S_risk,Biotechnology & Pharmaceuticals,2016,0.4,0.6931471805599453,Drug_Safety
Novo Nordisk A/S,4295865996,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,373,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.15,372,S_risk,Biotechnology & Pharmaceuticals,2021,0.86,1.1474024528375415,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.05,372,S_risk,Biotechnology & Pharmaceuticals,2022,0.02,0.048790164169432,Drug_Safety
Biocon Ltd,4295873833,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,372,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Biocon Ltd,4295873833,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,372,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Biocon Ltd,4295873833,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,372,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Biocon Ltd,4295873833,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,372,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Biocon Ltd,4295873833,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,372,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Biocon Ltd,4295873833,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,372,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Siegfried Holding AG,5000066884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.3,371,S_risk,Biotechnology & Pharmaceuticals,2020,0.12,0.262364264467491,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.03,371,S_risk,Biotechnology & Pharmaceuticals,2023,0.012,0.0295588022415444,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Perrigo Company PLC,5040203322,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Perrigo Company PLC,5040203322,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.37,371,S_risk,Biotechnology & Pharmaceuticals,2019,0.548,0.8628899551470398,Drug_Safety
Siegfried Holding AG,5000066884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Perrigo Company PLC,5040203322,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Perrigo Company PLC,5040203322,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.1,371,S_risk,Biotechnology & Pharmaceuticals,2020,0.44,0.7419373447293773,Drug_Safety
Perrigo Company PLC,5040203322,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Siegfried Holding AG,5000066884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Siegfried Holding AG,5000066884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Siegfried Holding AG,5000066884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Siegfried Holding AG,5000066884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Perrigo Company PLC,5040203322,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.15,371,S_risk,Biotechnology & Pharmaceuticals,2021,0.06,0.1397619423751586,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Perrigo Company PLC,5040203322,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.05,371,S_risk,Biotechnology & Pharmaceuticals,2024,0.02,0.048790164169432,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.55,371,S_risk,Biotechnology & Pharmaceuticals,2018,0.22,0.4382549309311553,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Perrigo Company PLC,5040203322,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.1,371,S_risk,Biotechnology & Pharmaceuticals,2019,0.04,0.0953101798043248,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.3,371,S_risk,Biotechnology & Pharmaceuticals,2022,0.12,0.262364264467491,Drug_Safety
Perrigo Company PLC,5040203322,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.11,371,S_risk,Biotechnology & Pharmaceuticals,2022,0.444,0.7466879474879752,Drug_Safety
Perrigo Company PLC,5040203322,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Glenmark Pharmaceuticals Ltd,4295873669,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Glenmark Pharmaceuticals Ltd,4295873669,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Perrigo Company PLC,5040203322,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Perrigo Company PLC,5040203322,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,371,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Perrigo Company PLC,5040203322,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Perrigo Company PLC,5040203322,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Siegfried Holding AG,5000066884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Glenmark Pharmaceuticals Ltd,4295873669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,371,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,370,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.63,370,S_risk,Biotechnology & Pharmaceuticals,2023,0.252,0.4885800148186709,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.14,370,S_risk,Biotechnology & Pharmaceuticals,2018,0.8560000000000001,1.144222799920162,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,370,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.5,370,S_risk,Biotechnology & Pharmaceuticals,2019,0.2,0.4054651081081644,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,370,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.2,370,S_risk,Biotechnology & Pharmaceuticals,2018,0.08,0.1823215567939546,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,370,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Eisai Co Ltd,4295876894,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.65,370,S_risk,Biotechnology & Pharmaceuticals,2024,0.26,0.5007752879124893,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,370,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.12,370,S_risk,Biotechnology & Pharmaceuticals,2019,0.048,0.1133286853070031,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Eisai Co Ltd,4295876894,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,370,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.23,370,S_risk,Biotechnology & Pharmaceuticals,2021,0.092,0.2070141693843261,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,370,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
China Traditional Chinese Medicine Holdings Co Ltd,4295871008,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.03,370,S_risk,Biotechnology & Pharmaceuticals,2020,0.012,0.0295588022415444,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.54,368,S_risk,Biotechnology & Pharmaceuticals,2019,0.216,0.4317824164255378,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Charles River Laboratories International Inc,4295900986,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,368,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,368,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Charles River Laboratories International Inc,4295900986,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,368,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.29,368,S_risk,Biotechnology & Pharmaceuticals,2023,0.1159999999999999,0.2546422183735807,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.22,368,S_risk,Biotechnology & Pharmaceuticals,2022,0.088,0.1988508587451652,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,368,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.36,368,S_risk,Biotechnology & Pharmaceuticals,2020,0.144,0.3074846997479606,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,368,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Charles River Laboratories International Inc,4295900986,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,368,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CSPC Pharmaceutical Group Ltd,4295870962,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,368,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Charles River Laboratories International Inc,4295900986,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,368,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
CSPC Pharmaceutical Group Ltd,4295870962,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.32,368,S_risk,Biotechnology & Pharmaceuticals,2021,0.128,0.2776317365982795,Drug_Safety
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
CSL Ltd,4295856855,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,367,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ucb SA,4295859381,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.99,367,S_risk,Biotechnology & Pharmaceuticals,2018,0.796,1.095273387402595,Drug_Safety
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Ucb SA,4295859381,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Ucb SA,4295859381,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Ucb SA,4295859381,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,367,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ucb SA,4295859381,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.6,367,S_risk,Biotechnology & Pharmaceuticals,2020,0.64,0.9555114450274363,Drug_Safety
Ucb SA,4295859381,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,367,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ucb SA,4295859381,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Ucb SA,4295859381,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,367,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Ucb SA,4295859381,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
CSL Ltd,4295856855,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,367,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
CSL Ltd,4295856855,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,367,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CSL Ltd,4295856855,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,367,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
CSL Ltd,4295856855,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,367,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Ucb SA,4295859381,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Ucb SA,4295859381,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Ucb SA,4295859381,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.87,367,S_risk,Biotechnology & Pharmaceuticals,2023,0.748,1.0543120297715298,Drug_Safety
Ucb SA,4295859381,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.05,367,S_risk,Biotechnology & Pharmaceuticals,2021,0.82,1.1151415906193205,Drug_Safety
Ucb SA,4295859381,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.21,367,S_risk,Biotechnology & Pharmaceuticals,2022,0.884,1.1662709371419244,Drug_Safety
CSL Ltd,4295856855,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,367,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Lupin Ltd,4295873497,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,366,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Lupin Ltd,4295873497,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,366,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Lupin Ltd,4295873497,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,366,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Lupin Ltd,4295873497,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,366,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Lupin Ltd,4295873497,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,366,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Lupin Ltd,4295873497,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,366,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Lupin Ltd,4295873497,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,366,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Lupin Ltd,4295873497,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,366,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Grifols SA,4295889506,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,365,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Grifols SA,4295889506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,365,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Grifols SA,4295889506,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,365,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Grifols SA,4295889506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,365,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Grifols SA,4295889506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,365,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Grifols SA,4295889506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,365,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Grifols SA,4295889506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,365,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,363,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,363,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Drug_Safety
Sino Biopharmaceutical Ltd,4295871031,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sino Biopharmaceutical Ltd,4295871031,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sino Biopharmaceutical Ltd,4295871031,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.56,363,S_risk,Biotechnology & Pharmaceuticals,2023,0.224,0.4446858212614457,Drug_Safety
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.72,363,S_risk,Biotechnology & Pharmaceuticals,2022,0.288,0.5423242908253617,Drug_Safety
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Drug_Safety
Divi's Laboratories Ltd,4295872463,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.65,363,S_risk,Biotechnology & Pharmaceuticals,2021,0.26,0.5007752879124893,Drug_Safety
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.72,363,S_risk,Biotechnology & Pharmaceuticals,2021,0.288,0.5423242908253617,Drug_Safety
Sino Biopharmaceutical Ltd,4295871031,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
Sino Biopharmaceutical Ltd,4295871031,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Divi's Laboratories Ltd,4295872463,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Divi's Laboratories Ltd,4295872463,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,363,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Divi's Laboratories Ltd,4295872463,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.18,363,S_risk,Biotechnology & Pharmaceuticals,2024,0.072,0.1655144384775733,Drug_Safety
Virbac SA,4295866672,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,362,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Virbac SA,4295866672,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,362,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Virbac SA,4295866672,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,362,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Virbac SA,4295866672,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,362,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Virbac SA,4295866672,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,362,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Virbac SA,4295866672,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,362,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,360,S_risk,Biotechnology & Pharmaceuticals,2021,0.6,0.9162907318741552,Drug_Safety
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.4,360,S_risk,Biotechnology & Pharmaceuticals,2020,0.16,0.3364722366212129,Drug_Safety
Alnylam Pharmaceuticals Inc,4295916167,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,360,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alnylam Pharmaceuticals Inc,4295916167,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,360,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.05,360,S_risk,Biotechnology & Pharmaceuticals,2023,0.82,1.1151415906193205,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,360,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alnylam Pharmaceuticals Inc,4295916167,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,360,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Adcock Ingram Holdings Ltd,4298082482,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.94,360,S_risk,Biotechnology & Pharmaceuticals,2023,0.776,1.0784095813505905,Drug_Safety
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,2.0,359,S_risk,Biotechnology & Pharmaceuticals,2024,0.8,1.0986122886681098,Workforce_Development
Nippon Shinyaku Co Ltd,4295877838,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,359,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.92,359,S_risk,Biotechnology & Pharmaceuticals,2023,0.768,1.0715836162801904,Workforce_Development
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,359,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,359,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.25,359,S_risk,Biotechnology & Pharmaceuticals,2019,0.5,0.8109302162163288,Drug_Safety
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.56,359,S_risk,Biotechnology & Pharmaceuticals,2023,0.224,0.4446858212614457,Drug_Safety
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.92,359,S_risk,Biotechnology & Pharmaceuticals,2022,0.768,1.0715836162801904,Workforce_Development
Nippon Shinyaku Co Ltd,4295877838,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,359,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Nippon Shinyaku Co Ltd,4295877838,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,359,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.29,359,S_risk,Biotechnology & Pharmaceuticals,2022,0.1159999999999999,0.2546422183735807,Drug_Safety
Nippon Shinyaku Co Ltd,4295877838,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,359,S_risk,Biotechnology & Pharmaceuticals,2017,0.4,0.6931471805599453,Business_Ethics
Nippon Shinyaku Co Ltd,4295877838,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,359,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Nippon Shinyaku Co Ltd,4295877838,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,359,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tsumura & Co,4295878528,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.95,357,S_risk,Biotechnology & Pharmaceuticals,2018,0.38,0.6678293725756554,Workforce_Development
Tsumura & Co,4295878528,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,357,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Tsumura & Co,4295878528,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.15,357,S_risk,Biotechnology & Pharmaceuticals,2021,0.86,1.1474024528375415,Drug_Safety
Tsumura & Co,4295878528,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.9,357,S_risk,Biotechnology & Pharmaceuticals,2017,0.36,0.6418538861723948,Workforce_Development
Tsumura & Co,4295878528,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.69,357,S_risk,Biotechnology & Pharmaceuticals,2022,0.6759999999999999,0.9895411936137476,Drug_Safety
Tsumura & Co,4295878528,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,357,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Tsumura & Co,4295878528,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.98,357,S_risk,Biotechnology & Pharmaceuticals,2020,0.392,0.6830968447064438,Workforce_Development
Tsumura & Co,4295878528,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.7,357,S_risk,Biotechnology & Pharmaceuticals,2016,0.2799999999999999,0.5306282510621704,Workforce_Development
Tsumura & Co,4295878528,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.8,357,S_risk,Biotechnology & Pharmaceuticals,2021,0.72,1.0296194171811583,Workforce_Development
Tsumura & Co,4295878528,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.44,357,S_risk,Biotechnology & Pharmaceuticals,2022,0.576,0.8919980393051105,Workforce_Development
Tsumura & Co,4295878528,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.98,357,S_risk,Biotechnology & Pharmaceuticals,2019,0.392,0.6830968447064438,Workforce_Development
Tsumura & Co,4295878528,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.21,357,S_risk,Biotechnology & Pharmaceuticals,2019,0.884,1.1662709371419244,Drug_Safety
Orion Oyj,4295866566,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Orion Oyj,4295866566,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,356,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Evotec SE,5068477440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Evotec SE,5068477440,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.9,356,S_risk,Biotechnology & Pharmaceuticals,2021,0.76,1.0647107369924282,Drug_Safety
Orion Oyj,4295866566,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,356,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Evotec SE,5068477440,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.42,356,S_risk,Biotechnology & Pharmaceuticals,2023,0.968,1.229640551074514,Drug_Safety
Orion Oyj,4295866566,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,356,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Evotec SE,5068477440,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.61,356,S_risk,Biotechnology & Pharmaceuticals,2022,0.244,0.4762341789963716,Drug_Safety
Orion Oyj,4295866566,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,356,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Evotec SE,5068477440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Orion Oyj,4295866566,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Evotec SE,5068477440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Orion Oyj,4295866566,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Evotec SE,5068477440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Orion Oyj,4295866566,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Orion Oyj,4295866566,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,356,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Evotec SE,5068477440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,356,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Orion Oyj,4295866566,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,356,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Orion Oyj,4295866566,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,356,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Evotec SE,5068477440,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.93,356,S_risk,Biotechnology & Pharmaceuticals,2020,0.772,1.075002423028976,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Prestige Consumer Healthcare Inc,4295907295,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sartorius Stedim Biotech SA,4295867687,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Samsung Biologics Co Ltd,5035458824,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.38,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.152,0.3220834991691133,Drug_Safety
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.47,355,S_risk,Biotechnology & Pharmaceuticals,2019,0.188,0.3852624007906449,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.83,355,S_risk,Biotechnology & Pharmaceuticals,2019,0.3319999999999999,0.6043159668533296,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.28,355,S_risk,Biotechnology & Pharmaceuticals,2020,0.512,0.8241754429663494,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.53,355,S_risk,Biotechnology & Pharmaceuticals,2018,0.612,0.9282193027394288,Drug_Safety
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.89,355,S_risk,Biotechnology & Pharmaceuticals,2021,0.356,0.636576829071551,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.66,355,S_risk,Biotechnology & Pharmaceuticals,2018,0.264,0.5068176023684519,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.16,355,S_risk,Biotechnology & Pharmaceuticals,2020,0.064,0.1484200051182732,Drug_Safety
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Samsung Biologics Co Ltd,5035458824,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.16,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.064,0.1484200051182732,Drug_Safety
Prestige Consumer Healthcare Inc,4295907295,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Samsung Biologics Co Ltd,5035458824,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Samsung Biologics Co Ltd,5035458824,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Joincare Pharmaceutical Group Industry Co Ltd,4295865048,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.25,355,S_risk,Biotechnology & Pharmaceuticals,2022,0.1,0.2231435513142097,Drug_Safety
Sartorius Stedim Biotech SA,4295867687,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,355,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Samsung Biologics Co Ltd,5035458824,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,355,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Dolby Laboratories Inc,4295899994,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Mesa Laboratories Inc,4295907138,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bio Rad Laboratories Inc,4295908554,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Kalbe Farma Tbk PT,4295874370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,354,S_risk,Biotechnology & Pharmaceuticals,2019,0.6,0.9162907318741552,Drug_Safety
Mesa Laboratories Inc,4295907138,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Bio Rad Laboratories Inc,4295908554,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Kalbe Farma Tbk PT,4295874370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Bio Rad Laboratories Inc,4295908554,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Drug_Safety
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
Bio Rad Laboratories Inc,4295908554,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bio Rad Laboratories Inc,4295908554,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.36,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.144,0.3074846997479606,Drug_Safety
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Kalbe Farma Tbk PT,4295874370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bio Rad Laboratories Inc,4295908554,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.46,354,S_risk,Biotechnology & Pharmaceuticals,2021,0.184,0.3784364357202451,Drug_Safety
Kalbe Farma Tbk PT,4295874370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Dolby Laboratories Inc,4295899994,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Mesa Laboratories Inc,4295907138,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dolby Laboratories Inc,4295899994,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Bio Rad Laboratories Inc,4295908554,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.28,354,S_risk,Biotechnology & Pharmaceuticals,2020,0.112,0.2468600779315258,Drug_Safety
Mesa Laboratories Inc,4295907138,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,354,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Kalbe Farma Tbk PT,4295874370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Dolby Laboratories Inc,4295899994,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.5,354,S_risk,Biotechnology & Pharmaceuticals,2021,0.2,0.4054651081081644,Drug_Safety
Dolby Laboratories Inc,4295899994,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,354,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Kalbe Farma Tbk PT,4295874370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.12,354,S_risk,Biotechnology & Pharmaceuticals,2018,0.048,0.1133286853070031,Drug_Safety
Biomarin Pharmaceutical Inc,4295912660,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,353,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Biomarin Pharmaceutical Inc,4295912660,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,353,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Biomarin Pharmaceutical Inc,4295912660,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,353,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.08,352,S_risk,Biotechnology & Pharmaceuticals,2018,0.8320000000000001,1.1249295969854831,Drug_Safety
DXP Enterprises Inc,4295906126,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,352,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,352,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,352,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.21,352,S_risk,Biotechnology & Pharmaceuticals,2021,0.484,0.7929925155296614,Drug_Safety
DXP Enterprises Inc,4295906126,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,352,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
DXP Enterprises Inc,4295906126,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,352,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.06,352,S_risk,Biotechnology & Pharmaceuticals,2019,0.8240000000000001,1.118414915964289,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,352,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.33,352,S_risk,Biotechnology & Pharmaceuticals,2020,0.532,0.8458682675776092,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,352,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Chugai Pharmaceutical Co Ltd,4295876884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,352,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,352,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,352,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,352,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,352,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.09,352,S_risk,Biotechnology & Pharmaceuticals,2023,0.436,0.7371640659767197,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.48,352,S_risk,Biotechnology & Pharmaceuticals,2022,0.592,0.9082585601768908,Drug_Safety
Chugai Pharmaceutical Co Ltd,4295876884,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,352,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,351,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,351,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hangzhou Tigermed Consulting Co Ltd,5035526612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,351,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hangzhou Tigermed Consulting Co Ltd,5035526612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,351,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,351,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,351,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,351,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,351,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.34,351,S_risk,Biotechnology & Pharmaceuticals,2023,0.136,0.29266961396282,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,351,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Hangzhou Tigermed Consulting Co Ltd,5035526612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,351,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hangzhou Tigermed Consulting Co Ltd,5035526612,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,351,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
IDEXX Laboratories Inc,4295906763,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,349,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
IDEXX Laboratories Inc,4295906763,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,349,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
IDEXX Laboratories Inc,4295906763,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,349,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
IDEXX Laboratories Inc,4295906763,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.6,349,S_risk,Biotechnology & Pharmaceuticals,2017,0.64,0.9555114450274363,Drug_Safety
IDEXX Laboratories Inc,4295906763,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,349,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
IDEXX Laboratories Inc,4295906763,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,349,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
USANA Health Sciences Inc,4295908218,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Laboratorios Farmaceuticos ROVI SA,4295889285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Genscript Biotech Corp,5047817370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.26,347,S_risk,Biotechnology & Pharmaceuticals,2022,0.104,0.2311117209633866,Drug_Safety
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Laboratorios Farmaceuticos ROVI SA,4295889285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.98,347,S_risk,Biotechnology & Pharmaceuticals,2020,0.392,0.6830968447064438,Drug_Safety
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.67,347,S_risk,Biotechnology & Pharmaceuticals,2021,0.268,0.5128236264286637,Drug_Safety
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.0,347,S_risk,Biotechnology & Pharmaceuticals,2022,0.8,1.0986122886681098,Drug_Safety
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.32,347,S_risk,Biotechnology & Pharmaceuticals,2020,0.528,0.8415671856782186,Workforce_Development
Genscript Biotech Corp,5047817370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Genscript Biotech Corp,5047817370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Laboratorios Farmaceuticos ROVI SA,4295889285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
USANA Health Sciences Inc,4295908218,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.99,347,S_risk,Biotechnology & Pharmaceuticals,2023,0.396,0.688134638736401,Drug_Safety
Laboratorios Farmaceuticos ROVI SA,4295889285,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
USANA Health Sciences Inc,4295908218,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,347,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.57,347,S_risk,Biotechnology & Pharmaceuticals,2018,0.2279999999999999,0.4510756193602167,Drug_Safety
Genscript Biotech Corp,5047817370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Laboratorios Farmaceuticos ROVI SA,4295889285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,347,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Genscript Biotech Corp,5047817370,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.4,347,S_risk,Biotechnology & Pharmaceuticals,2019,0.16,0.3364722366212129,Drug_Safety
Hypera SA,4297927148,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Celldex Therapeutics Inc,4297103233,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,346,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hypera SA,4297927148,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Drug_Safety
Hypera SA,4297927148,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,346,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hypera SA,4297927148,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,346,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tingyi (Cayman Islands) Holding Corp,4295871039,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Tingyi (Cayman Islands) Holding Corp,4295871039,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,346,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Tingyi (Cayman Islands) Holding Corp,4295871039,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Celldex Therapeutics Inc,4297103233,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hypera SA,4297927148,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.44,346,S_risk,Biotechnology & Pharmaceuticals,2021,0.976,1.235471471385307,Drug_Safety
Hypera SA,4297927148,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.11,346,S_risk,Biotechnology & Pharmaceuticals,2019,0.844,1.1346227261911428,Drug_Safety
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,346,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hypera SA,4297927148,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,346,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Hypera SA,4297927148,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Tingyi (Cayman Islands) Holding Corp,4295871039,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Hypera SA,4297927148,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tingyi (Cayman Islands) Holding Corp,4295871039,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,346,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Hypera SA,4297927148,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,346,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.16,344,S_risk,Biotechnology & Pharmaceuticals,2023,0.064,0.1484200051182732,Drug_Safety
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,2.3,344,S_risk,Biotechnology & Pharmaceuticals,2021,0.92,1.1939224684724346,Workforce_Development
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,344,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Ono Pharmaceutical Co Ltd,4295877874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,344,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.8,344,S_risk,Biotechnology & Pharmaceuticals,2019,0.72,1.0296194171811583,Workforce_Development
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,2.0,344,S_risk,Biotechnology & Pharmaceuticals,2017,0.8,1.0986122886681098,Workforce_Development
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.16,344,S_risk,Biotechnology & Pharmaceuticals,2018,0.064,0.1484200051182732,Drug_Safety
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,344,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.47,344,S_risk,Biotechnology & Pharmaceuticals,2021,0.188,0.3852624007906449,Drug_Safety
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.9,344,S_risk,Biotechnology & Pharmaceuticals,2016,0.76,1.0647107369924282,Workforce_Development
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,344,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,2.1,344,S_risk,Biotechnology & Pharmaceuticals,2018,0.8400000000000001,1.1314021114911006,Workforce_Development
Ono Pharmaceutical Co Ltd,4295877874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,344,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.8,344,S_risk,Biotechnology & Pharmaceuticals,2020,0.72,1.0296194171811583,Workforce_Development
Ono Pharmaceutical Co Ltd,4295877874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,344,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,344,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Ono Pharmaceutical Co Ltd,4295877874,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,344,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Ionis Pharmaceuticals Inc,4295906873,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.21,343,S_risk,Biotechnology & Pharmaceuticals,2021,0.0839999999999999,0.1906203596086497,Drug_Safety
Ionis Pharmaceuticals Inc,4295906873,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ionis Pharmaceuticals Inc,4295906873,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
West Pharmaceutical Services Inc,4295912317,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
WuXi Biologics (Cayman) Inc,5045916247,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.2,343,S_risk,Biotechnology & Pharmaceuticals,2022,0.08,0.1823215567939546,Drug_Safety
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.19,343,S_risk,Biotechnology & Pharmaceuticals,2020,0.076,0.173953307123438,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.05,343,S_risk,Biotechnology & Pharmaceuticals,2023,0.02,0.048790164169432,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.7,343,S_risk,Biotechnology & Pharmaceuticals,2019,0.2799999999999999,0.5306282510621704,Drug_Safety
West Pharmaceutical Services Inc,4295912317,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Ionis Pharmaceuticals Inc,4295906873,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Ionis Pharmaceuticals Inc,4295906873,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
WuXi Biologics (Cayman) Inc,5045916247,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
West Pharmaceutical Services Inc,4295912317,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,343,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
West Pharmaceutical Services Inc,4295912317,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,343,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
WuXi Biologics (Cayman) Inc,5045916247,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.22,343,S_risk,Biotechnology & Pharmaceuticals,2019,0.088,0.1988508587451652,Drug_Safety
Galapagos NV,4295859376,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,341,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Galapagos NV,4295859376,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,341,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Galapagos NV,4295859376,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,341,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Galapagos NV,4295859376,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.5,341,S_risk,Biotechnology & Pharmaceuticals,2023,0.2,0.4054651081081644,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,2.2,341,S_risk,Biotechnology & Pharmaceuticals,2020,0.8800000000000001,1.1631508098056809,Workforce_Development
Galapagos NV,4295859376,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.67,341,S_risk,Biotechnology & Pharmaceuticals,2020,0.268,0.5128236264286637,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,341,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,341,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,341,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,341,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.9,341,S_risk,Biotechnology & Pharmaceuticals,2021,0.36,0.6418538861723948,Drug_Safety
Galapagos NV,4295859376,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,341,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Galapagos NV,4295859376,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,341,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,341,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Galapagos NV,4295859376,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.5,341,S_risk,Biotechnology & Pharmaceuticals,2022,0.2,0.4054651081081644,Drug_Safety
Alkermes Plc,5035456435,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.3,340,S_risk,Biotechnology & Pharmaceuticals,2020,0.92,1.1939224684724346,Drug_Safety
Alkermes Plc,5035456435,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,340,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Alkermes Plc,5035456435,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,340,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alkermes Plc,5035456435,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.5,340,S_risk,Biotechnology & Pharmaceuticals,2023,1.0,1.252762968495368,Drug_Safety
Alkermes Plc,5035456435,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.0,340,S_risk,Biotechnology & Pharmaceuticals,2022,0.8,1.0986122886681098,Drug_Safety
Alkermes Plc,5035456435,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,340,S_risk,Biotechnology & Pharmaceuticals,2019,0.6,0.9162907318741552,Drug_Safety
Alkermes Plc,5035456435,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,340,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Alkermes Plc,5035456435,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,340,S_risk,Biotechnology & Pharmaceuticals,2021,0.6,0.9162907318741552,Drug_Safety
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.2,339,S_risk,Biotechnology & Pharmaceuticals,2022,0.48,0.7884573603642702,Drug_Safety
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Pacira Biosciences Inc,4297853578,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Merck KGaA,4295869098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
China Medical System Holdings Ltd,4295863681,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Merck KGaA,4295869098,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.6,339,S_risk,Biotechnology & Pharmaceuticals,2019,0.64,0.9555114450274363,Drug_Safety
Neurocrine Biosciences Inc,4295907381,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Neurocrine Biosciences Inc,4295907381,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Neurocrine Biosciences Inc,4295907381,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Neurocrine Biosciences Inc,4295907381,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,339,S_risk,Biotechnology & Pharmaceuticals,2020,0.52,0.832909122935104,Drug_Safety
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,339,S_risk,Biotechnology & Pharmaceuticals,2023,0.52,0.832909122935104,Drug_Safety
China Medical System Holdings Ltd,4295863681,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
China Medical System Holdings Ltd,4295863681,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
China Medical System Holdings Ltd,4295863681,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Merck KGaA,4295869098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pacira Biosciences Inc,4297853578,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Merck KGaA,4295869098,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
China Medical System Holdings Ltd,4295863681,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Merck KGaA,4295869098,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.2,339,S_risk,Biotechnology & Pharmaceuticals,2018,0.48,0.7884573603642702,Drug_Safety
Merck KGaA,4295869098,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
China Medical System Holdings Ltd,4295863681,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,339,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Merck KGaA,4295869098,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Pacira Biosciences Inc,4297853578,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,339,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.45,338,S_risk,Biotechnology & Pharmaceuticals,2019,0.18,0.371563556432483,Drug_Safety
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,338,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Genmab A/S,4295866092,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,338,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Silicon Laboratories Inc,4295914943,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,338,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.55,338,S_risk,Biotechnology & Pharmaceuticals,2021,0.22,0.4382549309311553,Drug_Safety
Genmab A/S,4295866092,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,338,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Genmab A/S,4295866092,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,338,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Genmab A/S,4295866092,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,338,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Silicon Laboratories Inc,4295914943,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,338,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Silicon Laboratories Inc,4295914943,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,338,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.12,337,S_risk,Biotechnology & Pharmaceuticals,2023,0.048,0.1133286853070031,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Insight Enterprises Inc,4295906810,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,337,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Insight Enterprises Inc,4295906810,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,337,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Insight Enterprises Inc,4295906810,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,337,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.03,337,S_risk,Biotechnology & Pharmaceuticals,2019,0.012,0.0295588022415444,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,337,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Insight Enterprises Inc,4295906810,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,337,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,337,S_risk,Biotechnology & Pharmaceuticals,2017,0.4,0.6931471805599453,Drug_Safety
Insight Enterprises Inc,4295906810,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,337,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,337,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
China Resources Sanjiu Medical & Pharmaceutical Co Ltd,4295864669,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,337,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Syngene International Ltd,4298178079,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,336,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Syngene International Ltd,4298178079,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.3,336,S_risk,Biotechnology & Pharmaceuticals,2020,0.12,0.262364264467491,Drug_Safety
Syngene International Ltd,4298178079,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,336,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Drug_Safety
Syngene International Ltd,4298178079,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.08,336,S_risk,Biotechnology & Pharmaceuticals,2023,0.032,0.0769610411361283,Drug_Safety
Syngene International Ltd,4298178079,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,336,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Syngene International Ltd,4298178079,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,336,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Syngene International Ltd,4298178079,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,336,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Syngene International Ltd,4298178079,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.06,336,S_risk,Biotechnology & Pharmaceuticals,2021,0.024,0.0582689081239757,Drug_Safety
Syngene International Ltd,4298178079,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.2,336,S_risk,Biotechnology & Pharmaceuticals,2022,0.08,0.1823215567939546,Drug_Safety
Syngene International Ltd,4298178079,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,336,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Syngene International Ltd,4298178079,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,336,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Syngene International Ltd,4298178079,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.06,336,S_risk,Biotechnology & Pharmaceuticals,2024,0.024,0.0582689081239757,Drug_Safety
Viatris Inc,5035523437,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,335,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Viatris Inc,5035523437,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.95,335,S_risk,Biotechnology & Pharmaceuticals,2022,0.78,1.0818051703517284,Drug_Safety
Viatris Inc,5035523437,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,335,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
Amicus Therapeutics Inc,4295902550,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,335,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Viatris Inc,5035523437,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,335,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Viatris Inc,5035523437,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,335,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Viatris Inc,5035523437,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,335,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Viatris Inc,5035523437,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,335,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Viatris Inc,5035523437,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.4,335,S_risk,Biotechnology & Pharmaceuticals,2021,0.96,1.2237754316221157,Drug_Safety
Amicus Therapeutics Inc,4295902550,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,335,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Amicus Therapeutics Inc,4295902550,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,335,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Viatris Inc,5035523437,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,335,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Amicus Therapeutics Inc,4295902550,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,335,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Viatris Inc,5035523437,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,335,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
ICON PLC,4295874891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,334,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
ICON PLC,4295874891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,334,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Torrent Pharmaceuticals Ltd,4295872667,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,334,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,334,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
ICON PLC,4295874891,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.38,334,S_risk,Biotechnology & Pharmaceuticals,2022,0.5519999999999999,0.8671004876833833,Drug_Safety
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.12,334,S_risk,Biotechnology & Pharmaceuticals,2021,0.048,0.1133286853070031,Drug_Safety
ICON PLC,4295874891,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.25,334,S_risk,Biotechnology & Pharmaceuticals,2023,0.1,0.2231435513142097,Drug_Safety
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.15,334,S_risk,Biotechnology & Pharmaceuticals,2024,0.06,0.1397619423751586,Drug_Safety
Torrent Pharmaceuticals Ltd,4295872667,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,334,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
ICON PLC,4295874891,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.26,334,S_risk,Biotechnology & Pharmaceuticals,2021,0.504,0.8153648132841945,Drug_Safety
ICON PLC,4295874891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,334,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
ICON PLC,4295874891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,334,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,334,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,334,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.1,334,S_risk,Biotechnology & Pharmaceuticals,2022,0.04,0.0953101798043248,Drug_Safety
ICON PLC,4295874891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,334,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
ICON PLC,4295874891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,334,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Torrent Pharmaceuticals Ltd,4295872667,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,334,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
ICON PLC,4295874891,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,334,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.45,333,S_risk,Biotechnology & Pharmaceuticals,2019,0.98,1.2383742310432684,Drug_Safety
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.05,333,S_risk,Biotechnology & Pharmaceuticals,2021,0.42,0.7178397931503169,Drug_Safety
Vertex Pharmaceuticals Inc,4295908317,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,333,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.05,333,S_risk,Biotechnology & Pharmaceuticals,2020,0.42,0.7178397931503169,Drug_Safety
Vertex Pharmaceuticals Inc,4295908317,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,333,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.65,333,S_risk,Biotechnology & Pharmaceuticals,2023,0.6599999999999999,0.9745596399981308,Drug_Safety
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,333,S_risk,Biotechnology & Pharmaceuticals,2018,0.6,0.9162907318741552,Drug_Safety
Vertex Pharmaceuticals Inc,4295908317,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.2,333,S_risk,Biotechnology & Pharmaceuticals,2022,0.48,0.7884573603642702,Drug_Safety
Vertex Pharmaceuticals Inc,4295908317,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,333,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
American Superconductor Corp,4295905527,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,332,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
American Superconductor Corp,4295905527,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,332,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Phibro Animal Health Corp,5034074360,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,332,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
American Superconductor Corp,4295905527,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,332,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Phibro Animal Health Corp,5034074360,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,332,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Phibro Animal Health Corp,5034074360,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,332,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
American Superconductor Corp,4295905527,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,332,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.58,331,S_risk,Biotechnology & Pharmaceuticals,2021,0.2319999999999999,0.4574248470388754,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,331,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,331,S_risk,Biotechnology & Pharmaceuticals,2019,0.8,1.0986122886681098,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.77,331,S_risk,Biotechnology & Pharmaceuticals,2023,0.308,0.5709795465857378,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,331,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,331,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.52,331,S_risk,Biotechnology & Pharmaceuticals,2022,0.208,0.418710334858185,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,331,S_risk,Biotechnology & Pharmaceuticals,2018,0.8,1.0986122886681098,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,331,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,331,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hansoh Pharmaceutical Group Company Ltd,5065366702,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,331,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hansoh Pharmaceutical Group Company Ltd,5065366702,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,331,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
Hansoh Pharmaceutical Group Company Ltd,5065366702,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,331,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
ACADIA Pharmaceuticals Inc,4295903398,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,330,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Fate Therapeutics Inc,4296275166,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,330,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Fate Therapeutics Inc,4296275166,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,330,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
ACADIA Pharmaceuticals Inc,4295903398,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,330,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Fate Therapeutics Inc,4296275166,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,330,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
ACADIA Pharmaceuticals Inc,4295903398,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,330,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bavarian Nordic A/S,4295866173,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,329,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bavarian Nordic A/S,4295866173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,329,S_risk,Biotechnology & Pharmaceuticals,2022,0.52,0.832909122935104,Drug_Safety
Supernus Pharmaceuticals Inc,4297350707,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,329,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Supernus Pharmaceuticals Inc,4297350707,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,329,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Bavarian Nordic A/S,4295866173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.5,329,S_risk,Biotechnology & Pharmaceuticals,2019,1.0,1.252762968495368,Drug_Safety
ANI Pharmaceuticals Inc,4295902157,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,329,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Bavarian Nordic A/S,4295866173,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,329,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Supernus Pharmaceuticals Inc,4297350707,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,329,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Bavarian Nordic A/S,4295866173,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,329,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
ANI Pharmaceuticals Inc,4295902157,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,329,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Wockhardt Ltd,4295873567,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,328,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Wockhardt Ltd,4295873567,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,328,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Wockhardt Ltd,4295873567,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,328,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Wockhardt Ltd,4295873567,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,328,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Werner Enterprises Inc,4295908451,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,327,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.39,327,S_risk,Biotechnology & Pharmaceuticals,2023,0.156,0.3293037471426004,Drug_Safety
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.18,327,S_risk,Biotechnology & Pharmaceuticals,2024,0.072,0.1655144384775733,Drug_Safety
IPCA Laboratories Ltd,4295873554,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,327,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,327,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
IPCA Laboratories Ltd,4295873554,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,327,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
IPCA Laboratories Ltd,4295873554,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,327,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
IPCA Laboratories Ltd,4295873554,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,327,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Werner Enterprises Inc,4295908451,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,327,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Roche Holding AG,4295890594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.04,326,S_risk,Biotechnology & Pharmaceuticals,2021,0.016,0.0392207131532812,Drug_Safety
Roche Holding AG,4295890594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.04,326,S_risk,Biotechnology & Pharmaceuticals,2023,0.416,0.712949807856125,Drug_Safety
Roche Holding AG,4295890594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.05,326,S_risk,Biotechnology & Pharmaceuticals,2020,0.02,0.048790164169432,Drug_Safety
Roche Holding AG,4295890594,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,326,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Roche Holding AG,4295890594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.96,326,S_risk,Biotechnology & Pharmaceuticals,2018,0.784,1.085189268335969,Drug_Safety
Roche Holding AG,4295890594,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,326,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Roche Holding AG,4295890594,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,326,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Roche Holding AG,4295890594,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,326,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Roche Holding AG,4295890594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.25,326,S_risk,Biotechnology & Pharmaceuticals,2022,0.1,0.2231435513142097,Drug_Safety
Roche Holding AG,4295890594,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,326,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Roche Holding AG,4295890594,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,326,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Roche Holding AG,4295890594,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.88,326,S_risk,Biotechnology & Pharmaceuticals,2019,0.752,1.0577902941478543,Drug_Safety
Roche Holding AG,4295890594,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,326,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Integra Lifesciences Holdings Corp,4295906823,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,324,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Integra Lifesciences Holdings Corp,4295906823,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,324,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Integra Lifesciences Holdings Corp,4295906823,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,324,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.9,323,S_risk,Biotechnology & Pharmaceuticals,2021,0.36,0.6418538861723948,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.34,323,S_risk,Biotechnology & Pharmaceuticals,2022,0.136,0.29266961396282,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.7,323,S_risk,Biotechnology & Pharmaceuticals,2020,0.6799999999999999,0.9932517730102832,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,323,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,323,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,323,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.1,323,S_risk,Biotechnology & Pharmaceuticals,2019,0.8400000000000001,1.1314021114911006,Drug_Safety
Dechra Pharmaceuticals PLC,4295895791,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,323,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Starpharma Holdings Ltd,4295856781,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
3SBio Inc,4295863999,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Starpharma Holdings Ltd,4295856781,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
3SBio Inc,4295863999,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
3SBio Inc,4295863999,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Starpharma Holdings Ltd,4295856781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
3SBio Inc,4295863999,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Quest Diagnostics Inc,4295904788,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
3SBio Inc,4295863999,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
3SBio Inc,4295863999,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Quest Diagnostics Inc,4295904788,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
3SBio Inc,4295863999,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Quest Diagnostics Inc,4295904788,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Starpharma Holdings Ltd,4295856781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
3SBio Inc,4295863999,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.19,322,S_risk,Biotechnology & Pharmaceuticals,2022,0.076,0.173953307123438,Drug_Safety
Starpharma Holdings Ltd,4295856781,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
3SBio Inc,4295863999,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
3SBio Inc,4295863999,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Starpharma Holdings Ltd,4295856781,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
3SBio Inc,4295863999,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Drug_Safety
Starpharma Holdings Ltd,4295856781,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
3SBio Inc,4295863999,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Quest Diagnostics Inc,4295904788,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
3SBio Inc,4295863999,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,322,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
3SBio Inc,4295863999,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,322,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Blackmores Ltd,4295856664,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,321,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Blackmores Ltd,4295856664,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,321,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Blackmores Ltd,4295856664,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,321,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Blackmores Ltd,4295856664,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,321,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Blackmores Ltd,4295856664,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,321,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Blackmores Ltd,4295856664,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,321,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Blackmores Ltd,4295856664,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,321,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Blackmores Ltd,4295856664,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,321,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Blackmores Ltd,4295856664,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,321,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
United Therapeutics Corp,4295915261,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.5,320,S_risk,Biotechnology & Pharmaceuticals,2020,0.2,0.4054651081081644,Drug_Safety
United Therapeutics Corp,4295915261,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,320,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Omega Healthcare Investors Inc,4295904656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,320,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
United Therapeutics Corp,4295915261,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,320,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Omega Healthcare Investors Inc,4295904656,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.94,320,S_risk,Biotechnology & Pharmaceuticals,2021,0.776,1.0784095813505905,Workforce_Development
United Therapeutics Corp,4295915261,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.5,320,S_risk,Biotechnology & Pharmaceuticals,2021,0.2,0.4054651081081644,Drug_Safety
United Therapeutics Corp,4295915261,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,320,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
United Therapeutics Corp,4295915261,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,320,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
United Therapeutics Corp,4295915261,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,320,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Omega Healthcare Investors Inc,4295904656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,320,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
United Therapeutics Corp,4295915261,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,320,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
United Therapeutics Corp,4295915261,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,320,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Omega Healthcare Investors Inc,4295904656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,320,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Omega Healthcare Investors Inc,4295904656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,320,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,319,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,319,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Amphastar Pharmaceuticals Inc,4297971432,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,319,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Amphastar Pharmaceuticals Inc,4297971432,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,319,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,319,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Amphastar Pharmaceuticals Inc,4297971432,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,319,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC,4295887324,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,319,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Amphastar Pharmaceuticals Inc,4297971432,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,319,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,318,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Zhejiang Nhu Co Ltd,4295864955,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,318,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
BioCryst Pharmaceuticals Inc,4295905725,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Zhejiang Nhu Co Ltd,4295864955,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,318,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Sumitomo Pharma Co Ltd,4295877685,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.22,318,S_risk,Biotechnology & Pharmaceuticals,2022,0.088,0.1988508587451652,Drug_Safety
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.25,318,S_risk,Biotechnology & Pharmaceuticals,2019,0.5,0.8109302162163288,Workforce_Development
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.11,318,S_risk,Biotechnology & Pharmaceuticals,2020,0.444,0.7466879474879752,Workforce_Development
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,318,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
argenx SE,5000263797,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
argenx SE,5000263797,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,318,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.16,318,S_risk,Biotechnology & Pharmaceuticals,2021,0.4639999999999999,0.7701082216960736,Workforce_Development
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.79,318,S_risk,Biotechnology & Pharmaceuticals,2018,0.716,1.0260415958332745,Workforce_Development
argenx SE,5000263797,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,318,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Zhejiang Nhu Co Ltd,4295864955,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,318,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sumitomo Pharma Co Ltd,4295877685,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Zhejiang Nhu Co Ltd,4295864955,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
BioCryst Pharmaceuticals Inc,4295905725,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
argenx SE,5000263797,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.8,318,S_risk,Biotechnology & Pharmaceuticals,2021,0.32,0.5877866649021191,Drug_Safety
argenx SE,5000263797,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sumitomo Pharma Co Ltd,4295877685,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.68,318,S_risk,Biotechnology & Pharmaceuticals,2022,0.6719999999999999,0.9858167945227652,Workforce_Development
argenx SE,5000263797,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
BioCryst Pharmaceuticals Inc,4295905725,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sumitomo Pharma Co Ltd,4295877685,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Zhejiang Nhu Co Ltd,4295864955,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,318,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Sumitomo Pharma Co Ltd,4295877685,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,318,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Novavax Inc,4295904633,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Heron Therapeutics Inc,4295905439,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Novavax Inc,4295904633,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Luye Pharma Group Ltd,4295887822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Heron Therapeutics Inc,4295905439,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Luye Pharma Group Ltd,4295887822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Heron Therapeutics Inc,4295905439,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Novavax Inc,4295904633,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Luye Pharma Group Ltd,4295887822,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Sihuan Pharmaceutical Holdings Group Ltd,4295865257,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,316,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Luye Pharma Group Ltd,4295887822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Luye Pharma Group Ltd,4295887822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2018,0.4,0.6931471805599453,Business_Ethics
Luye Pharma Group Ltd,4295887822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,316,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Oriola Oyj,4295866498,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,315,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Agenus Inc,4295912530,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Oriola Oyj,4295866498,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Oriola Oyj,4295866498,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,315,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aclaris Therapeutics Inc,5037844397,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Agenus Inc,4295912530,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Bachem Holding AG,5000073936,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Bachem Holding AG,5000073936,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pacific Biosciences of California Inc,4296988897,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Oriola Oyj,4295866498,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Pacific Biosciences of California Inc,4296988897,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Oriola Oyj,4295866498,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,315,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Oriola Oyj,4295866498,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bachem Holding AG,5000073936,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Agenus Inc,4295912530,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Oriola Oyj,4295866498,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,315,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Aclaris Therapeutics Inc,5037844397,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Oriola Oyj,4295866498,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,315,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Beigene Ltd,5046048089,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.05,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.02,0.048790164169432,Drug_Safety
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Beigene Ltd,5046048089,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Beigene Ltd,5046048089,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Beigene Ltd,5046048089,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.18,313,S_risk,Biotechnology & Pharmaceuticals,2021,0.072,0.1655144384775733,Drug_Safety
Rigel Pharmaceuticals Inc,4295915993,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Denali Therapeutics Inc,5045948499,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Beigene Ltd,5046048089,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.39,313,S_risk,Biotechnology & Pharmaceuticals,2019,0.156,0.3293037471426004,Drug_Safety
Beigene Ltd,5046048089,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Denali Therapeutics Inc,5045948499,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Beigene Ltd,5046048089,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Rigel Pharmaceuticals Inc,4295915993,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Denali Therapeutics Inc,5045948499,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Zydus Lifesciences Ltd,4295873709,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Beigene Ltd,5046048089,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.01,313,S_risk,Biotechnology & Pharmaceuticals,2024,0.004,0.009950330853168,Drug_Safety
Zydus Lifesciences Ltd,4295873709,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Rigel Pharmaceuticals Inc,4295915993,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Rigel Pharmaceuticals Inc,4295915993,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.12,313,S_risk,Biotechnology & Pharmaceuticals,2023,0.048,0.1133286853070031,Drug_Safety
Beigene Ltd,5046048089,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Beigene Ltd,5046048089,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Denali Therapeutics Inc,5045948499,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Beigene Ltd,5046048089,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Beigene Ltd,5046048089,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Fox Factory Holding Corp,5000166256,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Beigene Ltd,5046048089,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.65,313,S_risk,Biotechnology & Pharmaceuticals,2022,0.26,0.5007752879124893,Drug_Safety
Fox Factory Holding Corp,5000166256,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Fox Factory Holding Corp,5000166256,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,313,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Beigene Ltd,5046048089,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zydus Lifesciences Ltd,4295873709,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,313,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Tong Ren Tang Technologies Co Ltd,4295864045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,312,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Tong Ren Tang Technologies Co Ltd,4295864045,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,312,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tong Ren Tang Technologies Co Ltd,4295864045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,312,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
Tong Ren Tang Technologies Co Ltd,4295864045,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,312,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ligand Pharmaceuticals Inc,4295907009,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,312,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ligand Pharmaceuticals Inc,4295907009,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,312,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Tong Ren Tang Technologies Co Ltd,4295864045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,312,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Tong Ren Tang Technologies Co Ltd,4295864045,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,312,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Tong Ren Tang Technologies Co Ltd,4295864045,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,312,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Tong Ren Tang Technologies Co Ltd,4295864045,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,312,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Ligand Pharmaceuticals Inc,4295907009,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,312,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Tong Ren Tang Technologies Co Ltd,4295864045,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,312,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sarepta Therapeutics Inc,4295905395,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Precigen Inc,4297774183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Precigen Inc,4297774183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Elanco Animal Health Inc,4296365146,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Precigen Inc,4297774183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Asymchem Laboratories Tianjin Co Ltd,5000567947,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sarepta Therapeutics Inc,4295905395,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Precigen Inc,4297774183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Elanco Animal Health Inc,4296365146,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Asymchem Laboratories Tianjin Co Ltd,5000567947,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Asymchem Laboratories Tianjin Co Ltd,5000567947,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.35,311,S_risk,Biotechnology & Pharmaceuticals,2019,0.54,0.8544153281560676,Drug_Safety
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.2,311,S_risk,Biotechnology & Pharmaceuticals,2020,0.8800000000000001,1.1631508098056809,Drug_Safety
Sarepta Therapeutics Inc,4295905395,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Asymchem Laboratories Tianjin Co Ltd,5000567947,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Asymchem Laboratories Tianjin Co Ltd,5000567947,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,311,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.1,311,S_risk,Biotechnology & Pharmaceuticals,2022,0.8400000000000001,1.1314021114911006,Drug_Safety
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Asymchem Laboratories Tianjin Co Ltd,5000567947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Elanco Animal Health Inc,4296365146,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,311,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Dermapharm Holding SE,5060556153,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Dermapharm Holding SE,5060556153,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Dermapharm Holding SE,5060556153,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Intellia Therapeutics Inc,5044066446,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.6,310,S_risk,Biotechnology & Pharmaceuticals,2021,0.24,0.4700036292457355,Drug_Safety
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Intellia Therapeutics Inc,5044066446,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
WuXi AppTec Co Ltd,5000217387,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Intellia Therapeutics Inc,5044066446,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Vanda Pharmaceuticals Inc,4295899966,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
WuXi AppTec Co Ltd,5000217387,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.55,310,S_risk,Biotechnology & Pharmaceuticals,2022,0.22,0.4382549309311553,Drug_Safety
Dermapharm Holding SE,5060556153,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
WuXi AppTec Co Ltd,5000217387,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.4,310,S_risk,Biotechnology & Pharmaceuticals,2023,0.16,0.3364722366212129,Drug_Safety
Vanda Pharmaceuticals Inc,4295899966,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
WuXi AppTec Co Ltd,5000217387,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Dermapharm Holding SE,5060556153,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,310,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Dermapharm Holding SE,5060556153,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,310,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
H Lundbeck A/S,4295866154,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,308,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Science Applications International Corp,5039584611,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,308,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
H Lundbeck A/S,4295866154,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,308,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
H Lundbeck A/S,4295866154,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,308,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
H Lundbeck A/S,4295866154,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,308,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
H Lundbeck A/S,4295866154,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,308,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
H Lundbeck A/S,4295866154,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,308,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
H Lundbeck A/S,4295866154,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,308,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Science Applications International Corp,5039584611,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,308,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
H Lundbeck A/S,4295866154,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,308,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
H Lundbeck A/S,4295866154,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,308,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Enanta Pharmaceuticals Inc,4296904058,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,307,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Enanta Pharmaceuticals Inc,4296904058,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,307,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Fulgent Genetics Inc,5051396874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,306,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Fulgent Genetics Inc,5051396874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,306,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Fulgent Genetics Inc,5051396874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,306,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Fulgent Genetics Inc,5051396874,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,306,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Fulgent Genetics Inc,5051396874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,306,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
MannKind Corp,4295903432,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,305,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
MannKind Corp,4295903432,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,305,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
MannKind Corp,4295903432,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,305,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
MannKind Corp,4295903432,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,305,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hikma Pharmaceuticals PLC,4295897408,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,304,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,304,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,304,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Agios Pharmaceuticals Inc,4298032874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,304,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Hikma Pharmaceuticals PLC,4295897408,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,304,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hikma Pharmaceuticals PLC,4295897408,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,304,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hikma Pharmaceuticals PLC,4295897408,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,304,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Agios Pharmaceuticals Inc,4298032874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,304,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hikma Pharmaceuticals PLC,4295897408,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,304,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Agios Pharmaceuticals Inc,4298032874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,304,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Agios Pharmaceuticals Inc,4298032874,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,304,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Prothena Corporation PLC,5037961722,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
ScinoPharm Taiwan Ltd,5000056362,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
ScinoPharm Taiwan Ltd,5000056362,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.62,303,S_risk,Biotechnology & Pharmaceuticals,2020,0.248,0.4824261492442927,Drug_Safety
ScinoPharm Taiwan Ltd,5000056362,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,303,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Prothena Corporation PLC,5037961722,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,303,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,303,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Mesoblast Ltd,4295858844,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sangamo Therapeutics Inc,4295914874,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Mesoblast Ltd,4295858844,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Mesoblast Ltd,4295858844,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,303,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,303,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,303,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
ScinoPharm Taiwan Ltd,5000056362,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,303,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Inovio Pharmaceuticals Inc,4295901003,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,302,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Inovio Pharmaceuticals Inc,4295901003,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,302,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Inovio Pharmaceuticals Inc,4295901003,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,302,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Inovio Pharmaceuticals Inc,4295901003,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,302,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Halozyme Therapeutics Inc,4295915674,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,302,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Halozyme Therapeutics Inc,4295915674,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,302,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Halozyme Therapeutics Inc,4295915674,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,302,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Halozyme Therapeutics Inc,4295915674,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,302,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Seres Therapeutics Inc,5037639494,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,301,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Seres Therapeutics Inc,5037639494,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,301,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Wolverine World Wide Inc,4295905354,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,301,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Wolverine World Wide Inc,4295905354,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,301,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Wolverine World Wide Inc,4295905354,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,301,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,300,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Drug_Safety
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,300,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Editas Medicine Inc,5040699642,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Drug_Safety
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Zealand Pharma A/S,4295989612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,300,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Editas Medicine Inc,5040699642,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Zealand Pharma A/S,4295989612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Collegium Pharmaceutical Inc,5045917401,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,300,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Collegium Pharmaceutical Inc,5045917401,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Editas Medicine Inc,5040699642,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Editas Medicine Inc,5040699642,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Collegium Pharmaceutical Inc,5045917401,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd,4295864231,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,300,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zealand Pharma A/S,4295989612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Zealand Pharma A/S,4295989612,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,300,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Akebia Therapeutics Inc,4297878446,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Apellis Pharmaceuticals Inc,5000744891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Akebia Therapeutics Inc,4297878446,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Amneal Pharmaceuticals Inc,5062782308,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Amneal Pharmaceuticals Inc,5062782308,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Akebia Therapeutics Inc,4297878446,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Eagle Pharmaceuticals Inc,4296474346,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Amneal Pharmaceuticals Inc,5062782308,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Apellis Pharmaceuticals Inc,5000744891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Amneal Pharmaceuticals Inc,5062782308,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Akebia Therapeutics Inc,4297878446,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Apellis Pharmaceuticals Inc,5000744891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,299,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ultragenyx Pharmaceutical Inc,5035304895,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,298,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Anika Therapeutics Inc,5068320253,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,298,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,298,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ultragenyx Pharmaceutical Inc,5035304895,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,298,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.4,298,S_risk,Biotechnology & Pharmaceuticals,2022,0.16,0.3364722366212129,Drug_Safety
Ultragenyx Pharmaceutical Inc,5035304895,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,298,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,298,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,298,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Ultragenyx Pharmaceutical Inc,5035304895,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,298,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ultragenyx Pharmaceutical Inc,5035304895,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,298,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Anika Therapeutics Inc,5068320253,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,298,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.75,297,S_risk,Biotechnology & Pharmaceuticals,2021,0.3,0.5596157879354227,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.36,297,S_risk,Biotechnology & Pharmaceuticals,2020,0.144,0.3074846997479606,Drug_Safety
Hisamitsu Pharmaceutical Co Inc,4295877610,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,297,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,297,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,297,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hisamitsu Pharmaceutical Co Inc,4295877610,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
American Vanguard Corp,4295903372,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.4,297,S_risk,Biotechnology & Pharmaceuticals,2022,0.16,0.3364722366212129,Drug_Safety
American Vanguard Corp,4295903372,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
American Vanguard Corp,4295903372,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hisamitsu Pharmaceutical Co Inc,4295877610,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hisamitsu Pharmaceutical Co Inc,4295877610,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.85,297,S_risk,Biotechnology & Pharmaceuticals,2023,0.3399999999999999,0.6151856390902335,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,297,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.2,297,S_risk,Biotechnology & Pharmaceuticals,2023,0.08,0.1823215567939546,Drug_Safety
Hanmi Pharm Co Ltd,5000805170,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,297,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
MorphoSys AG,4295869785,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.81,296,S_risk,Biotechnology & Pharmaceuticals,2020,0.324,0.5933268452777344,Drug_Safety
Guardant Health Inc,5041079009,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Guardant Health Inc,5041079009,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
MorphoSys AG,4295869785,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Guardant Health Inc,5041079009,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
MorphoSys AG,4295869785,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
MorphoSys AG,4295869785,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Innovent Biologics Inc,5066579901,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Innovent Biologics Inc,5066579901,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,296,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
MorphoSys AG,4295869785,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,296,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Seagen Inc,4295901424,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,295,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Seagen Inc,4295901424,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,295,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Seagen Inc,4295901424,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,295,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Seagen Inc,4295901424,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.95,295,S_risk,Biotechnology & Pharmaceuticals,2020,0.78,1.0818051703517284,Drug_Safety
Seagen Inc,4295901424,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,295,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Seagen Inc,4295901424,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,295,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Seagen Inc,4295901424,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.15,295,S_risk,Biotechnology & Pharmaceuticals,2018,0.86,1.1474024528375415,Drug_Safety
Seagen Inc,4295901424,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.35,295,S_risk,Biotechnology & Pharmaceuticals,2021,0.1399999999999999,0.300104592450338,Drug_Safety
Seagen Inc,4295901424,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,295,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Seagen Inc,4295901424,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.45,295,S_risk,Biotechnology & Pharmaceuticals,2022,0.58,0.8960880245566356,Drug_Safety
Seagen Inc,4295901424,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,295,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Myriad Genetics Inc,4295907228,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,294,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Nektar Therapeutics,4295906807,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,294,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Humanwell Healthcare Group Co Ltd,4295865648,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,294,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Humanwell Healthcare Group Co Ltd,4295865648,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,294,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Humanwell Healthcare Group Co Ltd,4295865648,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,294,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Humanwell Healthcare Group Co Ltd,4295865648,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,294,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Myriad Genetics Inc,4295907228,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,294,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Humanwell Healthcare Group Co Ltd,4295865648,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,294,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Humanwell Healthcare Group Co Ltd,4295865648,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,294,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Myriad Genetics Inc,4295907228,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,294,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Avid Bioservices Inc,4295915112,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,293,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Avid Bioservices Inc,4295915112,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,293,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Avid Bioservices Inc,4295915112,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,293,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Knight Therapeutics Inc,5046438291,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,292,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Theravance Biopharma Inc,5040202678,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,292,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Knight Therapeutics Inc,5046438291,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,292,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Knight Therapeutics Inc,5046438291,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,292,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Theravance Biopharma Inc,5040202678,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,292,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Veru Inc,4295906439,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,292,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Yuhan Corp,4295881557,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Sosei Group Corp,4295880658,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Yuhan Corp,4295881557,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Yuhan Corp,4295881557,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Yuhan Corp,4295881557,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Yuhan Corp,4295881557,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2017,0.4,0.6931471805599453,Business_Ethics
Biogaia AB,4295890085,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Yuhan Corp,4295881557,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sosei Group Corp,4295880658,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Yuhan Corp,4295881557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Yuhan Corp,4295881557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Yuhan Corp,4295881557,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Biogaia AB,4295890085,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sosei Group Corp,4295880658,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Yuhan Corp,4295881557,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,291,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Yuhan Corp,4295881557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Yuhan Corp,4295881557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Yuhan Corp,4295881557,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Biogaia AB,4295890085,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,291,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Pharmaron Beijing Co Ltd,5042948573,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,290,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Oxford Biomedica PLC,4295895244,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,290,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Accelerate Diagnostics Inc,5038034917,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,290,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Oxford Biomedica PLC,4295895244,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Pharmaron Beijing Co Ltd,5042948573,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,290,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Oxford Biomedica PLC,4295895244,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,290,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Oxford Biomedica PLC,4295895244,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,290,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Huadong Medicine Co Ltd,4295864428,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Huadong Medicine Co Ltd,4295864428,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,290,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Huadong Medicine Co Ltd,4295864428,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Pharmaron Beijing Co Ltd,5042948573,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.64,290,S_risk,Biotechnology & Pharmaceuticals,2022,0.256,0.494696241836107,Drug_Safety
Huadong Medicine Co Ltd,4295864428,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Huadong Medicine Co Ltd,4295864428,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,290,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Moderna Inc,5066596648,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,289,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Moderna Inc,5066596648,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,289,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Moderna Inc,5066596648,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,289,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Coherus BioSciences Inc,5037455589,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,289,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Moderna Inc,5066596648,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,289,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ironwood Pharmaceuticals Inc,4295940206,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,289,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Moderna Inc,5066596648,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,289,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ironwood Pharmaceuticals Inc,4295940206,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,289,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Moderna Inc,5066596648,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.15,289,S_risk,Biotechnology & Pharmaceuticals,2023,0.4599999999999999,0.7654678421395714,Drug_Safety
Coherus BioSciences Inc,5037455589,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,289,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
SIGA Technologies Inc,4295914936,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,288,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Natural Grocers By Vitamin Cottage Inc,5037624117,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,288,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pharma Mar SA,5000066579,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,288,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pharma Mar SA,5000066579,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.82,288,S_risk,Biotechnology & Pharmaceuticals,2019,0.728,1.0367368849500225,Drug_Safety
Pharma Mar SA,5000066579,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,288,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Pharma Mar SA,5000066579,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,288,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pharma Mar SA,5000066579,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,288,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Natural Grocers By Vitamin Cottage Inc,5037624117,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,288,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pharma Mar SA,5000066579,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.64,288,S_risk,Biotechnology & Pharmaceuticals,2018,0.6559999999999999,0.9707789171582248,Drug_Safety
SIGA Technologies Inc,4295914936,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,288,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Pharma Mar SA,5000066579,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,288,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Krka dd Novo Mesto,4295888307,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,286,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,286,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Krka dd Novo Mesto,4295888307,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,286,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,286,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Krka dd Novo Mesto,4295888307,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,286,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Krka dd Novo Mesto,4295888307,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,286,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,286,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Krka dd Novo Mesto,4295888307,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,286,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,286,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Jiangsu Hengrui Pharmaceuticals Co Ltd,4295864294,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,286,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Lineage Cell Therapeutics Inc,4295903583,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Travere Therapeutics Inc,4296438961,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Travere Therapeutics Inc,4296438961,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Catalyst Pharmaceuticals Inc,4295902234,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
PTC Therapeutics Inc,4296025423,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
PTC Therapeutics Inc,4296025423,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
PTC Therapeutics Inc,4296025423,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Travere Therapeutics Inc,4296438961,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Arvinas Inc,5046736907,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Catalyst Pharmaceuticals Inc,4295902234,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Arvinas Inc,5046736907,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Catalyst Pharmaceuticals Inc,4295902234,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Arvinas Inc,5046736907,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
PTC Therapeutics Inc,4296025423,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,285,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Jazz Pharmaceuticals PLC,4297329846,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,284,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Jazz Pharmaceuticals PLC,4297329846,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,284,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Jazz Pharmaceuticals PLC,4297329846,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,284,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,283,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
VBI Vaccines Inc,4295861984,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Vifor Pharma AG,4295890653,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,283,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
VBI Vaccines Inc,4295861984,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Harrow Health Inc,4295902339,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.98,283,S_risk,Biotechnology & Pharmaceuticals,2021,0.792,1.091923300517313,Workforce_Development
Mitsubishi Tanabe Pharma Corp,4295878022,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,283,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,283,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
VBI Vaccines Inc,4295861984,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Vaxart Inc,4295907233,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Mitsubishi Tanabe Pharma Corp,4295878022,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,283,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.12,283,S_risk,Biotechnology & Pharmaceuticals,2021,0.048,0.1133286853070031,Drug_Safety
Vifor Pharma AG,4295890653,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,283,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.78,283,S_risk,Biotechnology & Pharmaceuticals,2022,0.712,1.0224509277025458,Workforce_Development
Vifor Pharma AG,4295890653,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Vifor Pharma AG,4295890653,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,283,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vifor Pharma AG,4295890653,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,283,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.11,283,S_risk,Biotechnology & Pharmaceuticals,2022,0.044,0.1043600153242427,Drug_Safety
Vaxart Inc,4295907233,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Almirall SA,4295889280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2018,0.4,0.6931471805599453,Business_Ethics
Almirall SA,4295889280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Almirall SA,4295889280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
VBI Vaccines Inc,4295861984,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Mitsubishi Tanabe Pharma Corp,4295878022,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,283,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Mitsubishi Tanabe Pharma Corp,4295878022,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.79,283,S_risk,Biotechnology & Pharmaceuticals,2019,0.716,1.0260415958332745,Workforce_Development
WAVE Life Sciences Ltd,5041069029,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,282,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Cara Therapeutics Inc,4297277386,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,282,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Cara Therapeutics Inc,4297277386,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,282,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Cara Therapeutics Inc,4297277386,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,282,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Cara Therapeutics Inc,4297277386,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,282,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
WAVE Life Sciences Ltd,5041069029,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,282,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
XOMA Corp,5037133783,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,281,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
XOMA Corp,5037133783,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,281,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,280,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,280,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,280,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hubei Jumpcan Pharmaceutical Co Ltd,4295864718,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,280,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Proto Labs Inc,4298059665,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Genomma Lab Internacional SAB de CV,4298025343,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Puma Biotechnology Inc,4297723879,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
OptiNose Inc,5043339171,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Otsuka Holdings Co Ltd,5000073379,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Puma Biotechnology Inc,4297723879,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Boiron SA,4295867491,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,279,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,279,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,279,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,279,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Proto Labs Inc,4298059665,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Boiron SA,4295867491,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,279,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,279,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Otsuka Holdings Co Ltd,5000073379,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,279,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,279,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Puma Biotechnology Inc,4297723879,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Otsuka Holdings Co Ltd,5000073379,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Genomma Lab Internacional SAB de CV,4298025343,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.34,279,S_risk,Biotechnology & Pharmaceuticals,2021,0.136,0.29266961396282,Drug_Safety
Genomma Lab Internacional SAB de CV,4298025343,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Puma Biotechnology Inc,4297723879,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
OptiNose Inc,5043339171,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,279,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Alliance Pharma PLC,4295896230,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Biotest AG,4295868772,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Retail Opportunity Investments Corp,4295912075,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,278,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Alliance Pharma PLC,4295896230,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
MeiraGTx Holdings PLC,5063761745,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
MeiraGTx Holdings PLC,5063761745,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Retail Opportunity Investments Corp,4295912075,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Arbutus Biopharma Corp,5063095367,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Arbutus Biopharma Corp,5063095367,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Revance Therapeutics Inc,4296286413,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Biotest AG,4295868772,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Alliance Pharma PLC,4295896230,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Biotest AG,4295868772,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Arbutus Biopharma Corp,5063095367,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
MeiraGTx Holdings PLC,5063761745,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Biotest AG,4295868772,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alliance Pharma PLC,4295896230,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,1.3,278,S_risk,Biotechnology & Pharmaceuticals,2019,0.52,0.832909122935104,Workforce_Development
Biotest AG,4295868772,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Arbutus Biopharma Corp,5063095367,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
MeiraGTx Holdings PLC,5063761745,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
MeiraGTx Holdings PLC,5063761745,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Revance Therapeutics Inc,4296286413,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Revance Therapeutics Inc,4296286413,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,278,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Taisho Pharmaceutical Holdings Co Ltd,5035303233,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,277,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Taisho Pharmaceutical Holdings Co Ltd,5035303233,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,277,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Twist Bioscience Corp,5040185976,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,277,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Twist Bioscience Corp,5040185976,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,277,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Twist Bioscience Corp,5040185976,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,277,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Royalty Pharma PLC,5031889023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,276,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Royalty Pharma PLC,5031889023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,276,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Royalty Pharma PLC,5031889023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,276,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,274,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,274,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Alembic Pharmaceuticals Ltd,5035899285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Organogenesis Holdings Inc,5067949286,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Organogenesis Holdings Inc,5067949286,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Alembic Pharmaceuticals Ltd,5035899285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Shenzhen Kangtai Biological Products Co Ltd,5036199903,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.01,274,S_risk,Biotechnology & Pharmaceuticals,2024,0.004,0.009950330853168,Drug_Safety
Shenzhen Kangtai Biological Products Co Ltd,5036199903,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,274,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Revolution Medicines Inc,5044506598,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,274,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,274,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Revolution Medicines Inc,5044506598,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,274,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Drug_Safety
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.07,274,S_risk,Biotechnology & Pharmaceuticals,2023,0.028,0.0676586484738148,Drug_Safety
Revolution Medicines Inc,5044506598,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,274,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alembic Pharmaceuticals Ltd,5035899285,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,274,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Shenzhen Kangtai Biological Products Co Ltd,5036199903,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,274,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Camurus AB,5035523580,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,273,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,273,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,273,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Intra-Cellular Therapies Inc,5038989170,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,273,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
EyePoint Pharmaceuticals Inc,4295857066,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,273,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Camurus AB,5035523580,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,273,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,273,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Intra-Cellular Therapies Inc,5038989170,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,273,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
EyePoint Pharmaceuticals Inc,4295857066,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,273,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Camurus AB,5035523580,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,273,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Camurus AB,5035523580,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,273,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
EyePoint Pharmaceuticals Inc,4295857066,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,273,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Camurus AB,5035523580,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,273,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Probi AB,4295890448,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Core Laboratories NV,4295884861,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Indivior PLC,5044066242,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Core Laboratories NV,4295884861,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.55,272,S_risk,Biotechnology & Pharmaceuticals,2022,0.62,0.9360933591703348,Drug_Safety
Core Laboratories NV,4295884861,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Probi AB,4295890448,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Core Laboratories NV,4295884861,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.4,272,S_risk,Biotechnology & Pharmaceuticals,2021,0.96,1.2237754316221157,Drug_Safety
Indivior PLC,5044066242,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Core Laboratories NV,4295884861,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2016,0.0,0.0,Drug_Safety
Core Laboratories NV,4295884861,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Core Laboratories NV,4295884861,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Core Laboratories NV,4295884861,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Core Laboratories NV,4295884861,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Probi AB,4295890448,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Probi AB,4295890448,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Core Laboratories NV,4295884861,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.25,272,S_risk,Biotechnology & Pharmaceuticals,2018,0.9,1.1786549963416462,Drug_Safety
Core Laboratories NV,4295884861,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Core Laboratories NV,4295884861,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.05,272,S_risk,Biotechnology & Pharmaceuticals,2019,0.42,0.7178397931503169,Drug_Safety
Core Laboratories NV,4295884861,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Probi AB,4295890448,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,272,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Core Laboratories NV,4295884861,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.28,272,S_risk,Biotechnology & Pharmaceuticals,2020,0.112,0.2468600779315258,Drug_Safety
Indivior PLC,5044066242,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Indivior PLC,5044066242,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,272,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
United Laboratories International Holdings Ltd,4295870909,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,271,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,271,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,271,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
United Laboratories International Holdings Ltd,4295870909,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Meridian Bioscience Inc,4295907136,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,271,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
United Laboratories International Holdings Ltd,4295870909,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,271,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Deciphera Pharmaceuticals Inc,5057832486,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,271,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
United Laboratories International Holdings Ltd,4295870909,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Drug_Safety
Vir Biotechnology Inc,5052795509,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Deciphera Pharmaceuticals Inc,5057832486,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Vir Biotechnology Inc,5052795509,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Vir Biotechnology Inc,5052795509,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,271,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Horizon Therapeutics PLC,5037276891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,270,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Horizon Therapeutics PLC,5037276891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,270,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,270,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Lifecore Biomedical Inc,4295906967,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,270,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Axsome Therapeutics Inc,5039864624,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,270,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,270,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Lifecore Biomedical Inc,4295906967,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,270,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Axsome Therapeutics Inc,5039864624,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,270,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shijiazhuang Yiling Pharmaceutical Co Ltd,5000577580,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,270,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Horizon Therapeutics PLC,5037276891,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,270,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,269,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aquestive Therapeutics Inc,5031994451,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,269,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,269,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,269,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,269,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Harvard Bioscience Inc,4295902196,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,269,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,269,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aquestive Therapeutics Inc,5031994451,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,269,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,269,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Harvard Bioscience Inc,4295902196,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,269,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shenzhen Hepalink Pharmaceutical Group Co Ltd,5000712764,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,269,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Acrux Ltd,4295858548,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,268,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
TG Therapeutics Inc,4295912581,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,267,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Marker Therapeutics Inc,5066581785,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,267,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Celltrion Inc,5000076514,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,267,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Celltrion Inc,5000076514,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.69,267,S_risk,Biotechnology & Pharmaceuticals,2022,0.2759999999999999,0.5247285289349821,Drug_Safety
TG Therapeutics Inc,4295912581,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,267,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Celltrion Inc,5000076514,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,267,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Marker Therapeutics Inc,5066581785,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,267,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Celltrion Inc,5000076514,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,267,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Celltrion Inc,5000076514,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,267,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Celltrion Inc,5000076514,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.03,267,S_risk,Biotechnology & Pharmaceuticals,2023,0.412,0.708035793053696,Drug_Safety
Marker Therapeutics Inc,5066581785,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,267,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Celltrion Inc,5000076514,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,267,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Mallinckrodt PLC,5038068684,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Endo International PLC,5040791002,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.0,266,S_risk,Biotechnology & Pharmaceuticals,2022,0.8,1.0986122886681098,Drug_Safety
Endo International PLC,5040791002,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Polynovo Ltd,4295857937,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,266,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Mallinckrodt PLC,5038068684,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,266,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,266,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Polynovo Ltd,4295857937,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,266,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Zhangzhou Pientzehuang Pharmaceutical Co Ltd,4295864697,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,266,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Endo International PLC,5040791002,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Polynovo Ltd,4295857937,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Protagonist Therapeutics Inc,5037933405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Protagonist Therapeutics Inc,5037933405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Protagonist Therapeutics Inc,5037933405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Polynovo Ltd,4295857937,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Mallinckrodt PLC,5038068684,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Polynovo Ltd,4295857937,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,266,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
G1 Therapeutics Inc,5035526162,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,266,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Zai Lab Ltd,5057819640,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
STADA Arzneimittel AG,4295869543,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.2,265,S_risk,Biotechnology & Pharmaceuticals,2021,0.8800000000000001,1.1631508098056809,Drug_Safety
Alaunos Therapeutics Inc,4295902600,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Benchmark Holdings PLC,5003638730,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
STADA Arzneimittel AG,4295869543,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Benchmark Holdings PLC,5003638730,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.13,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.052,0.1222176327242492,Drug_Safety
Alaunos Therapeutics Inc,4295902600,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,265,S_risk,Biotechnology & Pharmaceuticals,2020,0.52,0.832909122935104,Drug_Safety
Zai Lab Ltd,5057819640,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
STADA Arzneimittel AG,4295869543,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.75,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.7,1.01160091167848,Drug_Safety
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.6,265,S_risk,Biotechnology & Pharmaceuticals,2021,0.64,0.9555114450274363,Drug_Safety
Benchmark Holdings PLC,5003638730,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Ibio Inc,4298054794,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.1,265,S_risk,Biotechnology & Pharmaceuticals,2018,0.8400000000000001,1.1314021114911006,Drug_Safety
Zai Lab Ltd,5057819640,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Zai Lab Ltd,5057819640,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Zai Lab Ltd,5057819640,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Zai Lab Ltd,5057819640,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.56,265,S_risk,Biotechnology & Pharmaceuticals,2023,0.224,0.4446858212614457,Drug_Safety
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.1,265,S_risk,Biotechnology & Pharmaceuticals,2019,0.8400000000000001,1.1314021114911006,Drug_Safety
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Alaunos Therapeutics Inc,4295902600,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
STADA Arzneimittel AG,4295869543,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
STADA Arzneimittel AG,4295869543,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
STADA Arzneimittel AG,4295869543,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
STADA Arzneimittel AG,4295869543,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Alaunos Therapeutics Inc,4295902600,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Zai Lab Ltd,5057819640,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Zai Lab Ltd,5057819640,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Benchmark Holdings PLC,5003638730,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Zai Lab Ltd,5057819640,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,265,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
GlaxoSmithKline Pharmaceuticals Ltd,4295872267,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Benchmark Holdings PLC,5003638730,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,265,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Redcare Pharmacy NV,5052123270,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Oneness Biotech Co Ltd,5000031535,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Redcare Pharmacy NV,5052123270,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Chongqing Zhifei Biological Products Co Ltd,5001143439,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hansa Biopharma AB,4298014997,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Oneness Biotech Co Ltd,5000031535,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Redcare Pharmacy NV,5052123270,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Oneness Biotech Co Ltd,5000031535,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Chongqing Zhifei Biological Products Co Ltd,5001143439,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Voyager Therapeutics Inc,5041076755,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Voyager Therapeutics Inc,5041076755,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hansa Biopharma AB,4298014997,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Voyager Therapeutics Inc,5041076755,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Chongqing Zhifei Biological Products Co Ltd,5001143439,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Oneness Biotech Co Ltd,5000031535,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hansa Biopharma AB,4298014997,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,264,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Hansa Biopharma AB,4298014997,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Chongqing Zhifei Biological Products Co Ltd,5001143439,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,264,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.92,263,S_risk,Biotechnology & Pharmaceuticals,2021,0.368,0.6523251860396903,Drug_Safety
Hapag Lloyd AG,4295869164,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Syneos Health Inc,5040258481,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Midsona AB,4295890221,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Midsona AB,4295890221,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Syneos Health Inc,5040258481,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,263,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Syneos Health Inc,5040258481,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.54,263,S_risk,Biotechnology & Pharmaceuticals,2023,0.216,0.4317824164255378,Drug_Safety
Midsona AB,4295890221,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,263,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,263,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Reata Pharmaceuticals Inc,5000090491,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,263,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Midsona AB,4295890221,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.19,263,S_risk,Biotechnology & Pharmaceuticals,2017,0.876,1.1600209167967532,Drug_Safety
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,263,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,263,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Syneos Health Inc,5040258481,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hapag Lloyd AG,4295869164,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,2.0,263,S_risk,Biotechnology & Pharmaceuticals,2019,0.8,1.0986122886681098,Drug_Safety
Pieris Pharmaceuticals Inc,5040241774,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pieris Pharmaceuticals Inc,5040241774,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pieris Pharmaceuticals Inc,5040241774,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Midsona AB,4295890221,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Hapag Lloyd AG,4295869164,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,263,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Celltrion Pharm Inc,4295882372,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,263,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Faes Farma SA,4295889471,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,262,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
AcelRx Pharmaceuticals Inc,4297543075,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,262,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Cellectis SA,4295868150,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,262,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Faes Farma SA,4295889471,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,262,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Cellectis SA,4295868150,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,262,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Cellectis SA,4295868150,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,262,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cellectis SA,4295868150,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,262,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Faes Farma SA,4295889471,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,262,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Karyopharm Therapeutics Inc,5001437822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,261,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
SSY Group Ltd,4295865393,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,261,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
SSY Group Ltd,4295865393,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,261,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Karyopharm Therapeutics Inc,5001437822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,261,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
SSY Group Ltd,4295865393,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,261,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
SSY Group Ltd,4295865393,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,261,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
SSY Group Ltd,4295865393,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,261,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
SSY Group Ltd,4295865393,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,261,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
SSY Group Ltd,4295865393,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,261,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Karyopharm Therapeutics Inc,5001437822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,261,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Karyopharm Therapeutics Inc,5001437822,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,261,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Syros Pharmaceuticals Inc,5037818300,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,260,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Syros Pharmaceuticals Inc,5037818300,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,260,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Syros Pharmaceuticals Inc,5037818300,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,260,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ascendis Pharma A/S,4297931709,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,260,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ascendis Pharma A/S,4297931709,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,260,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ascendis Pharma A/S,4297931709,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,260,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ascendis Pharma A/S,4297931709,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,260,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.23,259,S_risk,Biotechnology & Pharmaceuticals,2023,0.092,0.2070141693843261,Drug_Safety
Cosmo Pharmaceuticals NV,5051001094,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,259,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Laurus Labs Ltd,4298499557,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,259,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,259,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Cosmo Pharmaceuticals NV,5051001094,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,259,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,259,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,259,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cosmo Pharmaceuticals NV,5051001094,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,259,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,259,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Cosmo Pharmaceuticals NV,5051001094,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,259,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Laurus Labs Ltd,4298499557,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,259,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,259,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Laurus Labs Ltd,4298499557,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,259,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
NGM Biopharmaceuticals Inc,4297800748,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Castle Biosciences Inc,5000451463,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Aurinia Pharmaceuticals Inc,5000451880,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.58,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.632,0.947789398933526,Drug_Safety
Evolus Inc,5038792215,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.36,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.144,0.3074846997479606,Drug_Safety
Urogen Pharma Ltd,5035535486,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Urogen Pharma Ltd,5035535486,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aurinia Pharmaceuticals Inc,5000451880,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
NGM Biopharmaceuticals Inc,4297800748,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Evolus Inc,5038792215,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Castle Biosciences Inc,5000451463,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Castle Biosciences Inc,5000451463,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
CanSino Biologics Inc,5037456309,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Urogen Pharma Ltd,5035535486,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.64,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.256,0.494696241836107,Drug_Safety
Urogen Pharma Ltd,5035535486,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.44,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.176,0.3646431135879092,Drug_Safety
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
CanSino Biologics Inc,5037456309,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Consun Pharmaceutical Group Ltd,5040759700,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
CorMedix Inc,5000592140,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CanSino Biologics Inc,5037456309,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Castle Biosciences Inc,5000451463,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Aurinia Pharmaceuticals Inc,5000451880,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Castle Biosciences Inc,5000451463,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Urogen Pharma Ltd,5035535486,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.14,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.4559999999999999,0.76080582903376,Drug_Safety
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.33,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.132,0.2851789422336624,Drug_Safety
Aurinia Pharmaceuticals Inc,5000451880,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Aurinia Pharmaceuticals Inc,5000451880,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Consun Pharmaceutical Group Ltd,5040759700,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Consun Pharmaceutical Group Ltd,5040759700,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
CanSino Biologics Inc,5037456309,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,258,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
NGM Biopharmaceuticals Inc,4297800748,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
vTv Therapeutics Inc,5046056658,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Aurinia Pharmaceuticals Inc,5000451880,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,258,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
BioNTech SE,5071170280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
BioNTech SE,5071170280,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,257,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Vetoquinol SA,4298441722,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Vetoquinol SA,4298441722,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,257,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Vetoquinol SA,4298441722,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
BioNTech SE,5071170280,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.66,257,S_risk,Biotechnology & Pharmaceuticals,2021,0.264,0.5068176023684519,Drug_Safety
Arrowhead Pharmaceuticals Inc,4295913831,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Curis Inc,4295906080,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Curis Inc,4295906080,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Vetoquinol SA,4298441722,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.3,257,S_risk,Biotechnology & Pharmaceuticals,2023,0.52,0.832909122935104,Drug_Safety
BioNTech SE,5071170280,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,257,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
BioNTech SE,5071170280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
BioNTech SE,5071170280,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,257,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Arrowhead Pharmaceuticals Inc,4295913831,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,257,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
BioNTech SE,5071170280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Arrowhead Pharmaceuticals Inc,4295913831,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Vetoquinol SA,4298441722,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
BioNTech SE,5071170280,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,257,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Madrigal Pharmaceuticals Inc,4295899733,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,256,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Valneva SE,4297009143,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,256,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Valneva SE,4297009143,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.34,256,S_risk,Biotechnology & Pharmaceuticals,2019,0.936,1.205970806988609,Drug_Safety
Valneva SE,4297009143,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,256,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Valneva SE,4297009143,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,256,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Valneva SE,4297009143,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.86,256,S_risk,Biotechnology & Pharmaceuticals,2022,0.344,0.6205764877251099,Drug_Safety
Valneva SE,4297009143,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.49,256,S_risk,Biotechnology & Pharmaceuticals,2021,0.996,1.249901736214336,Drug_Safety
Valneva SE,4297009143,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.09,256,S_risk,Biotechnology & Pharmaceuticals,2020,0.436,0.7371640659767197,Drug_Safety
ECO Animal Health Group PLC,4295895203,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,256,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ECO Animal Health Group PLC,4295895203,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,256,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Harmony Biosciences Holdings Inc,5076167827,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,255,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Harmony Biosciences Holdings Inc,5076167827,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,255,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Idorsia Ltd,5056400072,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,255,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sutro Biopharma Inc,5017515126,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,255,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Harmony Biosciences Holdings Inc,5076167827,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,255,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Harmony Biosciences Holdings Inc,5076167827,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,255,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Harmony Biosciences Holdings Inc,5076167827,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,255,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Idorsia Ltd,5056400072,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,255,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Zentiva SA,4296393146,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,254,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Alector Inc,5066605183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,254,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alector Inc,5066605183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,254,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Medigene AG,4295869325,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,254,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Zentiva SA,4296393146,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,254,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Zentiva SA,4296393146,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.2,254,S_risk,Biotechnology & Pharmaceuticals,2023,0.08,0.1823215567939546,Drug_Safety
Zentiva SA,4296393146,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.31,254,S_risk,Biotechnology & Pharmaceuticals,2022,0.124,0.2700271372130601,Drug_Safety
Medigene AG,4295869325,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,254,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Alector Inc,5066605183,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,254,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Lotus Pharmaceutical Co Ltd,4295892568,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Lotus Pharmaceutical Co Ltd,4295892568,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Fortress Biotech Inc,5035420209,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,253,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Lotus Pharmaceutical Co Ltd,4295892568,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Mersana Therapeutics Inc,4298068040,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Mersana Therapeutics Inc,4298068040,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Atara Biotherapeutics Inc,5037937603,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Scandi Standard AB (publ),5040249601,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Inotiv Inc,4295905723,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Scandi Standard AB (publ),5040249601,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,253,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Inotiv Inc,4295905723,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Scandi Standard AB (publ),5040249601,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Scandi Standard AB (publ),5040249601,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Scandi Standard AB (publ),5040249601,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,253,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Atara Biotherapeutics Inc,5037937603,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Scandi Standard AB (publ),5040249601,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Mersana Therapeutics Inc,4298068040,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,253,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Mithra Pharmaceuticals SA,5000960352,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
AddLife AB,5050647517,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
CytomX Therapeutics Inc,5040944268,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Albioma SAS,4295866947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Albioma SAS,4295866947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Mithra Pharmaceuticals SA,5000960352,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
CytomX Therapeutics Inc,5040944268,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Addex Therapeutics Ltd,4295890551,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Addex Therapeutics Ltd,4295890551,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
AddLife AB,5050647517,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Albioma SAS,4295866947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AddLife AB,5050647517,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
AddLife AB,5050647517,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.47,252,S_risk,Biotechnology & Pharmaceuticals,2022,0.588,0.904218150639886,Drug_Safety
Albioma SAS,4295866947,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Mithra Pharmaceuticals SA,5000960352,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Albioma SAS,4295866947,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,252,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Drug_Safety
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Industri Jamu dan Farmasi Sido Muncul Tbk PT,5039926501,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,252,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Walvax Biotechnology Co Ltd,5001170754,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,251,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Pharming Group NV,4295884868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Molecular Templates Inc,4295908364,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Walvax Biotechnology Co Ltd,5001170754,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,251,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Pharming Group NV,4295884868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Walvax Biotechnology Co Ltd,5001170754,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Adaptive Biotechnologies Corp,5000627106,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CEL-SCI Corp,4295903677,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pharming Group NV,4295884868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Adaptive Biotechnologies Corp,5000627106,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CEL-SCI Corp,4295903677,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Pharming Group NV,4295884868,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,251,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CEL-SCI Corp,4295903677,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Pharming Group NV,4295884868,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Adaptive Biotechnologies Corp,5000627106,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Walvax Biotechnology Co Ltd,5001170754,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,251,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Molecular Templates Inc,4295908364,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Adaptive Biotechnologies Corp,5000627106,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,251,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Beam Therapeutics Inc,5063164263,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Sanofi India Ltd,4295872276,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,250,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Cue Biopharma Inc,5046434620,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sanofi India Ltd,4295872276,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Beam Therapeutics Inc,5063164263,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cue Biopharma Inc,5046434620,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Beam Therapeutics Inc,5063164263,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sanofi India Ltd,4295872276,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Arcturus Therapeutics Holdings Inc,5068339275,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sanofi India Ltd,4295872276,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,250,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Sanofi India Ltd,4295872276,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.03,250,S_risk,Biotechnology & Pharmaceuticals,2022,0.8119999999999999,1.1085626195212777,Drug_Safety
Cue Biopharma Inc,5046434620,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sanofi India Ltd,4295872276,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.66,250,S_risk,Biotechnology & Pharmaceuticals,2021,0.264,0.5068176023684519,Drug_Safety
Beam Therapeutics Inc,5063164263,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,250,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Lexicon Pharmaceuticals Inc,4295914055,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Kala Pharmaceuticals Inc,5000621507,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kala Pharmaceuticals Inc,5000621507,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Crinetics Pharmaceuticals Inc,5037611560,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Kala Pharmaceuticals Inc,5000621507,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Crinetics Pharmaceuticals Inc,5037611560,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Orexo AB,4295890191,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Orexo AB,4295890191,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Orexo AB,4295890191,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Lexicon Pharmaceuticals Inc,4295914055,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Orexo AB,4295890191,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,249,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Precision BioSciences Inc,5035539845,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,248,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cardiff Oncology Inc,4296438979,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,248,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cardiff Oncology Inc,4296438979,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,248,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Kaken Pharmaceutical Co Ltd,4295878524,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,248,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kaken Pharmaceutical Co Ltd,4295878524,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,248,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Precision BioSciences Inc,5035539845,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,248,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Kaken Pharmaceutical Co Ltd,4295878524,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,248,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kaken Pharmaceutical Co Ltd,4295878524,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.06,248,S_risk,Biotechnology & Pharmaceuticals,2021,0.424,0.7227059828014898,Drug_Safety
Kaken Pharmaceutical Co Ltd,4295878524,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.02,248,S_risk,Biotechnology & Pharmaceuticals,2018,0.008,0.0198026272961797,Drug_Safety
Kaken Pharmaceutical Co Ltd,4295878524,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.91,248,S_risk,Biotechnology & Pharmaceuticals,2023,0.764,1.068153081183401,Drug_Safety
Kaken Pharmaceutical Co Ltd,4295878524,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.43,248,S_risk,Biotechnology & Pharmaceuticals,2019,0.172,0.3576744442718159,Drug_Safety
MaxCyte Inc,4297024126,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Personalis Inc,5037652668,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Scholar Rock Holding Corp,5060509019,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Esperion Therapeutics Inc,4295900449,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
MaxCyte Inc,4297024126,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Assembly Biosciences Inc,5001158603,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Personalis Inc,5037652668,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Personalis Inc,5037652668,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Scholar Rock Holding Corp,5060509019,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Intercept Pharmaceuticals Inc,4296966741,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Scholar Rock Holding Corp,5060509019,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
MaxCyte Inc,4297024126,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.4,246,S_risk,Biotechnology & Pharmaceuticals,2020,0.5599999999999999,0.8754687373538999,Drug_Safety
CK Life Sciences Intl (Holdings) Inc,5000036103,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
CK Life Sciences Intl (Holdings) Inc,5000036103,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
MEI Pharma Inc,4295899598,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Piramal Enterprises Ltd,4295872692,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Syndax Pharmaceuticals Inc,4297793633,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
CK Life Sciences Intl (Holdings) Inc,5000036103,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Kiniksa Pharmaceuticals Ltd,5063731859,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kiniksa Pharmaceuticals Ltd,5063731859,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
CK Life Sciences Intl (Holdings) Inc,5000036103,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Viridian Therapeutics Inc,5034847971,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Syndax Pharmaceuticals Inc,4297793633,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.3,246,S_risk,Biotechnology & Pharmaceuticals,2018,0.12,0.262364264467491,Drug_Safety
MEI Pharma Inc,4295899598,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Morphic Holding Inc,5066537246,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.25,246,S_risk,Biotechnology & Pharmaceuticals,2019,0.1,0.2231435513142097,Drug_Safety
Piramal Enterprises Ltd,4295872692,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.28,246,S_risk,Biotechnology & Pharmaceuticals,2021,0.112,0.2468600779315258,Drug_Safety
CK Life Sciences Intl (Holdings) Inc,5000036103,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
CK Life Sciences Intl (Holdings) Inc,5000036103,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
CK Life Sciences Intl (Holdings) Inc,5000036103,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,246,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CK Life Sciences Intl (Holdings) Inc,5000036103,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,246,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Kura Oncology Inc,5044341506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hemas Holdings PLC,4295889739,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Clinuvel Pharmaceuticals Ltd,4295856451,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
BioArctic AB,5035561399,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Oxurion NV,4295859470,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hemas Holdings PLC,4295889739,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Oxurion NV,4295859470,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
BioArctic AB,5035561399,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CRISPR Therapeutics AG,5042268704,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hemas Holdings PLC,4295889739,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
BioArctic AB,5035561399,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
BioArctic AB,5035561399,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hemas Holdings PLC,4295889739,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
CRISPR Therapeutics AG,5042268704,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
BioArctic AB,5035561399,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Oxurion NV,4295859470,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
BioArctic AB,5035561399,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Hemas Holdings PLC,4295889739,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Kura Oncology Inc,5044341506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
CRISPR Therapeutics AG,5042268704,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Oxurion NV,4295859470,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hemas Holdings PLC,4295889739,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.5,245,S_risk,Biotechnology & Pharmaceuticals,2023,1.0,1.252762968495368,Drug_Safety
Hemas Holdings PLC,4295889739,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kura Oncology Inc,5044341506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Hemas Holdings PLC,4295889739,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
BioArctic AB,5035561399,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,245,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
BioArctic AB,5035561399,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,245,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Beijing Tiantan Biological Products Corp Ltd,4295865264,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,244,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Beijing Tiantan Biological Products Corp Ltd,4295865264,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,244,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Cyclerion Therapeutics Inc,5067843831,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,244,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Beijing Tiantan Biological Products Corp Ltd,4295865264,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,244,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Betta Pharmaceuticals Co Ltd,5000768225,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,244,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cyclerion Therapeutics Inc,5067843831,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,244,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Cyclerion Therapeutics Inc,5067843831,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,244,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Exagen Inc,4296127863,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
OBI Pharma Inc,5000693472,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ajanta Pharma Ltd,4295874157,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
OBI Pharma Inc,5000693472,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Y-mAbs Therapeutics Inc,5051611538,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
OBI Pharma Inc,5000693472,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Kalvista Pharmaceuticals Inc,4297340254,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Exagen Inc,4296127863,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ajanta Pharma Ltd,4295874157,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Orgenesis Inc,4298422934,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Kalvista Pharmaceuticals Inc,4297340254,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
OBI Pharma Inc,5000693472,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
OBI Pharma Inc,5000693472,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Exagen Inc,4296127863,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
OBI Pharma Inc,5000693472,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Orgenesis Inc,4298422934,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Y-mAbs Therapeutics Inc,5051611538,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
OBI Pharma Inc,5000693472,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Y-mAbs Therapeutics Inc,5051611538,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ajanta Pharma Ltd,4295874157,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.02,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.008,0.0198026272961797,Drug_Safety
OBI Pharma Inc,5000693472,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
OBI Pharma Inc,5000693472,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ajanta Pharma Ltd,4295874157,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,243,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ajanta Pharma Ltd,4295874157,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,243,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Sorrento Therapeutics Inc,4296491271,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,242,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
TTY Biopharm Co Ltd,4295891167,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Inhibrx Inc,5063750249,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sorrento Therapeutics Inc,4296491271,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.8,242,S_risk,Biotechnology & Pharmaceuticals,2018,0.72,1.0296194171811583,Drug_Safety
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,242,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
TTY Biopharm Co Ltd,4295891167,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,242,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Inhibrx Inc,5063750249,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Corbus Pharmaceuticals Holdings Inc,5040943458,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.75,242,S_risk,Biotechnology & Pharmaceuticals,2021,0.7,1.01160091167848,Drug_Safety
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,242,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
TTY Biopharm Co Ltd,4295891167,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sorrento Therapeutics Inc,4296491271,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,242,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,242,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,242,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Corbus Pharmaceuticals Holdings Inc,5040943458,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,242,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
TTY Biopharm Co Ltd,4295891167,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.7,242,S_risk,Biotechnology & Pharmaceuticals,2020,0.6799999999999999,0.9932517730102832,Drug_Safety
Taro Pharmaceutical Industries Ltd,4295875212,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Taro Pharmaceutical Industries Ltd,4295875212,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Essex Bio-Technology Ltd,4295871189,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.38,241,S_risk,Biotechnology & Pharmaceuticals,2022,0.952,1.2178757094949273,Drug_Safety
Essex Bio-Technology Ltd,4295871189,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
RVL Pharmaceuticals PLC,5065379339,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Essex Bio-Technology Ltd,4295871189,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,241,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
RVL Pharmaceuticals PLC,5065379339,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Essex Bio-Technology Ltd,4295871189,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Essex Bio-Technology Ltd,4295871189,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Essex Bio-Technology Ltd,4295871189,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,241,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
RVL Pharmaceuticals PLC,5065379339,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Essex Bio-Technology Ltd,4295871189,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,241,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Taro Pharmaceutical Industries Ltd,4295875212,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,241,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Abeona Therapeutics Inc,4295911990,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Oramed Pharmaceuticals Inc,5037660929,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,240,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Abeona Therapeutics Inc,4295911990,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Cidara Therapeutics Inc,5042263702,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Yunnan Baiyao Group Co Ltd,4295864051,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Yunnan Baiyao Group Co Ltd,4295864051,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,240,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
ADMA Biologics Inc,4297548856,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Yunnan Baiyao Group Co Ltd,4295864051,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,240,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Abeona Therapeutics Inc,4295911990,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
ADMA Biologics Inc,4297548856,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Abeona Therapeutics Inc,4295911990,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Oramed Pharmaceuticals Inc,5037660929,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,240,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Oramed Pharmaceuticals Inc,5037660929,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Yunnan Baiyao Group Co Ltd,4295864051,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,240,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Cidara Therapeutics Inc,5042263702,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,240,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Oramed Pharmaceuticals Inc,5037660929,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,240,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Assertio Holdings Inc,5073962717,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
BridgeBio Pharma Inc,5052793334,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Affimed NV,5043318185,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Apeloa Pharmaceutical Co Ltd,4295863743,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,239,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Affimed NV,5043318185,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Apeloa Pharmaceutical Co Ltd,4295863743,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,239,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Zhejiang Huahai Pharmaceutical Co Ltd,4295864835,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Jounce Therapeutics Inc,5038067073,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
BridgeBio Pharma Inc,5052793334,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
AB Science SA,5000727830,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,239,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Assertio Holdings Inc,5073962717,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Affimed NV,5043318185,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
BridgeBio Pharma Inc,5052793334,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Assertio Holdings Inc,5073962717,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,239,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Rhythm Pharmaceuticals Inc,5043464231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,238,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Dawnrays Pharmaceutical (Holdings) Ltd,4295870905,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,238,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Rhythm Pharmaceuticals Inc,5043464231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,238,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Clearside Biomedical Inc,5037247054,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,238,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Dawnrays Pharmaceutical (Holdings) Ltd,4295870905,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,238,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Rhythm Pharmaceuticals Inc,5043464231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,238,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dawnrays Pharmaceutical (Holdings) Ltd,4295870905,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,238,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Dawnrays Pharmaceutical (Holdings) Ltd,4295870905,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,238,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Dawnrays Pharmaceutical (Holdings) Ltd,4295870905,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,238,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Cogent Biosciences Inc,5043324118,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Viracta Therapeutics Inc,4295912556,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Cogent Biosciences Inc,5043324118,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Viracta Therapeutics Inc,4295912556,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Trulieve Cannabis Corp,4296507565,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Mayne Pharma Group Ltd,4295858866,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Trulieve Cannabis Corp,4296507565,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Trulieve Cannabis Corp,4296507565,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Mayne Pharma Group Ltd,4295858866,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Cogent Biosciences Inc,5043324118,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Viracta Therapeutics Inc,4295912556,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,237,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
HOOKIPA Pharma Inc,5067945220,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,236,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Mirati Therapeutics Inc,5039800567,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,236,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Mirati Therapeutics Inc,5039800567,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,236,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
HOOKIPA Pharma Inc,5067945220,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,236,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Krystal Biotech Inc,5057764486,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,236,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Krystal Biotech Inc,5057764486,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,236,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
HOOKIPA Pharma Inc,5067945220,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,236,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Iovance Biotherapeutics Inc,5056411750,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,235,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Pliant Therapeutics Inc,5046715672,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,235,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Iovance Biotherapeutics Inc,5056411750,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,235,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Iovance Biotherapeutics Inc,5056411750,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,235,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Pliant Therapeutics Inc,5046715672,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,235,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bionano Genomics Inc,4296225077,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,235,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bionano Genomics Inc,4296225077,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,235,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Iovance Biotherapeutics Inc,5056411750,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,235,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
bluebird bio Inc,5035523656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,234,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
bluebird bio Inc,5035523656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,234,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Paratek Pharmaceuticals Inc,4295902313,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,234,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
bluebird bio Inc,5035523656,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,234,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Paratek Pharmaceuticals Inc,4295902313,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,234,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Molecular Partners AG,4297804675,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,234,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Aptinyx Inc,5046706152,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,234,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Molecular Partners AG,4297804675,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,234,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Paratek Pharmaceuticals Inc,4295902313,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,234,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Aurora Cannabis Inc,4297776358,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Microbio Co Ltd,4295891098,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,233,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Microbio Co Ltd,4295891098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Microbio Co Ltd,4295891098,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Microbio Co Ltd,4295891098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Microbio Co Ltd,4295891098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Aeglea Bio Therapeutics Inc,5038915440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,233,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Aeglea Bio Therapeutics Inc,5038915440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,233,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Microbio Co Ltd,4295891098,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,233,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Microbio Co Ltd,4295891098,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.25,233,S_risk,Biotechnology & Pharmaceuticals,2022,0.9,1.1786549963416462,Drug_Safety
Microbio Co Ltd,4295891098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Microbio Co Ltd,4295891098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Natco Pharma Ltd,4295872173,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Aurora Cannabis Inc,4297776358,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,233,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Microbio Co Ltd,4295891098,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Microbio Co Ltd,4295891098,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,233,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Innate Pharma SA,4295866723,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,232,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Innate Pharma SA,4295866723,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,232,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
CStone Pharmaceuticals,5066609443,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,232,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
CStone Pharmaceuticals,5066609443,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,232,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
CStone Pharmaceuticals,5066609443,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,232,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
CStone Pharmaceuticals,5066609443,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,232,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Innate Pharma SA,4295866723,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,232,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
CStone Pharmaceuticals,5066609443,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,232,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
CStone Pharmaceuticals,5066609443,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,232,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CStone Pharmaceuticals,5066609443,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,232,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Immutep Ltd,4295857055,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,232,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
CStone Pharmaceuticals,5066609443,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,232,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Immutep Ltd,4295857055,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,232,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CStone Pharmaceuticals,5066609443,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,232,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Innate Pharma SA,4295866723,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,232,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cassava Sciences Inc,4295915956,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,231,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Acorda Therapeutics Inc,4295909042,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,231,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cassava Sciences Inc,4295915956,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,231,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Cassava Sciences Inc,4295915956,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,231,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Synlogic Inc,5000782315,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,231,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cassava Sciences Inc,4295915956,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,231,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Acorda Therapeutics Inc,4295909042,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,231,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Seegene Inc,5000846840,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,231,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Cassava Sciences Inc,4295915956,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,231,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Seegene Inc,5000846840,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,231,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Synlogic Inc,5000782315,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,231,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Alkem Laboratories Ltd,4297014373,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Joinn Laboratories China Co Ltd,5037992901,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Joinn Laboratories China Co Ltd,5037992901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Joinn Laboratories China Co Ltd,5037992901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.05,230,S_risk,Biotechnology & Pharmaceuticals,2023,0.02,0.048790164169432,Drug_Safety
Akero Therapeutics Inc,5064611248,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Joinn Laboratories China Co Ltd,5037992901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Joinn Laboratories China Co Ltd,5037992901,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Joinn Laboratories China Co Ltd,5037992901,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
C4 Therapeutics Inc,5048904801,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Champions Oncology Inc,4295912832,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Champions Oncology Inc,4295912832,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Alkem Laboratories Ltd,4297014373,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.02,230,S_risk,Biotechnology & Pharmaceuticals,2024,0.008,0.0198026272961797,Drug_Safety
Alkem Laboratories Ltd,4297014373,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Akero Therapeutics Inc,5064611248,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
YiChang HEC ChangJiang Pharmaceutical Co Ltd,4298151563,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,230,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Akero Therapeutics Inc,5064611248,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,230,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Solid Biosciences Inc,5040932912,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,229,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Solid Biosciences Inc,5040932912,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,229,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Solid Biosciences Inc,5040932912,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,229,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Solid Biosciences Inc,5040932912,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,229,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Homology Medicines Inc,5046317196,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,229,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Aravive Inc,4298508493,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,229,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Fulcrum Therapeutics Inc,5051602622,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Kymera Therapeutics Inc,5076089513,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Fulcrum Therapeutics Inc,5051602622,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Fulcrum Therapeutics Inc,5051602622,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Astrazeneca Pharma India Ltd,4295873481,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,228,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Astrazeneca Pharma India Ltd,4295873481,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Rocket Pharmaceuticals Inc,4297060461,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Astrazeneca Pharma India Ltd,4295873481,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Kymera Therapeutics Inc,5076089513,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Fulcrum Therapeutics Inc,5051602622,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,228,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Astrazeneca Pharma India Ltd,4295873481,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,228,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Harpoon Therapeutics Inc,5046317800,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
SAGE Therapeutics Inc,5036384269,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Selecta Biosciences Inc,4298128957,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Harpoon Therapeutics Inc,5046317800,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Harpoon Therapeutics Inc,5046317800,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
SAGE Therapeutics Inc,5036384269,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
SAGE Therapeutics Inc,5036384269,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Selecta Biosciences Inc,4298128957,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Harpoon Therapeutics Inc,5046317800,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,227,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Relay Therapeutics Inc,5051787387,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,226,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
UNITY Biotechnology Inc,5042242039,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.5,226,S_risk,Biotechnology & Pharmaceuticals,2021,1.0,1.252762968495368,Drug_Safety
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Gritstone bio Inc,5046716076,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,226,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
UNITY Biotechnology Inc,5042242039,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Relay Therapeutics Inc,5051787387,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,226,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
UNITY Biotechnology Inc,5042242039,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,226,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Relay Therapeutics Inc,5051787387,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,226,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Maravai LifeSciences Holdings Inc,5078367609,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,225,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Maravai LifeSciences Holdings Inc,5078367609,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,225,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Atreca Inc,5037061527,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,225,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Maravai LifeSciences Holdings Inc,5078367609,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,225,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
IDEAYA Biosciences Inc,5046317163,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,225,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
IDEAYA Biosciences Inc,5046317163,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,225,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Maravai LifeSciences Holdings Inc,5078367609,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.5,225,S_risk,Biotechnology & Pharmaceuticals,2023,0.6,0.9162907318741552,Drug_Safety
Atreca Inc,5037061527,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,225,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Avidity Biosciences Inc,5041069348,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,224,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Avidity Biosciences Inc,5041069348,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,224,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Arcutis Biotherapeutics Inc,5071515336,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,224,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Arcutis Biotherapeutics Inc,5071515336,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,224,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aytu Biopharma Inc,5046048674,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,224,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Aytu Biopharma Inc,5046048674,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,224,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aytu Biopharma Inc,5046048674,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,224,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
DermTech Inc,5071164163,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,224,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aytu Biopharma Inc,5046048674,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,224,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Duopharma Biotech Bhd,4295883043,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,223,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Duopharma Biotech Bhd,4295883043,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,223,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,223,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Duopharma Biotech Bhd,4295883043,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Photocure ASA,4295885687,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,223,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Photocure ASA,4295885687,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,223,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Duopharma Biotech Bhd,4295883043,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,223,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Beijing Tong Ren Tang Chinese Medicine Co Ltd,5015345762,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,223,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Photocure ASA,4295885687,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,223,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Duopharma Biotech Bhd,4295883043,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,223,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
NextCure Inc,5048904889,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,222,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
NextCure Inc,5048904889,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,222,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Athenex Inc,4297156651,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,221,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
X4 Pharmaceuticals Inc,5001432321,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,221,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Replimune Group Inc,5064609639,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,221,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Athenex Inc,4297156651,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,221,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Athenex Inc,4297156651,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,221,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Replimune Group Inc,5064609639,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,221,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Replimune Group Inc,5064609639,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,221,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
X4 Pharmaceuticals Inc,5001432321,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,221,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Fennec Pharmaceuticals Inc,4295862881,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Medipharm Labs Corp,5057974133,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Theratechnologies Inc,4295861528,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Medipharm Labs Corp,5057974133,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Medipharm Labs Corp,5057974133,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Fennec Pharmaceuticals Inc,4295862881,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Medipharm Labs Corp,5057974133,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Theratechnologies Inc,4295861528,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Fennec Pharmaceuticals Inc,4295862881,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,220,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Jilin Aodong Pharmaceutical Group Co Ltd,4295864286,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Jilin Aodong Pharmaceutical Group Co Ltd,4295864286,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,219,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Avalo Therapeutics Inc,5036216067,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Outlook Therapeutics Inc,5034864632,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Cronos Group Inc,5052536942,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
IGM Biosciences Inc,5000837249,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Outlook Therapeutics Inc,5034864632,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
IGM Biosciences Inc,5000837249,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
IGM Biosciences Inc,5000837249,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Allogene Therapeutics Inc,5063310679,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Allogene Therapeutics Inc,5063310679,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,219,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
IGM Biosciences Inc,5000837249,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Jilin Aodong Pharmaceutical Group Co Ltd,4295864286,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,219,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Avalo Therapeutics Inc,5036216067,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Allogene Therapeutics Inc,5063310679,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cronos Group Inc,5052536942,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cronos Group Inc,5052536942,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Allogene Therapeutics Inc,5063310679,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,219,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Strides Pharma Science Ltd,4295873295,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,218,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Hualan Biological Engineering Inc,4295865475,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Vistagen Therapeutics Inc,4296274076,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,218,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Strides Pharma Science Ltd,4295873295,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Sinovac Biotech Ltd,4295863966,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Sinovac Biotech Ltd,4295863966,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Vistagen Therapeutics Inc,4296274076,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,218,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Vistagen Therapeutics Inc,4296274076,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ovid Therapeutics Inc,5045853309,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ovid Therapeutics Inc,5045853309,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hualan Biological Engineering Inc,4295865475,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,218,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Ovid Therapeutics Inc,5045853309,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Vistagen Therapeutics Inc,4296274076,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,218,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sinovac Biotech Ltd,4295863966,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,218,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Hualan Biological Engineering Inc,4295865475,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,218,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Sinovac Biotech Ltd,4295863966,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Sinovac Biotech Ltd,4295863966,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,218,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Strides Pharma Science Ltd,4295873295,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,218,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
China Resources Double-Crane Pharmaceutical Co Ltd,4295864997,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Avecho Biotechnology Ltd,4295858250,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Beijing Tongrentang Co Ltd,4295865333,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Beijing Tongrentang Co Ltd,4295865333,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Marinus Pharmaceuticals Inc,4296927359,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Beijing SL Pharmaceutical Co Ltd,4295865485,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Beijing Tongrentang Co Ltd,4295865333,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
China Resources Double-Crane Pharmaceutical Co Ltd,4295864997,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Avecho Biotechnology Ltd,4295858250,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Beijing SL Pharmaceutical Co Ltd,4295865485,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Beijing Tongrentang Co Ltd,4295865333,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Marinus Pharmaceuticals Inc,4296927359,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Marinus Pharmaceuticals Inc,4296927359,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,217,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
China Resources Double-Crane Pharmaceutical Co Ltd,4295864997,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Beijing Tongrentang Co Ltd,4295865333,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,217,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Nkarta Inc,5061699475,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dong-E-E-Jiao Co Ltd,4295864992,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Recursion Pharmaceuticals Inc,5042238812,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,216,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Recursion Pharmaceuticals Inc,5042238812,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Karuna Therapeutics Inc,5036220029,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Recursion Pharmaceuticals Inc,5042238812,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.5,216,S_risk,Biotechnology & Pharmaceuticals,2021,1.0,1.252762968495368,Drug_Safety
Recursion Pharmaceuticals Inc,5042238812,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Drug_Safety
Recursion Pharmaceuticals Inc,5042238812,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dong-E-E-Jiao Co Ltd,4295864992,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,216,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Recursion Pharmaceuticals Inc,5042238812,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Karuna Therapeutics Inc,5036220029,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dong-E-E-Jiao Co Ltd,4295864992,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,216,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Nkarta Inc,5061699475,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Recursion Pharmaceuticals Inc,5042238812,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,216,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Nkarta Inc,5061699475,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,216,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kodiak Sciences Inc,4298009606,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Guangzhou Kingmed Diagnostics Group Co Ltd,5043415350,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,214,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Xeris Pharmaceuticals Inc,4297260021,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Kodiak Sciences Inc,4298009606,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Guangzhou Kingmed Diagnostics Group Co Ltd,5043415350,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,214,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kodiak Sciences Inc,4298009606,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Guangzhou Kingmed Diagnostics Group Co Ltd,5043415350,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kodiak Sciences Inc,4298009606,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Guangzhou Kingmed Diagnostics Group Co Ltd,5043415350,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,214,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Guangzhou Kingmed Diagnostics Group Co Ltd,5043415350,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,214,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Xeris Pharmaceuticals Inc,4297260021,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,214,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Forte Biosciences Inc,4297884814,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Forte Biosciences Inc,4297884814,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Altimmune Inc,4295902506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Beyondspring Inc,5052143727,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Forte Biosciences Inc,4297884814,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Altimmune Inc,4295902506,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Beyondspring Inc,5052143727,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,213,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dbv Technologies SA,4295983024,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,212,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Dbv Technologies SA,4295983024,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,212,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Lee's Pharmaceutical Holdings Ltd,4295871517,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,212,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Lee's Pharmaceutical Holdings Ltd,4295871517,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,212,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Dbv Technologies SA,4295983024,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,212,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Lee's Pharmaceutical Holdings Ltd,4295871517,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,212,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Lee's Pharmaceutical Holdings Ltd,4295871517,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.85,212,S_risk,Biotechnology & Pharmaceuticals,2022,0.74,1.0473189942805592,Drug_Safety
Lee's Pharmaceutical Holdings Ltd,4295871517,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,212,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lyra Therapeutics Inc,5000454023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,211,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Catalyst Biosciences Inc,4295899884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,211,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Laboratorio Reig Jofre SA,4295889665,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,211,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Laboratorio Reig Jofre SA,4295889665,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,211,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Laboratorio Reig Jofre SA,4295889665,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,211,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Laboratorio Reig Jofre SA,4295889665,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,211,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Savara Inc,4295915685,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,210,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Allergy Therapeutics PLC,4295894147,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,210,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Savara Inc,4295915685,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,210,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Chembio Diagnostics Inc,4295900231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,210,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Chembio Diagnostics Inc,4295900231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,210,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
BioXcel Therapeutics Inc,5059088690,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,210,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Kangmei Pharmaceutical Co Ltd,4295865533,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,210,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Kangmei Pharmaceutical Co Ltd,4295865533,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,210,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Poseida Therapeutics Inc,5048023521,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,210,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Zhejiang CONBA Pharmaceutical Co Ltd,4295865378,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,210,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kangmei Pharmaceutical Co Ltd,4295865533,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,210,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhejiang CONBA Pharmaceutical Co Ltd,4295865378,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,210,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Spectrum Pharmaceuticals Inc,4295907365,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Spectrum Pharmaceuticals Inc,4295907365,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Agile Therapeutics Inc,4295990208,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Spectrum Pharmaceuticals Inc,4295907365,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Stoke Therapeutics Inc,5044099417,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Centogene NV,5068331881,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Stoke Therapeutics Inc,5044099417,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Centogene NV,5068331881,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Centogene NV,5068331881,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Stoke Therapeutics Inc,5044099417,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Centogene NV,5068331881,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Agile Therapeutics Inc,4295990208,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,209,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
SpringWorks Therapeutics Inc,5068659971,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
SpringWorks Therapeutics Inc,5068659971,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Nurix Therapeutics Inc,5037639007,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Viking Therapeutics Inc,5042933582,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Transgene SA,4295868038,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,208,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aerie Pharmaceuticals Inc,4297213141,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Ctp NV,5076163128,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,208,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Nurix Therapeutics Inc,5037639007,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ctp NV,5076163128,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Nanjing King-friend Biochemical Pharmaceutical Co Ltd,5000520341,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,208,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Transgene SA,4295868038,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,208,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Transgene SA,4295868038,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ctp NV,5076163128,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ctp NV,5076163128,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Transgene SA,4295868038,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Viking Therapeutics Inc,5042933582,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,208,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Nanjing King-friend Biochemical Pharmaceutical Co Ltd,5000520341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,208,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Bioatla Inc,5076111023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,207,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Hexo Corp,5043460552,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,207,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
PDS Biotechnology Corp,5000474462,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,207,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Medical Developments International Ltd,4295857325,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,207,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Opthea Ltd,4295857664,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,207,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
PDS Biotechnology Corp,5000474462,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,207,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Bioatla Inc,5076111023,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,207,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
PDS Biotechnology Corp,5000474462,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,207,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Merus NV,4297392913,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
TaiMed Biologics Inc,4298124682,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cytek Biosciences Inc,5051007061,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tonghua Dongbao Pharmaceutical Co Ltd,4295865440,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Bellicum Pharmaceuticals Inc,5000448724,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Bellicum Pharmaceuticals Inc,5000448724,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Tonghua Dongbao Pharmaceutical Co Ltd,4295865440,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,206,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bellicum Pharmaceuticals Inc,5000448724,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Cytek Biosciences Inc,5051007061,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Merus NV,4297392913,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
TaiMed Biologics Inc,4298124682,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
TaiMed Biologics Inc,4298124682,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Bellicum Pharmaceuticals Inc,5000448724,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,206,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Shanghai RAAS Blood Products Co Ltd,4298025328,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,205,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Pulse Biosciences Inc,5064601827,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shenzhen Salubris Pharmaceuticals Co Ltd,4298150679,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shanghai RAAS Blood Products Co Ltd,4298025328,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,205,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Pulse Biosciences Inc,5064601827,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
BB Biotech AG,4295890616,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,205,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
BB Biotech AG,4295890616,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,205,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Adicet Bio Inc,5055941844,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Adicet Bio Inc,5055941844,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Rapt Therapeutics Inc,5046047686,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pulse Biosciences Inc,5064601827,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,205,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alpine Immune Sciences Inc,5035525548,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
T2 Biosystems Inc,5000751904,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Mirum Pharmaceuticals Inc,5066605934,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Relmada Therapeutics Inc,5037949940,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Relmada Therapeutics Inc,5037949940,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Relmada Therapeutics Inc,5037949940,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Organovo Holdings Inc,5037282896,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Mirum Pharmaceuticals Inc,5066605934,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,204,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
IVERIC bio Inc,4297721792,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tarsus Pharmaceuticals Inc,5070510044,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ascletis Pharma Inc,5037651630,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ascletis Pharma Inc,5037651630,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ascletis Pharma Inc,5037651630,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Ascletis Pharma Inc,5037651630,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ascletis Pharma Inc,5037651630,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Tarsus Pharmaceuticals Inc,5070510044,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ascletis Pharma Inc,5037651630,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Ascletis Pharma Inc,5037651630,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
IVERIC bio Inc,4297721792,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Ascletis Pharma Inc,5037651630,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,203,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Foghorn Therapeutics Inc.,5050713856,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Foghorn Therapeutics Inc.,5050713856,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,203,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Telix Pharmaceuticals Ltd,5053083994,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,202,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Alligator Bioscience AB,4295976193,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,202,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Iteos Therapeutics Inc,5073964452,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,202,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Alligator Bioscience AB,4295976193,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,202,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Checkpoint Therapeutics Inc,4296562024,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,202,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Alligator Bioscience AB,4295976193,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,202,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Telix Pharmaceuticals Ltd,5053083994,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,202,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Telix Pharmaceuticals Ltd,5053083994,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,202,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Iteos Therapeutics Inc,5073964452,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,202,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Ergomed PLC,5042964908,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,201,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ergomed PLC,5042964908,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,201,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Spero Therapeutics Inc,5042250852,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,201,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Spero Therapeutics Inc,5042250852,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,201,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
scPharmaceuticals Inc,5042230367,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,200,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
scPharmaceuticals Inc,5042230367,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,200,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Exicure Inc,5055416070,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,199,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Clovis Oncology Inc,4298504105,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,198,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Clovis Oncology Inc,4298504105,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,198,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Clovis Oncology Inc,4298504105,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,198,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
SQZ Biotechnologies Co,5042254800,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,198,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Adaptimmune Therapeutics PLC,5045847548,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,197,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shandong Buchang Pharmaceuticals Co Ltd,5000560344,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,197,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Liminal BioSciences Inc,4295861739,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,197,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Liminal BioSciences Inc,4295861739,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,197,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Adaptimmune Therapeutics PLC,5045847548,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,197,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shandong Buchang Pharmaceuticals Co Ltd,5000560344,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,197,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Liminal BioSciences Inc,4295861739,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,197,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Adaptimmune Therapeutics PLC,5045847548,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,197,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Gossamer Bio Inc,5060473928,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,196,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Eton Pharmaceuticals Inc,5064704765,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,196,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Gossamer Bio Inc,5060473928,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,196,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Etex NV,5000023330,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,196,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Applied Therapeutics Inc,5053942137,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,196,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Gossamer Bio Inc,5060473928,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,196,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Gossamer Bio Inc,5060473928,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,196,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Etex NV,5000023330,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,196,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Eton Pharmaceuticals Inc,5064704765,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,196,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Etex NV,5000023330,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,196,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Etex NV,5000023330,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,196,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Etex NV,5000023330,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,196,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Shilpa Medicare Ltd,4295873197,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,195,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Shilpa Medicare Ltd,4295873197,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,195,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shilpa Medicare Ltd,4295873197,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,195,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Genprex Inc,5036210734,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Genprex Inc,5036210734,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Amarin Corporation PLC,4295897405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Surface Oncology Inc,5044199583,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Surface Oncology Inc,5044199583,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Surface Oncology Inc,5044199583,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Genprex Inc,5036210734,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aldeyra Therapeutics Inc,4297349911,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Amarin Corporation PLC,4295897405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aldeyra Therapeutics Inc,4297349911,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Infinity Pharmaceuticals Inc,4295915855,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,194,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Xenon Pharmaceuticals Inc,4295968711,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Tasly Pharmaceutical Group Co Ltd,4295865148,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,192,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Guizhou Bailing Group Pharmaceutical Co Ltd,4298345796,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,192,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Keros Therapeutics Inc,5050915513,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Xenon Pharmaceuticals Inc,4295968711,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Xenon Pharmaceuticals Inc,4295968711,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
CymaBay Therapeutics Inc,4297588727,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Eloxx Pharmaceuticals Inc,4295914898,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Tasly Pharmaceutical Group Co Ltd,4295865148,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,192,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kezar Life Sciences Inc,5046058924,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
AVROBIO Inc,5050307187,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Guizhou Bailing Group Pharmaceutical Co Ltd,4298345796,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,192,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Kezar Life Sciences Inc,5046058924,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
CymaBay Therapeutics Inc,4297588727,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,192,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aligos Therapeutics Inc,5065980352,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aligos Therapeutics Inc,5065980352,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Jinyu Bio-Technology Co Ltd,4295864704,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,191,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
CTI Biopharma Corp,5060588775,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
CTI Biopharma Corp,5060588775,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Jinyu Bio-Technology Co Ltd,4295864704,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,191,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Antares Pharma Inc,4295914166,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,191,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Curaleaf Holdings Inc,5045851306,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,190,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Co-Diagnostics Inc,5040195339,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,190,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Curaleaf Holdings Inc,5045851306,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,190,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zentalis Pharmaceuticals Inc,5072818884,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,190,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Curaleaf Holdings Inc,5045851306,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,190,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Curaleaf Holdings Inc,5045851306,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,190,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Generation Bio Co,5060500613,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Burning Rock Biotech Ltd,5074555179,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Burning Rock Biotech Ltd,5074555179,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Generation Bio Co,5060500613,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Burning Rock Biotech Ltd,5074555179,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,189,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
PDL BioPharma Inc,4295907681,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Phathom Pharmaceuticals Inc,5069405688,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Allakos Inc,5037990289,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Albireo Pharma Inc,4295904266,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Bionomics Ltd,4295856352,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Albireo Pharma Inc,4295904266,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Phathom Pharmaceuticals Inc,5069405688,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Allakos Inc,5037990289,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Allakos Inc,5037990289,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Phathom Pharmaceuticals Inc,5069405688,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.25,188,S_risk,Biotechnology & Pharmaceuticals,2022,0.1,0.2231435513142097,Drug_Safety
Soleno Therapeutics Inc,4297184240,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,188,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Chengdu Kanghong Pharmaceutical Group Co Ltd,5000514619,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,188,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Black Diamond Therapeutics Inc,5044168456,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
AC Immune SA,4297285623,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Oncternal Therapeutics Inc,4295908396,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Evofem Biosciences Inc,4297632572,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Vistin Pharma ASA,5046040555,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
AC Immune SA,4297285623,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Protara Therapeutics Inc,4296048186,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
AC Immune SA,4297285623,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Vistin Pharma ASA,5046040555,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
La Jolla Pharmaceutical Co,4295906958,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Vistin Pharma ASA,5046040555,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Protara Therapeutics Inc,4296048186,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
AC Immune SA,4297285623,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Vistin Pharma ASA,5046040555,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
BGI Genomics Co Ltd,5043316839,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,186,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
BGI Genomics Co Ltd,5043316839,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,186,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
BGI Genomics Co Ltd,5043316839,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,186,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Anavex Life Sciences Corp,4295899501,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,185,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Anavex Life Sciences Corp,4295899501,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,185,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Towa Pharmaceutical Co Ltd,4295879059,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,185,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Yifan Pharmaceutical Co Ltd,4295865353,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,185,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Yifan Pharmaceutical Co Ltd,4295865353,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,185,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Anavex Life Sciences Corp,4295899501,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,185,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Eiger BioPharmaceuticals Inc,4297271351,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Eiger BioPharmaceuticals Inc,4297271351,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Global Blood Therapeutics Inc,5037622915,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Eiger BioPharmaceuticals Inc,4297271351,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Global Blood Therapeutics Inc,5037622915,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Global Blood Therapeutics Inc,5037622915,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Eiger BioPharmaceuticals Inc,4297271351,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Eiger BioPharmaceuticals Inc,4297271351,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,183,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Xbrane Biopharma AB,5035526276,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Xbrane Biopharma AB,5035526276,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,182,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Arix Bioscience PLC,5050720127,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,181,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Arix Bioscience PLC,5050720127,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,181,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Sichuan Languang Development Co Ltd,4295863639,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,180,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Cabaletta Bio Inc,5066607195,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,180,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Verrica Pharmaceuticals Inc,5045389384,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,178,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Verrica Pharmaceuticals Inc,5045389384,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,178,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Enochian Biosciences Inc,5036384219,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,177,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Enochian Biosciences Inc,5036384219,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,177,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Enochian Biosciences Inc,5036384219,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,177,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Enochian Biosciences Inc,5036384219,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,177,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Enochian Biosciences Inc,5036384219,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,177,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Taysha Gene Therapies Inc,5074235329,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,176,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Taysha Gene Therapies Inc,5074235329,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,176,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Taysha Gene Therapies Inc,5074235329,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,176,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hanmi Science Co Ltd,4295882141,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,175,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Turning Point Therapeutics Inc,5068346529,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,175,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Paradigm Biopharmaceuticals Ltd,5044166860,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,174,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Biohaven Pharmaceutical Holding Company Ltd,5040932194,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Biohaven Pharmaceutical Holding Company Ltd,5040932194,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Rubius Therapeutics Inc,5045880503,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,172,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Wuhu Token Sciences Co Ltd,5000539211,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,171,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Wuhu Token Sciences Co Ltd,5000539211,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,171,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Vyne Therapeutics Inc,5038045986,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,171,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Passage Bio Inc,5065980347,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,170,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Passage Bio Inc,5065980347,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,170,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Tianjin Chase Sun Pharmaceutical Co Ltd,5000446260,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,170,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Evelo Biosciences Inc,5047108020,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,170,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Oncopeptides AB,4298493813,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,168,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Frequency Therapeutics Inc,5052794794,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Galera Therapeutics Inc,5037989344,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Oncopeptides AB,4298493813,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Frequency Therapeutics Inc,5052794794,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Neoleukin Therapeutics Inc,4296262694,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Oncopeptides AB,4298493813,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Neoleukin Therapeutics Inc,4296262694,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,168,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Oncopeptides AB,4298493813,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,168,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Axcella Health Inc,5046040911,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Axcella Health Inc,5046040911,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Devoteam SAS,4295868217,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Devoteam SAS,4295868217,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Devoteam SAS,4295868217,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,164,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Neurobo Pharmaceuticals Inc,5045853684,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Provention Bio Inc,5056411135,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,159,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Concert Pharmaceuticals Inc,4297543586,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Aveo Pharmaceuticals Inc,4297278257,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,157,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
LogicBio Therapeutics Inc,5049432034,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,152,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Strongbridge Biopharma plc,5046703828,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,147,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Carisma Therapeutics Inc,5000661021,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,145,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Carisma Therapeutics Inc,5000661021,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,145,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Dicerna Pharmaceuticals Inc,5034137552,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Adamas Pharmaceuticals Inc,4297309035,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,135,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Flexion Therapeutics Inc,4297906483,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,134,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Flexion Therapeutics Inc,4297906483,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,134,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Oxford Nanopore Technologies PLC,4297080766,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,187,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Oxford Nanopore Technologies PLC,4297080766,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,187,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Imeik Technology Development Co Ltd,5056432599,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Imeik Technology Development Co Ltd,5056432599,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Imeik Technology Development Co Ltd,5056432599,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Imeik Technology Development Co Ltd,5056432599,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Imeik Technology Development Co Ltd,5056432599,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,184,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Imeik Technology Development Co Ltd,5056432599,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,184,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Simcere Pharmaceutical Group Ltd,5059956980,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Simcere Pharmaceutical Group Ltd,5059956980,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,179,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Simcere Pharmaceutical Group Ltd,5059956980,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
GoTo Gojek Tokopedia PT Tbk,5081055647,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,174,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
GoTo Gojek Tokopedia PT Tbk,5081055647,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,174,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Gan & Lee Pharmaceuticals,5000745370,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,170,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Gan & Lee Pharmaceuticals,5000745370,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,170,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Gan & Lee Pharmaceuticals,5000745370,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,170,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Saga Pure ASA,5000699570,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,160,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Shanghai Medicilon Inc,4297884856,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,157,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Shanghai Medicilon Inc,4297884856,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,157,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Shanghai Medicilon Inc,4297884856,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,157,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Hyloris Pharmaceuticals SA,5071511424,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,152,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Hyloris Pharmaceuticals SA,5071511424,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,152,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Ocumension Therapeutics,5066605178,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Ocumension Therapeutics,5066605178,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,151,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Ocumension Therapeutics,5066605178,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,151,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Vicore Pharma Holding AB,5035429047,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,143,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Vicore Pharma Holding AB,5035429047,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,143,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Vicore Pharma Holding AB,5035429047,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,143,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Vicore Pharma Holding AB,5035429047,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,143,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kintor Pharmaceutical Ltd,5072811065,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,140,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Kintor Pharmaceutical Ltd,5072811065,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,140,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Kancera AB,5001436678,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Kancera AB,5001436678,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Kancera AB,5001436678,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Kancera AB,5001436678,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Kancera AB,5001436678,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Neuren Pharmaceuticals Ltd,4295858589,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,138,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Neuren Pharmaceuticals Ltd,4295858589,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,138,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Moberg Pharma AB (publ),4297660803,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Moberg Pharma AB (publ),4297660803,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Moberg Pharma AB (publ),4297660803,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Moberg Pharma AB (publ),4297660803,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,137,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Novacyt SA,5035542125,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Novacyt SA,5035542125,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,134,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Armata Pharmaceuticals Inc,4295908105,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,133,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Stevanato Group SpA,5040058883,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,132,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Stevanato Group SpA,5040058883,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,132,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aino Health AB (publ),5052541224,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,132,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Stevanato Group SpA,5040058883,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,132,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Cyxone AB,5050718180,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Cyxone AB,5050718180,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Hero AG,4295890921,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,130,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Cyxone AB,5050718180,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Cyxone AB,5050718180,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Cyxone AB,5050718180,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,130,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Roivant Sciences Ltd,5046658821,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,129,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Bio-UV Group SA,5062723810,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bio-UV Group SA,5062723810,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,128,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Praemia Healthcare SA,5035467298,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,119,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Praemia Healthcare SA,5035467298,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Praemia Healthcare SA,5035467298,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
AcedrA Pharmaceutical Co,5076114133,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,118,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hbm Holdings Ltd,5079208296,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hbm Holdings Ltd,5079208296,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,116,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hbm Holdings Ltd,5079208296,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Chenguang Biotech Group Co Ltd,5000460305,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,114,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Immatics NV,5074189653,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,113,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Immatics NV,5074189653,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,113,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Immatics NV,5074189653,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,113,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
PharmaBlock Sciences Nanjing Inc,5052792291,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
PharmaBlock Sciences Nanjing Inc,5052792291,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PharmaBlock Sciences Nanjing Inc,5052792291,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.1,112,S_risk,Biotechnology & Pharmaceuticals,2023,0.44,0.7419373447293773,Drug_Safety
JW (Cayman) Therapeutics Co Ltd,5076109832,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,112,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
JW (Cayman) Therapeutics Co Ltd,5076109832,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,112,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Arcellx Inc,5052143148,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,112,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Selvita SA,5070828947,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,111,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Mind Medicine (MindMed) Inc,5001198706,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,111,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Selvita SA,5070828947,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,111,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Jiangxi Fushine Pharmaceutical Co Ltd,5000532978,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,108,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
China Biotech Services Holdings Ltd,5043954284,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,107,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Chengdu Kanghua Biological Products Co Ltd,5062225726,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,106,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Chengdu Kanghua Biological Products Co Ltd,5062225726,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,106,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Center Laboratories Inc,4295892655,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,105,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Center Laboratories Inc,4295892655,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,105,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
BioLASCO Taiwan Co Ltd,5059999200,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,105,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Center Laboratories Inc,4295892655,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,105,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Wuhan Hvsen Biotechnology Co Ltd,5038865285,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,104,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Zhaoke Ophthalmology Ltd,5076909548,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,104,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Zhaoke Ophthalmology Ltd,5076909548,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,104,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Wuhan Hvsen Biotechnology Co Ltd,5038865285,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,104,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhejiang Wecome Pharmaceutical Co Ltd,5039953006,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Aurisco Pharmaceutical Co Ltd,5000519656,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhejiang Wecome Pharmaceutical Co Ltd,5039953006,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aurisco Pharmaceutical Co Ltd,5000519656,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Hainan Huluwa Pharmaceutical Group Co Ltd,5037349930,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Hainan Huluwa Pharmaceutical Group Co Ltd,5037349930,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Welgene Biotech Co Ltd,5045505689,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,101,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Xiamen Amoytop Biotech Co Ltd,5035558350,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,101,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Xiamen Amoytop Biotech Co Ltd,5035558350,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,101,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jiangsu Jibeier Pharmaceutical Co Ltd,5070520264,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,100,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Jiangsu Jibeier Pharmaceutical Co Ltd,5070520264,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,100,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Wepon Pharmaceutical Holding Group Co Ltd,4295864513,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,99,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
IRLAB Therapeutics AB,5054560015,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
IRLAB Therapeutics AB,5054560015,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
IRLAB Therapeutics AB,5054560015,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
IRLAB Therapeutics AB,5054560015,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Energenesis Biomedical Co Ltd,5044022281,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
OliX Pharmaceuticals Inc,5035526712,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,97,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Friulchem SpA,5037954315,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,96,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jiangsu Aidea Pharmaceutical Co Ltd,5051395627,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,95,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Korea Pharma Co Ltd,5000038082,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,95,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Soho Global Health Tbk PT,5044253935,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,95,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
RemeGen Co Ltd,5035564100,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,95,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Korea Pharma Co Ltd,5000038082,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,95,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aadi Bioscience Inc,5055374136,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,95,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Soho Global Health Tbk PT,5044253935,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,95,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jiangsu Aidea Pharmaceutical Co Ltd,5051395627,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,95,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Cardiol Therapeutics Inc,5055424486,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,93,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Orion Infusion Ltd,4295917403,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,93,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Yantai Zhenghai Bio-Tech Co Ltd,5035559079,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,93,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Everest Organics Ltd,4296861914,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,93,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Quantum-Si Inc,5076354106,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,91,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Soligenix Inc,4295903924,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,90,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
NanJing Research Institute of Surveying Mapping & Geotechnical Investigation Co Ltd,5066609085,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,90,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
NanJing Research Institute of Surveying Mapping & Geotechnical Investigation Co Ltd,5066609085,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,90,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Ever Supreme Bio Technology Co Ltd,5062406838,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,89,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Ever Supreme Bio Technology Co Ltd,5062406838,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,89,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Cytogen Inc,5059048574,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,89,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
XSpray Pharma AB (publ),5035546429,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
TRG Pakistan Ltd,4297081341,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
XSpray Pharma AB (publ),5035546429,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
XSpray Pharma AB (publ),5035546429,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
TRG Pakistan Ltd,4297081341,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,88,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
XSpray Pharma AB (publ),5035546429,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Ribomic Inc,4297898511,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Magforce AG,4297745497,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,87,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Enimmune Corp,5050988231,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,87,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tango Therapeutics Inc,5076353517,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,87,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Voss Veksel og Landmandsbank ASA,4295885496,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,86,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
C4X Discovery Holdings PLC,5044027878,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,86,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
C4X Discovery Holdings PLC,5044027878,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,86,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
E-Therapeutics PLC,4295896493,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,85,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Perseus Proteomics Inc,4296269454,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,85,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Tanvex BioPharma Inc,5046457659,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.53,85,S_risk,Biotechnology & Pharmaceuticals,2022,0.212,0.4252677354043441,Drug_Safety
E-Therapeutics PLC,4295896493,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,85,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Perseus Proteomics Inc,4296269454,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,85,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tanvex BioPharma Inc,5046457659,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,85,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Magle Chemoswed Holding AB,5057821322,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,84,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Magle Chemoswed Holding AB,5057821322,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,84,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Kinarus Therapeutics Holding AG,4295890891,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,83,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Withus Pharmaceutical Co Ltd,5037639012,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,82,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Withus Pharmaceutical Co Ltd,5037639012,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,82,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Laboratorios Richmond SACIF,4296573600,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,82,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Melinta Therapeutics Inc,4298504748,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,81,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
GlycoNex Inc,5035548960,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,80,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Trimuda Nuansa Citra Tbk PT,5063771915,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,78,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bergenbio ASA,5035526218,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,78,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Bergenbio ASA,5035526218,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,78,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Pymepharco JSC,4298076643,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,73,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Metabolic Explorer SA,4296093632,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,69,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aprea Therapeutics Inc,5071168699,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,69,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Biotechnology Assets SA,5035561500,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,68,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Mabpharm Ltd,5065321886,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,66,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Mabpharm Ltd,5065321886,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,66,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Imago BioSciences Inc,5044017757,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,66,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Imago BioSciences Inc,5044017757,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,66,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Autolus Therapeutics PLC,5063744039,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,65,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Autolus Therapeutics PLC,5063744039,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,65,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Suntar Eco-City Ltd,4295865270,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,63,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Spark Therapeutics Inc,5040271210,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,63,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
ASKA Pharmaceutical Co Ltd,4295878116,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,62,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Somalogic Inc,5079707680,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,62,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Foundation Medicine Inc,5000714889,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,61,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
MMJ Group Holdings Ltd,5044166983,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,58,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lundbeck Seattle Biopharmaceuticals Inc,4296032231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,55,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Lundbeck Seattle Biopharmaceuticals Inc,4296032231,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,55,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Shedir Pharma Srl Unipersonale,5044738011,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,54,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Dova Pharmaceuticals Inc,5052128613,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,53,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Synthorx Inc,5042373556,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,52,S_risk,Biotechnology & Pharmaceuticals,2018,0.4,0.6931471805599453,Business_Ethics
Mydecine Innovations Group Inc,5042946439,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,52,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Audentes Therapeutics Inc,5040171536,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,49,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Majid Al Futtaim Holding LLC,5000030405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Majid Al Futtaim Holding LLC,5000030405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Majid Al Futtaim Holding LLC,5000030405,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,1.0,247,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Drug_Safety
Santhera Pharmaceuticals Holding AG,4295890728,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,186,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Santhera Pharmaceuticals Holding AG,4295890728,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,186,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Santhera Pharmaceuticals Holding AG,4295890728,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,186,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Santhera Pharmaceuticals Holding AG,4295890728,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,186,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Santhera Pharmaceuticals Holding AG,4295890728,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,186,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Alphamab Oncology,5070827750,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,179,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Alphamab Oncology,5070827750,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Alphamab Oncology,5070827750,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Alphamab Oncology,5070827750,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Alphamab Oncology,5070827750,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,179,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Alphamab Oncology,5070827750,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,179,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Alphamab Oncology,5070827750,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,179,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Oryzon Genomics SA,4297159438,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,175,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Oryzon Genomics SA,4297159438,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,175,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Oryzon Genomics SA,4297159438,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,175,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hua Medicine,5046653844,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,173,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Hua Medicine,5046653844,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,173,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Hua Medicine,5046653844,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,173,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Hua Medicine,5046653844,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,173,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Hua Medicine,5046653844,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,173,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Hua Medicine,5046653844,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,173,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
ADC Therapeutics SA,5037362072,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
ADC Therapeutics SA,5037362072,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
ADC Therapeutics SA,5037362072,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,167,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
ADC Therapeutics SA,5037362072,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,167,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Gensight Biologics SA,5039191405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,166,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Bora Pharmaceuticals Co Ltd,5044006942,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,165,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Equillium Inc,5065627715,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,165,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Bora Pharmaceuticals Co Ltd,5044006942,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.28,165,S_risk,Biotechnology & Pharmaceuticals,2022,0.512,0.8241754429663494,Drug_Safety
Bora Pharmaceuticals Co Ltd,5044006942,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,165,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Medigen Biotechnology Corp,4295892209,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,163,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Saniona AB,5041982010,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,163,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Medigen Biotechnology Corp,4295892209,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,163,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Saniona AB,5041982010,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,163,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Zhong Jia Guo Xin Holdings Co Ltd,4295871820,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,162,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Blau Farmaceutica SA,5037838687,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Everest Medicines Ltd,5061949182,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,158,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Everest Medicines Ltd,5061949182,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,158,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Everest Medicines Ltd,5061949182,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,158,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Everest Medicines Ltd,5061949182,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,158,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Everest Medicines Ltd,5061949182,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,158,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Everest Medicines Ltd,5061949182,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.16,158,S_risk,Biotechnology & Pharmaceuticals,2023,0.4639999999999999,0.7701082216960736,Drug_Safety
Blau Farmaceutica SA,5037838687,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,2.37,158,S_risk,Biotechnology & Pharmaceuticals,2020,0.948,1.2149127443642704,Workforce_Development
Everest Medicines Ltd,5061949182,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,158,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Paion AG,4295870315,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,157,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Paion AG,4295870315,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,157,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Paion AG,4295870315,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,157,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Heidelberg Pharma AG,5057984015,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
GT Biopharma Inc,4295907505,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Suven Life Sciences Ltd,4295873926,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Suven Life Sciences Ltd,4295873926,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Suven Life Sciences Ltd,4295873926,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,154,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Heidelberg Pharma AG,5057984015,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Suven Life Sciences Ltd,4295873926,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,154,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Diamyd Medical AB,5035530036,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,153,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Business_Ethics
Diamyd Medical AB,5035530036,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,153,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Rana Gruber ASA,4297660032,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,150,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
InnoCare Pharma Ltd,5071511883,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,150,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Rana Gruber ASA,4297660032,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,150,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
InnoCare Pharma Ltd,5071511883,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,150,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
InnoCare Pharma Ltd,5071511883,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,150,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
VNV Global AB (publ),5000064507,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,149,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Karolinska Development AB,4298129740,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,147,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Karolinska Development AB,4298129740,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,147,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Celyad Oncology SA,5000454045,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,145,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Oxford Biodynamics PLC,5035548501,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,145,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Oxford Biodynamics PLC,5035548501,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,145,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
4Sc AG,4295870097,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,144,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
4Sc AG,4295870097,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,144,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tonix Pharmaceuticals Holding Corp,4297915579,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,142,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Tonix Pharmaceuticals Holding Corp,4297915579,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Tonix Pharmaceuticals Holding Corp,4297915579,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Tonix Pharmaceuticals Holding Corp,4297915579,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tonix Pharmaceuticals Holding Corp,4297915579,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,142,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Allovir Inc,5044174285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,141,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Allovir Inc,5044174285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,141,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Allovir Inc,5044174285,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,141,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
PCI Biotech Holding ASA,4298025346,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,139,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Nuvalent Inc,5071514083,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,139,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Nuvalent Inc,5071514083,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,139,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
PCI Biotech Holding ASA,4298025346,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
PCI Biotech Holding ASA,4298025346,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,139,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Nuvalent Inc,5071514083,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,139,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Oncimmune Holdings PLC,5050903730,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,138,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Business_Ethics
Oncimmune Holdings PLC,5050903730,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,138,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Solara Active Pharma Sciences Ltd,5063388054,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Solara Active Pharma Sciences Ltd,5063388054,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,1.62,134,S_risk,Biotechnology & Pharmaceuticals,2024,0.648,0.9631743177730056,Drug_Safety
Solara Active Pharma Sciences Ltd,5063388054,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,134,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Solara Active Pharma Sciences Ltd,5063388054,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,134,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Vor Biopharma Inc,5050921121,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,133,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Vor Biopharma Inc,5050921121,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,133,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Vor Biopharma Inc,5050921121,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,133,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
ATAI Life Sciences NV,5080054459,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,132,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Day One Biopharmaceuticals Inc,5079901024,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,130,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Neximmune Inc,5037275804,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,128,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Nykode Therapeutics ASA,5035525105,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,127,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Nykode Therapeutics ASA,5035525105,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2018,0.0,0.0,Drug_Safety
Nykode Therapeutics ASA,5035525105,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2022,0.0,0.0,Drug_Safety
Nykode Therapeutics ASA,5035525105,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Drug_Safety
Nykode Therapeutics ASA,5035525105,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,127,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Nykode Therapeutics ASA,5035525105,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Drug_Safety
Nykode Therapeutics ASA,5035525105,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.0,127,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Drug_Safety
Bioventix PLC,4296127814,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bioventix PLC,4296127814,quantitative,REPORTED,Percentage of employee turnover.,TURNOVEREMPLOYEES,0.0,125,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Workforce_Development
Bioventix PLC,4296127814,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,125,S_risk,Biotechnology & Pharmaceuticals,2024,0.4,0.6931471805599453,Business_Ethics
Shield Therapeutics PLC,5046664318,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,124,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
High Tide Inc,5064659143,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,123,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
M Cash Integrasi Tbk PT,5057939443,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,122,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
M Cash Integrasi Tbk PT,5057939443,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,122,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Active Biotech AB publ,4295889837,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hokuyaku Takeyama Holdings Inc,4295880290,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Active Biotech AB publ,4295889837,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Active Biotech AB publ,4295889837,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
HPGC Renmintongtai Pharmaceutical Corp,4295864235,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,122,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
M Cash Integrasi Tbk PT,5057939443,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,122,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Aileron Therapeutics Inc,4297864562,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,120,S_risk,Biotechnology & Pharmaceuticals,2020,0.4,0.6931471805599453,Business_Ethics
Aileron Therapeutics Inc,4297864562,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,120,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Micro Systemation AB (publ),4296345132,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,120,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Micro Systemation AB (publ),4296345132,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,120,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Aileron Therapeutics Inc,4297864562,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,120,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
AgeX Therapeutics Inc,5055459435,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,119,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
AgeX Therapeutics Inc,5055459435,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,119,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Okomu Oil Palm Company PLC,4295986151,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,119,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Zhejiang Cheng Yi Pharmaceutical Co Ltd,5000555547,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,118,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Inventiva SA,5037845589,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Arab Drug Company for Pharmaceuticals and Chemical Industries SAE,4297007407,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Abion Inc,5041069127,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Inventiva SA,5037845589,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,116,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Abion Inc,5041069127,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,116,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Beijing Konruns Pharmaceutical Co Ltd,5046658461,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,115,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ESSA Pharma Inc,5037363591,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,115,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Obseva SA,5040245412,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,114,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Elicio Therapeutics Inc,5000644263,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,113,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Financiere de Tubize SA,4295859367,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,113,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Elicio Therapeutics Inc,5000644263,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,113,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Elicio Therapeutics Inc,5000644263,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,113,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Gamida Cell Ltd,4296875405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,113,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Financiere de Tubize SA,4295859367,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,113,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Gamida Cell Ltd,4296875405,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,113,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Jack Chia Industries Thailand PCL,4295893193,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Tourist Company of Nigeria PLC,4296680627,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
CellSeed Inc,5000642891,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,112,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Baudax Bio Inc,5071518682,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,112,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aeterna Zentaris Inc,4295862603,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,111,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Aeterna Zentaris Inc,4295862603,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,111,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Shinnihonseiyaku Co Ltd,5035523877,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,111,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
SenzaGen AB,5037451815,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,110,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Jeevan Scientific Technology Ltd,5044175835,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,110,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Ryvu Therapeutics SA,5001229336,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,109,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Tibet Weixinkang Pharmaceutical Co Ltd,5052535251,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,109,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Guangdong VTR Bio-Tech Co Ltd,5034761543,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,109,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Boji Medical Technology Co Ltd,5001212343,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,108,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Haemato AG,4295870134,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,108,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Qingdao Vland Biotech INC,5038082674,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,108,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Forma Therapeutics Holdings Inc,5037435569,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,107,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Forma Therapeutics Holdings Inc,5037435569,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,107,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Medico Remedies Ltd,4297909697,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,107,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
NextCell Pharma AB,5051611984,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,106,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
NextCell Pharma AB,5051611984,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,106,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Alexandria Company for Pharmaceuticals and Chemical Industries SAE,4296746971,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,106,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
2Invest AG,4295869583,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Beijing Science Sun Pharmaceutical Co Ltd,5037941644,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
2Invest AG,4295869583,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,103,S_risk,Biotechnology & Pharmaceuticals,2021,0.0,0.0,Business_Ethics
Cosmo Bio Co Ltd,4295880839,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Ibnsina Pharma Co SAE,5050305288,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,102,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Lumosa Therapeutics Co Ltd,4297456593,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,101,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
El Nile Company for Pharmaceuticals and Chemical Industries SAE,4295917158,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,100,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
ExpreS2ion Biotech Holding AB,5050991877,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,100,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
OptiPharm Co Ltd,5000044975,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,100,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Healios KK,5037646546,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,100,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Amoy Diagnostics Co Ltd,5047816706,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,100,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Celgene Corp,4295905897,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,99,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Celgene Corp,4295905897,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,99,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
INSYS Therapeutics Inc,5035155013,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,99,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Celgene Corp,4295905897,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,2.2,99,S_risk,Biotechnology & Pharmaceuticals,2018,0.8800000000000001,1.1631508098056809,Drug_Safety
Celgene Corp,4295905897,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,99,S_risk,Biotechnology & Pharmaceuticals,2017,0.0,0.0,Drug_Safety
Allena Pharmaceuticals Inc,5036777605,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,98,S_risk,Biotechnology & Pharmaceuticals,2019,0.4,0.6931471805599453,Business_Ethics
Allena Pharmaceuticals Inc,5036777605,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,98,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Vimedimex Medi Pharma JSC,5000839729,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,98,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
SDS Biotech KK,4295879320,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,97,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
HL Science Co Ltd,5035550632,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,96,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
IX Biopharma Ltd,5035548825,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,96,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Bio Solution Co Ltd,5000039216,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,96,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Bio Solution Co Ltd,5000039216,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,96,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Handa Pharmaceuticals Inc,5052544604,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,96,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Luoxin Pharmaceuticals Group Stock Co Ltd,5041082929,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,94,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Chuang Yi Biotech Co Ltd,5040194169,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,94,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Icure Pharmaceutical Inc,5035524432,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,94,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
"Codiak BioSciences, Inc.",5047640766,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,93,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Sichuan Development Lomon Co Ltd,5000588533,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,91,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Biodexa Pharmaceuticals PLC,5044099529,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,90,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Immunic Inc,4295983152,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,90,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Phaxiam Therapeutics SA,4297184949,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,88,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Impel Pharmaceuticals Inc,4298072043,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,88,S_risk,Biotechnology & Pharmaceuticals,2021,0.4,0.6931471805599453,Business_Ethics
Phaxiam Therapeutics SA,4297184949,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Cellivery Therapeutics Inc,5050471497,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd,5037365637,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,88,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Aptorum Group Ltd,5045946995,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,85,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Pharmadax Inc,5040054905,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,83,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Balaxi Pharmaceuticals Ltd,5047746676,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,75,S_risk,Biotechnology & Pharmaceuticals,2020,0.0,0.0,Business_Ethics
Balaxi Pharmaceuticals Ltd,5047746676,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,75,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Om Residual UK Ltd,8589934234,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,72,S_risk,Biotechnology & Pharmaceuticals,2018,0.4,0.6931471805599453,Business_Ethics
ABL Bio Inc,5052144031,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,68,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Hamburger Sparkasse AG,4296880258,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,127,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Hamburger Sparkasse AG,4296880258,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,127,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Ventyx Biosciences Inc,5076372318,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,100,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Ventyx Biosciences Inc,5076372318,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,100,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Biophytis SA,5035564282,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,89,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
AIM Vaccine Co Ltd,5046390793,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,86,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Entrada Therapeutics Inc,5052506477,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,80,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Piramal Pharma Ltd,5074845229,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,63,S_risk,Biotechnology & Pharmaceuticals,2024,0.0,0.0,Drug_Safety
Piramal Pharma Ltd,5074845229,quantitative,REPORTED,Rate of total number of injuries (Total Injury Rate TIR) and fatalities in the workforce (employees and contractors) relative to 1 million hours worked.,TIRTOTAL,0.12,63,S_risk,Biotechnology & Pharmaceuticals,2024,0.048,0.1133286853070031,Drug_Safety
ING Diba AG,4296540296,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,61,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
CARsgen Therapeutics Holdings Ltd,5080202137,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,55,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
CARsgen Therapeutics Holdings Ltd,5080202137,quantitative,REPORTED,Number of employee fatalities resulting from operational accidents.,EMPLOYEEFATALITIES,0.0,55,S_risk,Biotechnology & Pharmaceuticals,2023,0.0,0.0,Drug_Safety
Mizuho International PLC,4296699872,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,53,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Mizuho International PLC,4296699872,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,53,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Pharvaris NV,5063647310,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,47,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Lepu Biopharma Co Ltd,5070762226,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,42,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Genelux Corp,5000449809,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,39,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Jasper Therapeutics Inc,5071521904,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,19,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Tibet Pharmaceuticals Inc,5000836600,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,18,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Greenlight Biosciences Holdings PBC,5079236516,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,17,S_risk,Biotechnology & Pharmaceuticals,2022,0.4,0.6931471805599453,Business_Ethics
Greenlight Biosciences Holdings PBC,5079236516,qualitative,REPORTED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,1.0,17,S_risk,Biotechnology & Pharmaceuticals,2023,0.4,0.6931471805599453,Business_Ethics
Danang Pharmaceutical Medical Equipment JSC,5000495372,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,9,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Central Pharmaceutical CPC1 JSC,5046649799,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,9,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Pharbaco Central Pharmaceutical No1 JSC,5037348904,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,9,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
Navetco National Veterinary JSC,5058981636,qualitative,CALCULATED,Does the company have a policy and/or processes in place to avoid bribery and corruption in all its operations?,POLICY_BRIBERYAND_CORRUPTION,0.0,9,S_risk,Biotechnology & Pharmaceuticals,2019,0.0,0.0,Business_Ethics
